















































Diabetes	 is	 a	 complex	 disease	 characterised	 by	 hyperglycaemia,	 which	 often	
leads	 to	 microvascular	 complications	 including	 diabetic	 nephropathy	 and	
cardiomyopathy.	 In	 this	 thesis,	 I	 have	 investigated	 the	 role	 of	 Annexin-A1	
(ANXA1),	 an	 endogenous	 anti-inflammatory	 peptide,	 in	 two	 experimental	
murine	models	of	diabetes	caused	by	streptozotocin	(STZ)	or	high-fat	high-sugar	





type	 1	 diabetes	 loss	 of	 endogenous	 ANXA1	 aggravates	 both	 cardiac	 and	 renal	
dysfunction	in	mice.	Specifically,	 I	have	shown	that	key	mediators	of	 the	MAPK	
pathway	 (p38,	 JNK	 and	 ERK1/2)	 are	 constitutively	 activated	 in	 ANXA1-/-	mice,	
and	 activation	 of	 these	 pathways	 is	 exacerbated	 in	 diabetic	 ANXA1-/-	 mice.	
Administration	 of	 human	 recombinant	 (hr)	 ANXA1	 did	 not	 alter	 the	 diabetic	
phenotype	in	diabetic	WT	mice,	but	attenuated	the	cardiac	and	renal	dysfunction	




Patients	 with	 T2DM	 have	 increased	 plasma	 ANXA1	 levels.	 HFD-fed	 ANXA1-/-	
mice	 have	 a	 more	 severe	 diabetic	 phenotype	 compared	 to	 HFD-fed	WT	mice.	
Therapeutic	administration	of	hrANXA1	prevented	the	development	of	a	diabetic	
phenotype.	 Specifically,	 I	 have	 shown	 that	 the	 insulin	 signalling	 pathway	 is	
further	perturbed	in	diabetic	mice	resulting	in	severe	insulin	resistance,	and	that	
these	signalling	abnormalities	were	prevented	by	therapeutic	administration	of	
hrANXA1.	 	 In	addition,	 loss	of	endogenous	ANXA1	aggravates	both	cardiac	and	
renal	 dysfunction	 in	 mice	 with	 experimental	 T2DM.	 The	 GTPase	 RhoA	 is	
constituently	 activated	 in	 ANXA1-/-	 mice	 leading	 downstream	 activation	 of	
MYPT1.	 Feeding	 a	 HFD	 also	 activated	 the	 small	 GTPase	 RhoA,	 leading	 to	
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increased	 MYPT1	 activity,	 which	 could	 be	 attenuated	 with	 treatment	 with	
hrANXA1.	
Mice	 subjected	 to	 HFD	 for	 12	 weeks	 had	 a	 more	 ‘leaky’	 blood	 brain	 barrier	
(BBB),	which	 is	 further	 exacerbated	 in	ANXA1-/-	mice	 fed	 a	HFD.	 Compared	 to	
mice	fed	a	chow	diet,	mice	fed	a	HFD	had	an	augmented	CD4+	T-cell	profile;	with	
a	 clear	decline	 in	CD4+FoxP3+	 (anti-inflammatory)	and	 increase	 in	CD4+RORgt+	
(pro-inflammatory)	 cells.	 Administration	 of	 hrANXA1	 to	 mice	 fed	 on	 HFD	
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2.3.3. Effect	 of	 late	 treatment	 with	 hrANXA1	 (weeks	 8-13)	 on	 STZ-induced	
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2.4.3. Protein	 levels	 of	 ANXA1	 in	 a	 murine	 model	 of	 STZ-induced	 type-1	
diabetes	mellitus.	
	








2.4.8. The	 effect	 of	 endogenous	 ANXA1	 on	 renal	 fibrosis	 in	 a	 model	 of	 STZ-
induced	type-1	diabetes	mellitus.		






2.4.12. Effect	of	endogenous	ANXA1	on	phosphorylation	of	Akt	 in	kidneys	 from	
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mellitus.	
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2.4.18. The	 effect	 of	 late	 administration	 with	 hrANXA1	 on	 non-fasted	 blood	
glucose,	serum	insulin	and	OGTT	subjected	to	STZ-induced	type-1	diabetes	
mellitus.	





































































































































































































































The	principal	hormone	involved	 in	blood	glucose	regulation	 is	 insulin,	which	 is	
produced	 within	 beta	 cells	 in	 the	 islets	 of	 Langerhans	 of	 the	 pancreas.	 When	
blood	glucose	 levels	 increase,	 insulin	 is	 immediately	released	 from	 its	granular	
stores	in	the	pancreas.	To	ensure	immediate	release,	insulin	production	is	highly	
regulated	(Hou	et	al.,	2009).	Specifically,	mRNA	transcripts	are	translated	into	an	
inactive	 protein	 called	 preproinsulin.	 This	 contains	 a	 terminal	 amino	 acid	





granules,	 which	 accumulate	 in	 the	 cytoplasm	 ready	 for	 release	 when	 blood	
glucose	levels	rise.	
Glucose	 in	 taken	 up	 into	 beta	 cells	 using	 the	 specific	 glucose	 transporter	 2	
(GLUT2).	 As	 blood	 glucose	 levels	 increase,	more	 glucose	 is	 taken	 up	 into	 beta	
cells.	 	Once	inside	the	beta	cells,	glucokinase	phosphorylates	glucose	allowing	it	
to	 enter	 into	 glycolysis	 to	 produce	 adenosine	 triphosphate	 (ATP)	 in	 a	 rate-




to	 depolarisation	 of	 the	 membrane	 due	 to	 an	 accumulation	 of	 K+.	 As	 a	
consequence,	 voltage-gated	 calcium	 channels	 open	 allowing	 for	 an	 influx	 of	
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calcium	 ion	 (Ca2+)	 into	 the	 cell	 (Figure	 1.1).	 	 The	 increase	 in	 cytosolic	 Ca2+	
initiates	exocytosis	of	insulin-storing	granules,	allowing	insulin	to	readily	diffuse	
into	 the	 vessels	 that	 surround	 the	highly	 vascularised	 islets.	 	 Insulin	 release	 is	





























cells	 by	 glucose	 transporter	 2	 	 (GLUT2).	 	 Glucokinase	 ‘senses’	 increases	 in	 glucose	 levels	 and	
metabolises	 glucose	 (by	glycolysis)	 to	 generate	ATP.	This	 leads	 to	 the	 closure	of	ATP-sensitive	







conditions	 (normal	 physiological	 blood	 glucose	 levels),	 the	 IRS-1	 complex	 is	





(Tyr)-608/628	 (Figure	 1.2)	 allowing	 signal	 transduction	 though	
phosphoinositide	3-kinase	(PI3K)/protein	kinase	B	(Akt).		
	
The	 signalling	 cascade	 is	 initiated	 by	 insulin	 binding	 to	 the	 insulin	 receptor,	
which	 facilitates	 the	 translocation	 of	 glucose	 transporter	 4	 (GLUT4)	 positive	
vesicles	 to	 the	 cell	 membrane	 to	 allow	 the	 uptake	 of	 glucose	 from	 the	 blood	
stream	 (Figure	 1.2).	 	 GLUT4	membrane	 channels	 are	 present	 on	 a	 number	 of	
peripheral	cell	types,	including	hepatocytes,	skeletal	muscle	and	adipocytes	that	
utilise	dietary	glucose	for	energy	metabolism	or	storage.	Under	basal	conditions	
very	 few	 GLUT4	 transporters	 are	 present	 on	 the	 cell	 surface,	 however,	 upon	
insulin	 release	 after	 a	 spike	 in	 blood	 glucose,	 a	 large	 number	 of	 GLUT4	
transporters	are	trafficked	to	the	cell	membrane	(James	et	al.,	1988).		
	
There	 are	 also	 other	 proteins	 involved	 in	 the	 regulation	 of	 insulin	 release.	
Glucagon-like-peptide-1	 (GLP-1)	 is	 a	 potent	 incretinGLP	 hormone	 produced	 in	
the	L-cells	of	the	distal	ileum	and	colon.	Nutrients,	including	glucose,	fatty	acids,	
and	 dietary	 fiber,	 are	 all	 known	 to	 up	 regulate	 the	 transcription	 of	 the	 gene	
encoding	GLP-1,	and	they	can	stimulate	the	release	of	this	hormone.	In	the	gut	is	
has	 very	 distinct	 effects	 to	 those	 that	 are	 involved	 in	 insulin	 secretion	 (gut	
motility,	 inhibition	 of	 gastric	 acid	 secretion	 and	 inhibiting	 glucagon	 secretion)	
(Holst	 et	 al.,	 2007).	 As	 previously	 mentioned	 insulin	 secretion	 to	 occurs	 as	 a	
result	 of	 glucose	 metabolism.	 When	 glucose	 levels	 rise,	 the	 rate	 of	 glycolysis	
increases,	 which	 generates	 substrates	 (mainly	 pyruvate)	 for	 mitochondrial	
oxidative	 metabolism,	 the	 result	 of	 which	 is	 the	 generation	 of	 ATP,	 or	 more	
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correctly	 an	 increase	 in	 the	 ATP-to-ADP	 ratio.	 GLP-1	 is	 proposed	 to	modulate	
glucose	 stimulated	 insulin	 secretion	 by	 regulating	 the	 activity	 of	 several	 ion	
channels	 involved	 in	KATP-dependent	 insulin	 secretion	 (MacDonald	et	 al.	 2002)	
(Figure	 1.1).	 Indeed,	 GLP-1	 receptor	 agonists	 are	 now	 part	 of	 a	 repertoire	 of	
drugs	 used	 to	 enhance	 glucose	 secretion	 (Garder	 et	 al	 2011).	 Another	 is	 the	
dipeptidyl	peptidase	4	(DPP-4)	inhibitors	these	work	by	blocking	the	production	





























was	 only	 in	 1776	 that	 the	 English	 physician	 Matthew	 Dobson	 confirmed	 that	
excessive	sugar	 in	the	urine	and	blood	was	the	cause	of	 the	sweetness	(Ahmed	
2002).	It	wasn’t	until	much	later	that	the	role	of	the	pancreas	was	elucidated	by	
Joseph	 von	Mering	 and	Oskar	Minkowski	 (1889);	 they	 conducted	 experiments	
with	dogs	who	had	their	pancreas	removed	and	demonstrated	they	had	the	same	
phenotype	 as	 diabetic	 patients	 (Mering	&	Minkowski,	 1890).	 In	 1923	 Fredrick	
Banting	and	John	MacLeod	won	the	Noble	Prize	‘for	the	discovery	of	insulin’	and	
its	 use	 for	 the	 treatment	 of	 diabetes	 (Majumdar,	 2001).	 	 In	 1936,	 the	 first	
distinction	 between	 type-1	 (T1DM)	 and	 type-2	 diabetes	 mellitus	 (T2DM)	 was	
made.	T1DM	is	an	autoimmune	disease	caused	by	the	destruction	and	damage	of	
beta	 cells	 in	 the	 pancreas	 resulting	 in	 insulin	 deficiency	 resulting	 in	










account	 for	 around	 1	 to	 5	 percent	 of	 all	 cases	 of	 diabetes	 in	 young	 people	
(National	 Diabetes	 Statistics	 Report,	 2014).	 Genetic	 testing	 can	 diagnose	most	







finding	 from	 a	 nine	 country,	 multi-centre	 study	 (Buckey	 et	 al.	 2012).	 While	
maturity	onset	diabetes	of	 the	young	often	 referred	 to	MODY,	 is	not	 related	 to	
obesity	but	 the	patients	are	young	and	have	symptoms	comparable	 to	 those	of	
T2DM.	Interestingly,	this	form	of	diabetes	is	more	likely	to	be	inherited	than	as	





2014).	 	The	 care	burden	of	diabetes	 is	 financially	 significant	with	 conservative	
estimates	suggesting	that	diabetes	directly	and	 indirectly	cost	 the	UK	currently	





hyperglycaemia,	 but	 the	 cause	 of	 the	 hyperglycaemia	 is	 very	 different.	 	 The	
classical	model	of	T1DM	suggests	there	is	a	strong	genetic	susceptibility	(Pociot	
&	 Lernmark,	 2016).	 All	 adults	 have	 a	 fixed	 number	 of	 beta	 cells.	 Specific	
environmental	 factors	 can	 trigger	 beta	 cell	 autoimmunity	 (Atkinson	 2012)	
resulting	 in	 the	 development	 of	 islet	 reactive	 autoantibodies,	 the	 activation	 of	




production	 is	 reduced	 and	 sufficient	 amounts	 of	 insulin	 cannot	 be	 secreted	 in	
response	 to	 elevations	 in	 blood	 glucose.	 	 Clinically,	 patients	 with	 T1DM	 are	
asymptomatic	until	they	have	lost	~80-90	%	of	their	beta	cell	mass;	only	then	is	
there	 significant	 perturbation	 of	 the	 system	 that	 results	 in	 elevated	 blood	
glucose	levels.	The	environmental	factor(s)	that	triggers	beta	cell	autoimmunity	
remains	 very	 elusive,	 however,	 infectious	 agents	 are	 often	 cited.	 	 Rubella	 and	
enterovirus	 infection	are	 the	most	commonly	reported	to	having	a	relationship	
between	 beta	 cell	 autoimmunity	 and	 diabetes	 (Boettler	 &	 von	Herrath,	 2011).	
Other	potential	 candidates	 are	 from	dietary	 sources.	The	most	predominant	of	
these	is	the	effect	of	breastfeeding	and	the	early	exposure	to	cows	milk,	but	once	
again	 the	 idea	 is	 highly	 controversial.	However,	meta-analysis	 showed	a	 small,	
but	 significant,	 correlation	 between	 short	 periods	 of	 breast	 feeding	 and	 cow’s	
milk	exposure	before	3-4	months	of	age	(Gerstein,	1994).	
	
On	 the	 other	 hand,	 T2DM	 is	 characterised	 by	 peripheral	 insulin	 insensitivity	
(also	 called	 insulin	 resistance),	 leading	 to	 an	 increased	 insulin	 production	 and	
but	ultimately	in	pancreatic	beta	cell	failure.	Insulin-resistance	occurs	when	the	
signalling	cascade	activated	by	 insulin	 through	 IRS-1	 is	blunted	and	as	a	 result	
there	 is	 a	 reduction	 in	 PI3K/Akt	 signalling.	 It	 is	 now	widely	 accepted	 that	 an	
increase	in	the	phosphorylation	of	Ser-307	on	IRS-1	is	a	mechanistic	marker	of	
peripheral	 insulin	 resistance	 in	 experimental	 models	 of	 diabetes	 (Figure	 1.2).	
Unexpectedly,	Wilson	and	colleagues	have	reported	that	mice	with	specific	site-
specific	amino	acid	changes	in	Ser-307	developed	more	severe	insulin	resistance	
(Copps	 et	 al.,	 2010).	 This	 finding	 raises	 the	 question	 whether	 this	
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phosphorylation	 site	 is	 functionally	 the	 main	 driver	 of	 peripheral	 insulin	
resistance.		
	
The	 cause	 of	 the	 receptor	 insensitivity	 is	 multifaceted,	 but	 largely	 due	 to	
excessive	dietary	intake	of	calories;	there	is	also	a	strong	correlation	with	both	
obesity	 and	 lack	 of	 exercise	 (Sigal	 et	 al.,	 2004).	 Large	 quantities	 of	
monounsaturated	and	polyunsaturated	fats	are	harmful	to	rats	and	cause	insulin	
resistance,	while	other	studies	demonstrate	that	saturated	fats	appear	to	have	a	
more	 profound	 effect	 at	 eliciting	 insulin	 resistance	 (Storlien	 et	 al.,	 1991).	
Similarly,	elevated	levels	of	free	fatty	acids	and	triglyceride	in	the	blood	stream	




in	 part	 regulated	 by	 insulin.	 Hepatic	 steatosis	 is	 a	 common	 finding	 in	 patients	
with	T2DM,	which	is	causally	linked	to	features	of	the	metabolic	syndrome,	liver	
cirrhosis,	 and	 cardiovascular.	 Excessive	 fat	 intake	 leads	 initially	 to	
hypercholesterolaemia,	which	is	a	common	feature	in	patients	with	pre-diabetes.	
Indeed,	 clinically	 at	 this	 stage	 life	 style	 choices	 are	 very	 effective	 at	 correcting	
these	 abnormal	 test	 results.	 However,	 if	 left	 unchecked	 this	 compartment	
becomes	overwhelmed	and	fat	starts	to	become	deposited	in	the	liver	(initially).	
Indeed,	 elevated	 circulating	 free	 fatty	 acid	 levels,	 in	part	 related	 to	diminished	
suppression	 of	 adipose	 tissue	 lipolysis	 by	 insulin,	 this	 results	 in	 increased	










and	 the	 level	 of	 ALT/AST	 does	 not	 reliably	 predict	 the	 extent	 of	 inflammation	
and	cirrhosis.	
	
Indeed	 abdominal	 adiposity	 is	 very	 prevalent	 in	 patients	 with	 T2DM.	
Epidemiologic	investigations	have	consistently	shown	an	independent	increased	
risk	 for	 diabetes	 associated	 with	 overweight	 and	 obesity,	 with	 clear	 dose	
response	 patterning	 across	 categories	 of	 increasing	 body	 mass.	 While	 the	
importance	 of	 increased	 body	mass	 in	 diabetes	 etiology	 is	 unequivocal,	 it	 has	
been	 recognized	 for	 some	 time	 that	 the	 distribution	 of	 body	 fat	 provides	
additional	resolution	regarding	diabetes	risk	(Hanley	et	al.,	2008).	There	was	a	




The	 dietary	 component	 fructose,	 which	 is	 commonly	 added	 to	 fast	 foods	 and	
used	as	sweeteners,	 is	metabolised	by	the	 liver	 into	triglycerides.	This	not	only	
increases	sugar	intake,	but	also	adds	to	the	accumulation	of	triglycerides	 levels	





The	 long-term	 effects	 of	 diabetes	 include	 neuropathy,	 retinopathy,	
cardiomyopathy	 and	 nephropathy.	 These	 complications	 are	 classified	 as	
microvascular	 problems	 and	 their	 prevalence	 is	 very	 high.	 It	 is	 estimated	 that	
annually	10	%	of	 the	NHS	budget	 is	 spent	on	 the	 treatment	of	diabetes,	which	
equates	 to	around	£11	billion,	and	most	of	 this	budget	 is	 spent	on	 treating	 the	
vascular	 complications	 of	 diabetes.	 	 Retinopathy	 is	 present	 in	 13%	 of	 T1DM	























in	 1972	 who	 reviewed	 four	 autopsy	 cases	 of	 patients	 with	 diabetic	
glomerulosclerosis	 and	 no	 known	 cause	 of	 death	 (Rubler	 et	 al,	 1972).	 The	
authors	 concluded	 that	 these	 patients	 had	 an	 underlying	 condition,	 diabetic	
cardiomyopathy,	which	 contributed	 to	 their	 death.	 Diabetic	 cardiomyopathy	 is	
now	 known	 to	 be	 a	 potentially	 serious	 cardiac	 dysfunction	 induced	 by	 the	
alterations	 in	 structure	 and	 contractility	 of	 the	 myocardium	 in	 patients	 with	
severe	 diabetes.	 	 These	 fundamental	 changes	 stem	 from	 a	 lack	 of	 glycaemic	








risk	of	heart	 failure	 is	 increased	two	fold	by	diabetes.	The	 first	stage	of	DCM	is	
often	 an	 asymptomatic,	 but	 characterised	 by	 diastolic	 dysfunction	 (increased	
ventricular	 stiffness,	 left	 atrial	 enlargement,	 hypertrophy	 and	 elevated	 left	
ventricular	end	diastolic	pressure).	It	is	also	a	common	feature	however,	that	left	
ventricular	 function	 is	preserved	 in	 these	patients.	The	second	stage	of	DCM	 is	










diabetic	 cardiomyopathy.	 However,	 from	 here	 on	 the	 focus	 will	 be	 on	 the	
cardiomyopathy	 associated	 with	 T1DM.	 To	 date	 the	 progression	 DCM	 has	 not	
been	 fully	 characterised,	 but	 the	 pathophysiological	 of	 events	 associated	 with	








fibres	 accumulate	 in	 the	 epicardial	 and	 perivascular	 regions,	 whereas	 type	 IV	
fibres	are	predominantly	found	in	the	endocardium	(Way	et	al.	2002).	Glycated	
proteins	 undergo	 a	 series	 of	 chemical	 rearrangements	 to	 form	 complex	
compounds,	 which	 are	 referred	 to	 as	 advanced	 glycated	 end	 products	 (AGE).		
AGE’s	 are	 increased	 in	 plasma	 of	 patients	 that	 are	 older,	 or	 have	 diabetes	
(hyperglycaemia)	 or	 renal	 failure	 (Singh	 et	 al.,	 2014).	 	 However,	 the	
accumulation	 of	 AGE	 in	 collagen	 reduces	 collagen	 turnover	 rate,	 and	 AGE-
mediated	 cross-linking	 of	 collagen	 is	 responsible	 for	 increased	 stiffness	 of	
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arteries	and	the	myocardium.	 	 Indeed,	AGE	accumulation	 in	 the	myocardium	is	
proportional	to	the	levels	of	AGE	seen	in	the	serum.		Soluble	AGE	also	interacts	
with	 the	 receptor	 of	 AGE	 immunoglobulin’s	 on	 both	 endothelial	 cells	 and	
myocardiocyte	 to	 up-regulate	 production	 of	 transforming	 growth	 factor-Beta	
(TGF-β),	 and	 nicotinamide	 adenine	 dinucleotide	 phosphate	 (NADPH)	 oxidases,	
which	 in	 turn	 increases	 cytoplasmic	 and	 extracellular	 reactive	 oxygen	 species	
(ROS),	leading	to	cellular	death	and	the	need	for	production	of	ECM	components	
(Wang	et	al.,	2006)	(Giacco	&	Brownlee,	2010).	Low-grade	chronic	inflammation	





Inflammation	 plays	 a	 key	 role	 in	 the	 development	 of	 diabetes	 (Rehman	 et	 al.	
2016),	and	is	thought	to	be	one	of	the	main	contributors	to	the	development	of	
secondary	 microvascular	 complications.	 Pro-inflammatory	 signalling	 by	
cardiomyocytes	occurs	as	an	early	response	to	hyperglycaemia,	and	is	thought	to	
be	a	protective	response	 to	noxious	stimuli.	Nuclear	 transcription	 factor-kappa 
beta	 (NF-κB)	 is	 a	 highly	 potent	 nuclear	 pro-inflammatory	 transcription	 factor	
that	is	involved	in	initiating	the	transcription	cytokines,	adhesion	molecules	and	
mediators	under	hyperglycaemic	conditions	(Basu	et	al.,	2005).	Activation	of	NF-
𝜅B by hyperglycaemia	 is	 thought	 to	 be	 one	 of	 the	 key	 drivers	 of	 localised	





(interleukin	 (IL)-1β,	 IL-6	 and	 IL-17a),	 however,	 the	 site	 of	 production	of	 these	
cytokines	 is	 not	 known	 (King,	 2008).	 In	 vitro	 studies	 have	 shown	 that	




the	 activation	 of	 immune	 cells	 and	 their	 subsequent	 recruitment	 and	
transmigration	 into	 the	 tissue	 causing	 localised	 inflammation	 and	 injury.	 The	
infiltration	of	immune	cells,	initially	neutrophils	and	then	monocytes	can	further	
increase	localised	inflammation	in	the	heart,	which	can	cause	cell	apoptosis	and	






causes	 the	 hydrolysis	 of	 phosphatidylinositol	 4,5-bisphosphate	 (PIP2)	 to	
diacylglycerol	 (DAG)	and	 inositol	 trisphosphate	(IP3)	by	phospholipase	C	(PLC)	
(figure	1.3).	 IP3	causes	release	of	Ca2+	from	the	sarcoplasmic	reticulum	that	can	
then	activate	PKC.	Likewise,	DAG	can	directly	 interact	with	PKC	 to	 increase	 its	
activation	 (Figure	 1).	 Under	 hyperglycaemic	 conditions,	 PKC	 is	 constitutively	
activated.	 In	 vitro	and	 ex	 vivo	 studies	 have	 shown	 that	 increased	 activation	 of	
PKC	 decreases	 Akt	 activation	 and	 increases	 the	 activation	 of	 the	 mitogen-
activated	protein	kinase	(MAPK)	signal	transduction	pathway.	Activated	PKC	and	




(Geraldes	 &	 King,	 2010a).	 	 PKC	 inhibition	 attenuates	 diastolic	 dysfunction,	
preserves	contractility	and	reduces	myocyte	hypertrophy	in	rats	with	genetically	
induced	 diabetes	 heart	 failure	 (Connelly	 et	 al.,	 2009).	 Cardiac	 hypertrophy	 is	
prevalent	 in	 many	 cases	 of	 DCM,	 and	 commonly	 seen	 in	 biopsy	 specimen	
obtained	 from	diabetic	 hearts.	 ERK1/2	 activation	 secondary	 to	 poor	 glycaemic	
management	results	in	activation	of	key	signal	transduction	pathways	of	cardiac	











Hyperglycaemia	 stimulates	de	novo	 synthesis	 of	 DAG	 and	 IP3.	 	 DAG	 can	 then	 activate	multiple	
isoforms	of	PKC.	This	will	in	turn	affect	the	activity	intracellular	signaling	pathways	such	as	the	
MAP	 kinases	 (p38,	 JNK	 and	 ERK1/2)	 and	 PI3K/Akt	 pathways,	 altering	 key	 enzymes	 that	
determine	 cellular	 homeostasis.	 	 IP3	 facilitates	 the	 release	 of	 Ca2+	 from	 the	 sarcoplasmic	






Energetic	 imbalances	 within	 cells	 are	 often	 caused	 by	 lack	 of	 glycaemic	
regulation	 and	 can	 lead	 to	mitochondrial	 uncoupling,	 which	 in	 turn	 generates	
excessive	amounts	of	ROS.		Small	changes	in	the	efficiency	of	ATP	production	can	





oxidation.	 	 Glucose	 oxidation	 is	 inhibited	 at	 multiple	 metabolic	 steps	 in	 the	





which	 is	 the	main	 source	 of	ATP	production	 in	 the	 cell.	Mitochondrial	 damage	
presents	itself	by	loss	of	membrane	potential	which	leads	to	a	further	increase	in	




form	 superoxide	 anions	 that	 can	 combine	 with	 nitric	 oxide	 to	 form	 highly	
reactive	and	damaging	peroxynitrite.		ROS	can	cause	damage	to	the	endothelium,	
proteins,	deoxyribonucleic	acid	(DNA)	and	 lead	 to	cell	death	(Stowe	&	Camara,	
2009).	 	 The	 damage	 caused	 by	 excessive	 ROS	 formation	 can	 also	 induce	














(≥	 30	 mg/24	 h)	 in	 the	 urine,	 referred	 to	 as	 microalbuminuria	 (Lim	 2014).		
Patients	 presenting	 with	 microalbuminuria	 are	 referred	 to	 as	 having	 diabetic	









Patients	with	 T2DM	 can	 present	with	microalbuminuria	 or	 overt	 nephropathy	
shortly	after	diagnosis.		This	is	partly	due	to	the	fact	that	their	diabetes	is	usually	
present	 for	 many	 years	 before	 the	 diagnosis	 is	 made.	 Without	 specific	




However,	 there	 is	no	difference	 in	 the	annual	decline	 in	GFR	between	patients	
with	T1DM	and	T2DM.	Proportionally	more	patients	with	T1DM	develop	ESRD,	
this	discrepancy	may	be	in	part	due	to	patients	with	T2DM	being	associated	with	
a	higher	 risk	of	dying	 from	coronary	artery	disease	 (CAD).	Therefore,	 entering	
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preventative	 treatment	 plans	 and	 therapies	 for	 CAD	 may	 prevent	 many	 with	
earlier	 stages	 of	 DN	 from	 progressing	 to	 ESRD	 (Bruno	 et	 al.,	 2003).	 Indeed	
patients	with	T1DM	also	have	a	high	risk	of	coronary	heart	disease	(Slim	et	al.	
2013).	Interestingly,	when	compared	to	Caucasians,	there	is	a	4-5	fold	increased	




The	 decline	 in	 renal	 function	 is	 associated	 with	 and	may	 be	 explained	 by	 the	




new,	 5-stage	 strategy	 of	 scoring	 has	 been	 developed	 that	 better	 mirrors	 the	
morphological	 changes	 that	 are	 specific	 for	 diabetic	 nephropathy.	 This	 scoring	
system	 postulates	 that	 the	 severity	 of	 tubulointerstitial	 injury	 represents	 an	
important	 factor	 in	diagnosing	 the	progression	of	DN.	Therefore,	depending	on	
the	 severity	 of	 DN,	 interstitial	 and	 vascular	 modifications	 patients	 are	 graded	
into	stages	(Table	1.1).	Although	it	is	clinically	useful	to	classify	patients	with	DN,	
this	 classification	 does	 not	 give	 any	 indication	 of	 the	 factors	 driving	 these	
changes.	This	 causes	problems	when	 targeting	patients	with	 specific	 therapies,	
as	the	underlying	cause	of	these	physical	end-points	is	not	clear	(Tervaert	et	al.,	
2010).	Again	 in	2014	 Joint	Committee	on	Diabetic	Nephropathy	has	revised	 its	
classification	of	DN	in	line	with	the	widespread	use	of	key	concepts,	such	as	the	






















Table	 2.	 Table	 describing	 the	 clinical	 scoring,	 set	 out	 as	 Classification	 of	 Diabetic	
Nephropathy	2014.	Adapted	from	Haneda	et	al.	2015.	
	




Urinary albumin (mg/g Cr) 
Or urinaryprotein (g/g Cr) 
GFR (eGFR)  
(mL/min/1.73 m2) 
Stage 1 (prenephropathy) Normoalbuminuria (<30) ≥30 
Stage 2 (incipient nephropathy) Microalbuminuria (30–299)§ ≥30 
Stage 3 (overt nephropathy) Macroalbuminuria (≥300) ≥30 
or 
persistent proteinuria (≥0.5) 
Stage 4 (kidney failure) Any albuminuria/ 
proteinuria status 
<30 





















≥300 (or increased 
proteinuria) (≥0.50) 
 
GFR category ≥90 Stage 1 Stage 2 Stage 3  
(mL/min/1.73 m2) 60–89 (pre-nephropathy) (incipient 
nephropathy) 
(overt nephropathy)  
45–59     
30–44     
15–29 Stage 4    
<15 (kidney failure)    
(Dialysis therapy) Stage 5    









The	mechanisms	 governing	 the	 development	 of	 diabetic	 nephropathy	 are	 very	
similar	 in	models	 of	 T1DM	 and	 T2DM.	 	 Clinically,	 the	 pathophysiology	 is	 also	
very	 similar	 and	 as	 such	 the	 mechanisms	 driving	 both	 are	 very	 similar.	
Histologically,	 DN	 is	 well	 characterised;	 mesangial	 expansion	 as	 a	 result	 of	
increased	ECM	production	and	cell	enlargement	can	be	seen	in	the	early	stages.	
This	 is	 proceeded	 by	 thickening	 of	 the	 basement	 membrane,	 reduction	 in	






cellular	 consequences	 that	 affect	 glucose	 metabolism,	 glycogen	 synthesis,	 cell	





have	other	 classical	 phenotypes	 that	mimic	T2DM,	 and	 go	 on	 to	 develop	overt	
DN.	There	are	3	main	isoforms	of	PKC,	and	it	has	been	demonstrated	that	each	
contributes	 to	 the	 complication	 of	 DN	 (Geraldes	 &	 King,	 2010b).	 Menne	 and	
colleagues	 have	 reported	 that	 diabetic	 PKC-α-/-	 mice	 are	 resistant	 to	 the	
development	 of	 albuminuria	 and	 glomerular	 hyperfiltration	 stimulated	 by	
vascular	 endothelial	 growth	 factor	 (VEGF)	 (Menne	 et	 al.,	 2004).	 	 PKC-𝛼	 is	
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associated	 with	 nicotinamide	 adenine	 dinucleotide	 phosphate	 (NADPH)-
dependant	 superoxide	 production	 (Thallas-Bonke	 et	 al.,	 2008).	 Deletion	 of	 the	
PKC-β	 protects	 against	 DN	 by	 preventing	 renal	 hypertrophy,	 glomerular	
hyperfiltration,	reduced	production	of	ECM,	TGF-β1	and	ROS)	(Koya	et	al.,	2000).	
It	 has	 also	 been	 demonstrated	 that	 down-regulation	 of	 Akt	 due	 to	




Hyperglycaemia	 leads	 to	 an	 excess	 of	 available	 glucose	 to	 enter	 the	
mitochondrial	 respiratory	 chain	 complex	 to	 create	 ATP.	 Simply,	 most	 glucose	
that	enters	cells	gets	converted	to	pyruvate,	which	then	enters	the	Kerbs	cycle	to	
generate	ATP,	NADH	and	 flavin	adenine	dinucleotide	 (FADH2).	Both	NADH	and	
FADH2	 are	 generated	 in	 the	 cytosol	 and	 become	 electron	 donors	 for	 oxidative	
phosphorylation.	 	 Electrons	 from	 these	molecules	 are	 transferred	 to	molecular	
oxygen	 in	 the	mitochondrial	 respiratory	 chain	 (complex	 I-IV)	 to	 generate	ATP.	
Under	 normal	 physiological	 states,	 less	 that	 1	 %	 of	 molecular	 oxygen	 is	
converted	to	superoxide	anion,	which	can	cause	pathological	damage.	However,	
in	hyperglycaemic	states	 there	 is	an	excess	of	 free	electrons	at	 two	sites	 in	 the	
electron	transport	chain:	one	at	complex	I,	and	the	other	at	the	interface	between	
coenzyme	Q	and	complex	III.	As	a	result,	there	is	an	excess	of	superoxide	anions	
produced	 that	 can	 combine	with	 other	 free	 radicals	 to	 produce	 damaging	ROS	
(Bondeva	 &	 Wolf,	 2014).	 Interestingly,	 glomerular	 mesangial	 cells,	 retinal	
capillary	 endothelial	 cells	 and	 neurons	 are	 known	 to	 be	 unable	 to	 regulate	
intracellular	 glucose	 levels	 in	 diabetes.	 	 This	 results	 in	 the	 generation	 of	
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excessive	 levels	 of	 superoxide	 within	 these	 cell	 types	 subjecting	 them	 to	
increased	ROS-mediated	oxidative	stress	and	leads	to	functional	decline.	
ROS	mediate	 cellular	damage	 in	a	number	of	ways.	Most	of	 the	effects	directly	
target	 DNA	 causing	 single	 or	 double	 strand	 breaks,	 or	 by	 disrupting	 histones.	
Mitochondrial	DNA	is	deficient	in	histones	and	is,	therefore,	more	susceptible	to	
damage	 from	ROS.	 ROS-mediated	 damage	 caused	 to	mtDNA	 is	more	 extensive	
and	more	persistent	than	damage	to	nuclear	DNA	(Yakes	&	Van	Houten,	1997).	
ROS	 can	 also	 induce	 cellular	 damage	 by	 disrupting	 the	 efficiency	 of	 numerous	
enzymes.	 The	 repetitive	 production	 of	 excessive	 ROS	 under	 hyperglycaemic	
conditions	 can	 damage	 various	 enzymes	 of	 the	 electron	 transport	 chain.	 This	
ultimately	 leads	 to	 reduced	 ATP	 production,	 effecting	 cytochrome	 C	
translocation,	 activation	 of	 caspases	 and	 predisposing	 the	 cell	 to	 undergo	
apoptosis	 or	 necrosis,	 which	 leads	 to	 loss	 of	 function	 and	 organ	 injury.	 The	
MAPK	 downstream	 mediators	 including	 c-Jun	 N-terminal	 kinase	 (JNK)	 is	
strongly	up-regulated	under	oxidative	stress	in	models	of	diabetes	(Hirosumi	et	
al.,	2002).	However,	in	mouse	models	of	DN,	JNK	activation	is	dependent	on	the	
age	 of	 the	 mice;	 young	 diabetic	 mice	 showed	 little	 phosphorylation	 of	 JNK	
(activated),	while	 old	 diabetic	mice	 had	 increased	 levels	 of	 phosphorylation	 of	
JNK.	 This	 is	 consistent	with	 other	 reports	 that	 older	 diabetic	mice	 had	 higher	
oxidative	stress	levels	in	mesangial	cells	compared	to	young	diabetic	mice.	This	
leads	 to	 cellular	 expansion	 and	 laying	 down	 of	 increased	mesangial	 expansion	
(Wu	 et	 al.,	 2009).	 Importantly,	 it	 is	 postulated	 that	 elderly	 patients	 have	
increased	levels	of	oxidative	stress	and	as	a	result	have	worse	clinical	outcome	
compared	 to	 younger	 patients	 presenting	with	 similar	 complaints.	 	 This	 could	
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suggest	 that	 conditions	 like	 diabetes,	 cause	 premature	 ageing	 (Ahima,	 2009).	
Other	 downstream	 mediators	 of	 the	 MAPK	 pathways	 are	 also	 activated	 in	
response	 to	 oxidative	 stress,	 activating	 a	 number	 of	 key	 survival	 pathways	
mainly,	 apoptosis	 of	 immune	 cells,	 inflammation,	 growth/cell	 cycle	 arrest	 and	
cell	differentiation	(Son	et	al.,	2011).	
The	 polyol	 pathway	 is	 up-regulated	 as	 a	 result	 of	 hyperglycaemia;	 meaning	
glucose	 is	 utilised	 and	 converted	 to	 sorbitol	 in	 an	 NADPH-dependant	manner.		
Sorbitol	 is	 enzymatically	 converted	 to	 fructose.	 	 This	 results	 in	 reduced	
availability	 of	 NADPH	 as	 an	 electron	 donor	 for	 oxidative	 phosphorylation	 and	
also	 for	 the	 regeneration	 of	 reduced	 glutathione	 (a	 potent	 antioxidant).		





injury	 (Beckerman	&	Susztak,	2014).	 Fructose	 is	 the	end	product	of	 the	polyol	





hypertrophy,	 which	 contributes	 to	 a	 decline	 in	 their	 function	 possibly	
contributing	 to	 the	 onset	 of	DN.	 	 TGF-β1	 is	 one	 of	 the	 key	 pro-fibrotic	 growth	




signalling	 cascade	 through	 the	 MAPK’s.	 In	 vitro	 studies	 have	 shown	 that	 the	
diabetic	milieu	can	activate	p38	signalling	 in	renal	mesangial	cells.	Exposure	to	
high	glucose	has	also	been	demonstrated	to	induce	the	phosphorylation	of	p38	in	
mesangial	 cells	 (Wilmer	 et	 al.,	 2001),	whilst	 glycated	 albumin	 can	 also	 induce	
phosphorylation	of	p38	 in	 fibroblasts;	both	of	 these	stimuli	are	key	 features	 in	
patients	 with	 DN	 (Daoud	 et	 al.,	 2001).	 	 Phosphorylation	 of	 p38	 promotes	 the	
production	 of	 TGF-β1	 and	 as	 a	 result	 the	 production	 of	 fibronectin.	 	 TGF-β1	
signalling	can	then	act	in	a	positive	feed	back	look	to	further	activate	p38,	induce	
the	 synthesis	 of	 collagen	 and	 other	 ECM	 components	 by	 mesangial	 cells	 and	





Hyperglycaemia	 is	 a	 key	 driver	 of	 low-grade	 chronic	 inflammation	 in	 diabetic	
patients	 with	 DN	 (García-García	 et	 al.,	 2014).	 On	 of	 the	 key	 pro-inflammatory	
pathways	 that	 hyperglycaemia	 directly	 activates	 is	 the	 NF-𝜅B	 pathway.	 Upon	
activation,	 NF-𝜅B	 translocates	 to	 the	 nucleus,	 where	 it	 acts	 as	 a	 potent	
transcription	 factor	 for	many	pro-inflammatory	 cytokines	 (IL-1b	and	 IL-6)	and	
mediators	 (pro-caspase1).	 	 NF-𝜅B	 can	 be	 found	 localised	 to	 the	 glomerulus,	
interstitial	 and	 tubular	 epithelial	 cells	 of	 the	 diabetic	 human	 kidney.	 Under	
hyperglycaemic	 condition,	NK-𝜅B	activation	 is	 increased	which	 correlates	with	
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proteinuria	and	 interstitial	 cell	 infiltration.	 	Acute	proteinuria	 is	also	known	 to	
further	 stimulate	 NK-𝜅B	 which	 is	 regarded	 as	 a	 key	 driver	 of	 long-term	
proteinuria	 (Sanz	 et	 al.,	 2010).	 	 Recruitment	 of	 macrophages	 to	 the	 diabetic	
kidney	 produces	 a	 plethora	 of	 pro-inflammatory	 factors	 that	 contribute	 to	 the	
progression	 of	 DN.	 	 The	 high	 number	 of	macrophages	 and	 over-production	 of	
macrophage-derived	 cytokines	 (IL-1β,	 TNF-α	 and	 IFN-𝛾)	 are	 responsible	 for	
increased	 vascular	 inflammation,	 leading	 to	 mesangial	 expansion	 and	 fibrosis,	
which	eventually	manifest	in	functional	decline	and	urinary	proteinuria.		
The	 JAK/STAT	 pathways	 can	 be	 activated	 by	 both	 hyperglycaemia	 and	 ROS;	
transducing	chemical	signals	from	outside	of	the	cell	to	regulate	gene	promoter	
activity	(Chuang	&	He,	2010).	JAK2	mRNA	levels	have	been	demonstrated	to	be	

































in	 1908,	 for	 his	 contribution	 to	 chemotherapy.	 Later	 work	 by	 Broman	 and	
Friedemann	 in	 the	 early	 1940’s	 demonstrated	 that	 the	 brain	 could	 be	 stained	
when	 lipid	soluble	dyes	where	 injected	 into	 the	peripheral	 circulation,	but	 this	
was	 by	 directed	 transport.	 	 They	 postulated	 that	 there	 were	 two	 protective	
barrier,	 the	blood-CSF	barrier	at	 the	chorid	plexus	and	the	BBB	at	 the	cerebral	
microvasculature	 that	 stopped	 the	 free	movement	of	 substance	 from	the	blood	
and	 interstitial	 fluids.	 	 Later	 work	 showed	 that	 the	 BBB	 has	 especially	 tight	
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Compared	 to	 endothelial	 cells	 of	 the	 peripheral	 capillaries	 BMEC	 demonstrate	
extreme	tightness,	is	this	has	been	evidenced	by	a	much	higher	transendothelial	
electrical	 resistance	 measurement	 of	 ~1500	 Ω.cm2	 in	 in	 vitro	 systems	 while	
values	 as	 high	 as	 5900	 Ω.cm2	 have	 been	 recorded	 in	 vivo	 (Srinivasan	 et	 al.	
2015)(Butt	 et	 al.,	 1990),	 compared	 to	 100-140	 Ω.cm2	 in	 peripheral	 gastro	
intestinal	 tract	 epithelial	 barriers	 (Artursson	 et	 al.,	 2001).	 This	 enhanced	
tightness	is	due,	in	part,	to	the	presence	of	strong	adhesion	molecules	including	
adhesion	junctions,	tight	junctions	and	other	actin	binding	structures.	
Adhesion	 junctions	play	a	key	role	 in	 the	development	and	maintenance	of	 the	
sealed	 endothelial	 as	 a	 barrier.	 The	 main	 component	 of	 this	 family	 is	 VE-
cadherin,	 a	 Ca2+	 regulated	 protein	 that	 mediates	 cell-cell	 adhesion	 via	
interactions	 with	 extracellular	 domains.	 The	 cytoplasmic	 portion	 of	 the	 VE-
cadherin	 is	 both	 directly	 and	 indirectly	 linked	 to	 the	 actin	 cytoskeleton	 by	
scaffolding	proteins	catenins	and	members	of	 the	p120	 family.	 	This	allows	 for	
the	neighbouring	cells	to	be	anchored	to	each	other	through	their	cytoskeleton.	





Similarly,	 tight	 junctions	 contribute	 directly	 to	 the	 tightness	 of	 the	 BBB.	 	 First	
discovered	 in	 1960s	 by	 electron	 microscope,	 they	 were	 described	 as	 kissing	
points	 between	 two	 endothelial	 cells	 on	 their	 outer	 leaflet	 of	 the	 cell.	 Tight	
junctions	have	a	complex	proteomic	composition	 that	greatly	depends	on	 their	
location.	 	 Post	 capillary	 venules	have	very	weak	 tight	 junction,	 to	 facilitate	 the	
rapid	blood-tissue	 exchanges.	While	 the	 tight	 junctions	present	 in	 the	BBB	are	
the	 most	 restrictive	 and	 complex,	 which	 results	 in,	 limited	 passage	 of	 polar	
molecules.	 The	 tight	 junctions	 are	 formed	 by	 an	 array	 of	 transmembrane	
molecules	including,	claudins,	occuldins	and	junction	adhesion	molecules,	these	
molecules	recruited	by	membrane-associated	cytoplasmic	proteins.	
BBB	 disruption	 has	 been	 implicated	 in	many	 diseases	 of	 the	 CNS	 (e.g.	 stroke,	
multiple	 sclerosis,	 cerebral	 infection,	 brain	 tumours,	 Parkinson’s	 and	
Alzheimer’s	 diseases).	 	 The	 most	 prominent	 mechanism(s)	 governing	 these	
disruptions	 have	 been	 associated	 with	 maintaining	 the	 integrity	 of	 tight	
junctions.	The	key	feature	that	regulates	BBB	tightness	tight	junctions	integrity	is	
site-specific	 phosphorylation;	 in	 many	 disease	 settings	 these	 key	 regulatory	
phosphorylation’s	are	 lost.	This	 can	 lead	 to	 tight	 junctions	being	degraded	and	
disrupts	their	cellular	translocation.	A	number	of	noxious	stimuli	including	ROS,	
hypoxia,	 glutamate	 and	 amyloid-β	peptide,	 have	been	 shown	 to	 signal	 through	


























bind	 specifically	 to	 the	 glucocorticoid	 receptor.	Glucocorticoids	 are	 involved	 in	
the	regulation	of	glucose	metabolism,	synthesised	in	the	adrenal	cortex,	but	their	
most	potent	 function	 is	 to	 reduce	 inflammation.	Tissue	 from	 the	adrenal	 gland	
was	 used	 to	 treat	 adrenal	 failure	 from	 as	 early	 as	 the	 1930’s.	 Research	 from	
Edward	Kendall	at	the	Mayo	Clinic,	and	Tadeusz	Reichstein	in	Zurich	suggested	
that	 it	 was	 not	 one	 single	 chemical	 (or	 cortical	 hormone)	 that	 exerted	 these	
effects,	 instead,	the	effect	was	caused	by	a	group	of	steroids	(Sternberg	&	Judd,	
2009)	 Early	 in	 the	 1940’s,	 it	 was	 understood	 that	 there	 were	 two	 types	 of	
steroids,	those	that	caused	sodium	and	fluid	retention	(mineralocorticoids)	and	
those	that	counteracted	shock	and	inflammation	(glucocorticoids)	(Neeck,	2002).	
In	 1948,	 the	 first	 glucocorticoid,	 cortisone,	 was	 administered	 to	 a	 patient	 by	




Much	 research	 has	 revolved	 around	 how	 glucocorticoids	 supress	 pro-




point	of	view,	however,	 they	may	result	 in	significant	side-effects	ranging	 from	
headaches	 and	 gastric	 ulcers,	 to	 life	 threatening	 immunosuppression	 (Strehl	&	
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Buttgereit,	 2016).	 It	was	historically	 thought	 that	 the	majority	of	 the	 effects	of	
glucocorticoids	resulted	from	the	direct	or	indirect	reduction	in	the	transcription	











the	 ‘annexin’	 repeat	 (a	 chain	 of	 around	 70	 amino	 acid	 residues),	 capable	 of	
binding	in	a	Ca2+	dependant	manner	to	negatively	charged	phospholipids	(Gerke	
&	 Moss,	 2002).	 ANXA1	 is	 a	 37-kDa	 protein	 comprising	 of	 a	 C-terminal	 core	
domain	containing	a	Ca2+/phospholipid	binding	site.	 	This	binding	site	contains	
four	 homologous	 repeats	 (numbered	 I	 –	 IV)	 of	 5	 α-helices	 each.	 This	 region	 is	
well	 conserved	 amongst	 all	 members	 of	 the	 annexin	 family;	 however,	 the	 N-
terminal	tail	varies	between	annexin	members.	It	is	this	specific	sequence	of	41	
amino	acids	 that	 gives	ANXA1	 its	unique	 function	 compared	 to	other	 annexins	
(Rosengarth	 et	 al.,	 2001).	 ANXA1	 is	widely	 distributed	 in	 numerous	 cell	 types	
including	the	endothelium,	cardiomyocytes,	glomerular	fibroblasts	and	platelets,	








Healthy	 volunteers	 administered	 glucocorticoids	 have	 increased	 ANXA1	
expression	 on	 circulating	 monocytes	 and	 neutrophils	 (Goulding	 et	 al.,	 1990).	
Interestingly,	ANXA1	levels	are	also	modulated	in	diseases	where	glucocorticoids	
levels	 are	 altered.	 In	 diseases	where	 cortisol	 is	 reduced,	 i.e.	 Addison’s	 disease,	
patients	exhibit	lower	levels	of	ANXA1	than	healthy	volunteers.	On	the	contrary,	
in	 diseases	 presenting	 with	 excessive	 cortisol	 levels,	 i.e.	 Cushing’s	 syndrome,	
ANXA1	 levels	 are	 elevated	 (Mulla	 et	 al.,	 2005).	 These	 data	 suggest	 that	 the	
regulation	 of	 ANXA1	 is	 under	 the	 control	 of	 the	 glucocorticoid	 receptor.	 	 The	
promoter	of	ANXA1	does	not	appear	to	have	a	canonical	glucocorticoid	response	
element,	however,	 it	has	a	partial	 consensus	binding-site	 for	 the	 IL-6	 response	





by	 which	 ANXA1	 is	 expressed	 upon	 dexamethasone	 stimulation	 of	 the	
macrophage	like	cell-line	U-937	(Solito	et	al.,	1991).		In	mature	macrophage-like	
U-937	cells,	there	were	no	time-dependant	effects	on	ANXA1	mRNA	production,	









neutrophils,	 thymocytes,	 fibroblasts	and	squamous	carcinoma	cells	 (D’Acquisto	
et	al.,	2008).	
	
ANXA1	 has	 a	 number	 of	 phosphorylation	 sites.	 	 The	 most	 notable	
phosphorylation	site	is	that	of	serine-27.		Early	experiments	using	mutant	clones	
proved	that	phosphorylation	of	this	site	is	needed	to	the	conformational	change	
allowing	 N-terminal	 domain	 release	 and	 for	 ANXA1	 membrane	 aggregation.	
Later	work	demonstrated	 that	PKC	catalysed	 the	phosphorylation	of	ANXA1	 in	
cultured	 rat	 mesangial	 cells	 in	 vitro,	 but	 only	 in	 the	 presence	 of	 Ca2	+	 and	
phospholipids.	However,	phospholipids	alone	were	not	sufficient	to	support	the	
phosphorylation.	 Further	 experiments	 on	 32P-labeled	 mesangial	 cells	
demonstrated	that	ANXA1	phosphorylation	was	increased	by	the	addition	of	PKC	
activators	such	as	angiotensin	II.	PKC	phosphorylation	of	ANXA1	is	essential	for	
both	 cellular	 export	 and	 biological	 activity.	 Interestingly,	 dexamethasone	
induced	 signaling	 that	 causes	 the	 translocation	 of	 a	 serine	 phosphorylated-
ANXA1	 to	 the	 cytoplasmic	 membrane	 of	 human	 folliculostellate	 cells.	 These	
results	suggest	that	glucocorticoids	induce	rapid	serine-27	phosphorylation	and	
membrane	 translocation	 of	 ANXA1	 via	 a	 novel	 glucocorticoid	 receptor-






Under	normal	physiological	 conditions,	ANXA1	 is	 stored	 in	granular	vesicles	of	







number	 of	 different	 mechanisms	 depending	 on	 the	 cell	 type,	 the	 most	 well	
studied	being	the	neutrophil.	ANXA1	can	be	rapidly	released	by	weak	activation	
signals,	 such	 as	 low	 concentrations	 of	 chemoattractants	 or	 upon	 adhesion	 to	
endothelial	 cell	monolayers	 (Perretti	 et	 al.,	 1996).	 	More	 often	 than	 not,	 these	
stimuli	result	in	ANXA1	relocating	to	the	outside	leaflet	of	the	plasma	membrane,	
where	 it	becomes	tethered	 in	a	Ca2+-dependent	manner	(Gerke	et	al.,	2005).	 In	














Upon	 cell	 activation,	 ANXA1	 can	 be	mobilised	 to	 the	 plasma	membrane	 and	 then	 secreted,	 or	
externalised	 in	 one	 of	 three	 mechanisms	 depending	 on	 the	 cell	 type	 involved.	 Mechanisms	
involve;	 through	 the	 activation	of	 the	ATP-binding	 cassette	 (ABC)	 transporter	 (1);	 through	 the	
phosphorylation	 of	 the	 serine-27	 residue	 followed	 by	 membrane	 localisation	 to	 specific	 lipid	
domains,	 before	 being	moved	 to	 the	 outer	 leaflet	 of	 the	 plasma	membrane	 to	 be	 secreted	 (2);	







functions,	 and	 ANXA1	 also	 plays	 an	 important	 role	 as	 intracellular	 mediator.	









bacterial	 and	 host	 cell-derived	 mitochondrial	 protein	 degradation),	 however,	
further	 research	 of	 the	 FPR	 receptors	 has	 identified	 a	 wide	 range	 of	 ligands,	
including	 endogenous	 acute	 phase	 response	 molecules	 (serum	 amyloid	 A),	
endogenous	 lipids	 (resolvin-D1,	 lipoxin	 A4)	 and	 pathogenic	 molecules	 (β-
amyloid)	(Le	et	al.,	2002).	 	To	date,	3	FPR	subtypes	have	been	characterised	 in	
humans:	FPR1,	FPR2	 (also	known	as	FPR	 like	1	or	FRPL-1,	 lipoxin	A4	 receptor	
and	FPR3,	all	of	which	have	a	wide	range	of	endogenous	and	exogenous	ligands,	
with	different	affinities	(Perretti,	2003).	However,	other	species	have	more	FPR	
subtypes,	 for	 example,	mice	 have	7.	 	 These	 receptors	 are	 expressed	on	 a	wide	
variety	of	cell	types,	but	are	more	abundant	on	immune	cells	such	as	leukocytes,	
neutrophils,	 but	 are	 also	 present	 on	 fibroblasts,	 endothelial	 cells,	 and	 stromal	
cells.	 It	 is	 now	 also	 clear	 that	 FPR’s	 are	 also	 expressed	 in	 the	 microvascular	
endothelium	(Solito	et	al.,	2008).	In	the	context	of	ANXA1	biology,	the	FPR2	has	
been	most	extensively	studied.	It	has	previously	been	demonstrated	that	ANXA1	










of	ANXA1	 is	 ‘buried’	 in	 the	core	domain.	 	When	extracellular	 concentrations	of	
calcium	exceed	1	mM,	and	upon	membrane	binding,	 the	 loop	of	repeat	III	 folds	
into	 the	D-helix	resulting	 in	a	conformational	change	of	ANXA1	(Figure	1.4A.B)	
(Rosengarth	 et	 al.,	 2001).	 This	 conformational	 change	 allows	 the	 hidden	 N-
























Annexin-A1	 has	 wide	 variety	 of	 biological	 effects	 ranging	 from	 cell-growth	
regulation,	 tumourigenesis,	 cell	 differentiation,	 and	 neuroendocrine	 regulation.	
The	majority	of	studies	have	focused	on	the	anti-inflammatory	effects	of	ANXA1	
in	 the	 periphery,	 and	 this	 research	 has	 been	 aided	 by	 the	 development	 of		
ANXA1-/-	mice.		These	mice	show	an	excessive	inflammatory	response	in	animal	
models	 of	 disease	 associated	 with	 inflammation.	 Moreover,	 the	 ability	 of	
glucocorticoids	 to	 reduce	 inflammation	 is	 attenuated	 in	 these	 mice.	 It	 is	 also	
important	 to	note	 that	ANXA1	has	been	shown	to	mimic	most,	 if	not	all,	of	 the	






phospholipase	 A2.	 These	 findings	 have	 also	 been	 confirmed	 in	 in	 vivo	 studies	
using	ANXA1-/-	mice;	during	 inflammatory	 conditions,	 demonstrating	 that	both	
PLA2	 expression	 and	 activity	 are	 decreased	 (McArthur	 et	 al.,	 2010).	 Other	
inducible	 enzymes	 are	 targets	 of	 ANXA1,	 including	 inducible	 cyclooxygenase-2	
(COX2)	 (Minghetti	 et	 al.,	 1999).	 COX-2	 is	 important	 in	 the	 conversion	 of	
arachidonic	 acid	 into	 pro-inflammatory	 mediators	 such	 as	 prostaglandins	
(Vishwanath	 et	 al.,	 1993)	 (De	 Caterina	 et	 al.,	 1993).	 Inducible	 nitric	 oxide	
synthase	is	also	regulated	by	ANXA1,	which	in	turn	is	involved	in	the	production	
of	 nitric	 oxide.	 ANXA1	 has	 the	 ability	 to	 directly	 and	 indirectly	 affect	 the	
production	 and	 release	 of	 other	 pro-inflammatory	 mediators	 including	
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Another	 striking	 feature	 of	 ANXA1	 biology	 is	 its	 potent	 ability	 to	 halt	 the	
migration	 and	 extravasation	 of	 leukocytes	 into	 inflamed	 tissue.	 Immune	 cells	
migrate	into	the	site	of	inflammation	in	a	highly	ordered	and	regulated	manner	
(Luscinskas	 et	 al.,	 1996).	 	 Firstly,	 endothelial	 cells	 at	 the	 site	 of	 inflammation	
cause	white	blood	cells	to	roll	in	a	process	mediated	by	selectins.	The	rolling	cells	
undergo	 firm	 adhesion	 and	 arrest,	 mediated	 by	 integrins,	 allowing	 the	 cell	 to	
undergo	 paracellular	 and	 transcellular	 extravasation	 into	 the	 site	 of	
inflammation.	 	 Interestingly,	 upon	 leukocyte-endothelium	 adhesion	 ANXA1	 is	
mobilised,	inhibiting	the	ability	of	neutrophils	to	adhere	and	transmigrate	to	the	
site	 of	 inflammation.	 Full	 length	 ANXA1	 and	 truncated	 ANXA1	 (Ac2-26)	 have	
differential	effects	on	these	processes;	full	 length	ANXA1	inhibits	firm	adhesion	









al.,	 2003).	These	 two	differing	anti-inflammatory	properties	 could	help	explain	
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why	 ANXA1	 and	 its	 truncated	 peptide	 are	 protective	 in	models	 of	 myocardial	
ischaemia-reperfusion	 injury	 (La	 et	 al.,	 2001)	 and	 stroke	 (Gavins,	 Granger,	 &	
Perretti,	2006),	as	large	immune	cell	infiltration	to	the	ischaemic	area	is	present	
upon	 reperfusion	 in	 both	 of	 these	models	 and	 contributes	 to	 the	 extension	 of	
infarct	size.	
	
It	 has	 also	 been	 suggested	 that	 ANXA1	 may	 negatively	 affect	 immune	 cell	
viability,	which	may	explain	some	of	 its	anti-inflammatory	properties,	and	may	
also	explain	how	glucocorticoids	potentially	elicit	their	potent	anti-inflammatory	
effects.	 	 ANXA1	 activates	 the	 caspase-3	 signalling	 pathway	 (Parente	 &	 Solito,	
2004),	which	is	highly	up-regulated	during	apoptosis.	Programmed	cell	death	is	
one	 of	 the	 mechanisms	 by	 which	 inflammatory	 cells	 mediate	 their	 anti-
inflammatory	actions	and	as	a	result	these	processes	tightly	regulated,	and	could	









exhibit	 significantly	 increased	 BBB	 permeability	 as	 a	 result	 if	 disrupted	 inter-
endothelial	 tight	 junctions.	 	 These	 findings	 support	 the	 view	 that	 ANXA1	
stabilises	 tight	 junction	 through	 the	 interaction	 with	 the	 actin	 cytoskeleton	
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(Cristante	et	al.,	2013).	 	 It	 is	also	 important	to	note	that	 in	 inflammatory	states	
BBB	 integrity	 is	 lost.	 Activation	 of	 FPR2	 by	 ANXA1	 inhibits	 the	 small	 GTPase	




Pharmacologically,	 ANXA1	 has	 been	 used	 in	 numerous	 models	 of	 acute	 and	
chronic	 inflammation.	 	 The	N-terminus	of	ANXA1,	 the	peptide	Ac2-26,	 reduces	
inflammation	and	tissue-injury	in	acute	models	of	inflammation	in	vivo,	including	
cardiac	 ischaemia-reperfusion	 injury	 (La	 et	 al.,	 2001)	 (Zhang	 et	 al.,	 2011),	
neutrophil-dependant	 oedema	 (Perretti	 et	 al.,	 1993)	 and	 antigen-induced	
arthritis	(Yang	et	al.,	2004).			Ac2-26	can	promote	locomotion	of	human	primary	
cells,	 peripheral	mono-nucleated	 cells	 and	monocytes;	 this	 effect	 is,	 at	 least	 in	
part,	due	to	a	chemokinetic	rather	than	chemotactic	effect	of	the	peptide.	These	
data	suggest	that	the	cleavage	of	ANXA1	and	the	consequent	generation	of	Ac2-
26	 during	 the	 resolution	 of	 inflammation	 may	 play	 an	 important	 role	 in	 the	
removal	of	blood-borne	cells	from	the	tissue.	Tissue	protective	effects	of	Ac2-26	
have	been	 reported	 to	be	mediated	primarily	 through	ERK,	but	not	 the	 JNK	or	
p38	pathways	 (Dalli	 et	 al.,	 2012).	 Thus,	Ac2-26	may	 enhance	 the	 resolution	 of	
inflammation,	 and	 delivery	 systems	 are	 in	 development	 to	 achieve	 sustained	
slow	 release	 and	 a	 longer	 half-life	 of	 Ac2-26.	 In	 an	 in	 vivo	 model	 of	 colitis,	










compared	 to	 full	 length	ANXA1	 (Solito	 et	 al.,	 2000).	 	 There	 is	 strong	 sequence	
homology	between	the	murine	and	human	ANXA1	peptide,	but	specifically,	there	
is	 near	 100%	 homology	 in	 the	 N-terminus.	 	 The	 full	 length	 peptide	 has	 been	
shown	 to	 be	 effective	 in	 treating	 acute	 inflammatory	 condition,	 but	 also	
prolonged	 treatment	 with	 the	 full	 length	 hrANXA1	 was	 able	 to	 reduce	
atherosclerotic	plaque	size	in	LDLR-/-	mice	on	a	high	fat	western	diet	(Kusters	et	
al.,	 2015a).	 This	 proof	 of	 concept	 study	 suggests	 that	 not	 only	 is	 prolonged	
treatment	 with	 ANXA1	 tolerated,	 but	 also	 that	 prolonged	 treatment	 does	 not	




To	 date	 little	 work	 has	 been	 conducted	 into	 ANXA1	 and	 diabetes.	 ANXA1	 is	
endogenously	expressed	in	the	islets	of	the	pancreas,	where	it	co-localises	with	
insulin	secretory	granules	(Ohnishi	et	al.,	1994),	and	ANXA1	has	been	suggested	
to	 influence	 glucose-stimulated	 insulin	 secretion	 in	 an	 autocrine	 or	 paracrine	
manner	 (Ohnishi	 et	 al.,	 1995).	 Extracellular	 ANXA1	 binding	 to	 a	 putative	 cell	
surface	receptor	increases	insulin	secretion	in	isolated	rat	pancreatic	islets.		In	a	
Ca2+	 independent	 fashion	 (Hong	et	al.,	2002).	However,	 insulin	secretion	 is	not	
altered	 when	 measured	 from	 pancreatic	 islets	 isolated	 from	 ANXA1-/-	 mice,	
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suggesting	 in	 the	acute	 control	of	 glucose-stimulated	 insulin	 release	by	ANXA1	
signalling	 is	 redundant	 (Rackham	 et	 al.,	 2016).	 	 More	 recently,	 it	 has	 been	
demonstrated	in	islet	graft	that	islet	cells	that	are	co-grafted	with	mesenchymal	











the	 protein	 containing	 the	 a	 phosphorylation	 site	 on	Tyrosine-21	 (Melki	 et	 al.,	
1994).	 	What	makes	 this	 function	 curious	 is	 that	 insulin-sensitive	 cells	 such	as	
hepatic	cells	or	differentiated	adipocytes	do	not	express	large	amounts	of	ANXA1	
(Karasik	 et	 al.,	 1988)	 (Wong	 etal.,	 1992).	 In	 contrast,	 endothelial	 cells	 contain	
high	contain	large	concentrations	of	ANXA1,	and	process	receptor-bound	insulin,	








HFD-induced	 insulin-resistance/type-2	diabetes	 in	mice	 (Akasheh	et	 al.,	 2013).	
Rand	et	al.	 discovered	 that	ANXA1-/-	mice	 fed	a	HFD	gained	more	 fat	mass	and	
had	 larger	 adipocyte	 size	 than	 their	 WT	 littermates	 fed	 the	 same	 diet,	 but	
critically	there	was	no	underlying	alteration	in	inflammation	arising	from	a	HFD	
compared	 to	 WT	 littermates,	 measured	 by	 a	 range	 of	 pro-inflammatory	
cytokines	 (IL-6,	 IL-1β	 and	 IL-10).	 One	 of	 the	 key	 drivers	 of	 secondary	
complications	 in	 animal	 models	 of	 T2DM	 is	 chronic	 low-grade	 inflammation;	
therefore,	 reducing	 the	 concentration	 of	 an	 anti-inflammatory	 molecule	 (e.g.	
ANXA1)	 may	 well	 exaggerate	 the	 problem.	 In	 an	 in	 vivo	 model	 of	 insulin	
resistance	(as	a	result	of	high	fat	diet)	Yoon	et	al.	 found	that	ANXA1	expression	
was	reduced	in	smooth	muscle	and	the	liver.	Similarly,	his	finding	was	confirmed	
in	 an	ex	vivo	 proteomic	 analysis	 of	 palmitate-induced	 insulin	 resistance,	which	
reported	 that	 both	 ANXA1	 and	 FPR2	 expression	 were	 decreased	 in	 smooth	
muscle	cells	(Yoon	et	al.,	2015).		Interestingly,	in	another	study,	mice	given	a	HFD	
exhibited	 increased	ANXA1	concentrations	 in	 adipose	 tissue	 compared	 to	mice	
given	a	normal	chow	diet.		This	study	demonstrated	macrophage	switching	from	
M1	to	M2	phenotype	within	 the	adipose	 tissue	 in	mice	 fed	on	HFD	mice,	when	
compared	to	control	chow	fed	mice.	This	suggests	that	ANXA1	may	up-regulate	
the	 number	 in	 M2	 (resolving)	macrophages	 aiding	 resolution	 of	 inflammation	




reporting	 that	 there	 is	a	strong	 inverse	relationship	between	 increased	weight,	




secreted	 form	 of	 ANXA1	 is	 inactivated,	 or	 that	 ANXA1	 expression	 is	 down-
regulated.	Furthermore,	Petrani	et	al.	compared	plasma	ANXA1	levels	in	patients	
with	T2DM	with	no	nephropathy	and	patients	with	T2DM	who	had	nephropathy.	




















The	 hypothesis	 of	 this	 thesis	 is	 that	 ANXA1	 play	 a	 key	 protective	 in	 diabetes.	
ANXA1	 is	 well	 known	 for	 its	 anti-inflammatory	 and	 pro-resolving	 actions	
therefore,	I	postulate	that	ANXA1	levels	may	be	modulated	in	diabetes	and	have	
an	 important	 function	 as	 an	 endogenously	produced	molecule.	 I	 postulate	 that	
AXNA1	maybe	 an	 endogenous	mediator	with	 protective	 properties	 against	 the	
development	of	microvascular	complications	in	diabetes.		Additionally,	ANXA1	is	
known	 to	play	 an	 important	 role	 in	 the	 regulation	of	 the	 tightness	of	 the	BBB,	



















There	 is	 a	 need	 for	 a	 better	 understanding	 of	 the	 pathophysiology	 of	 diabetes	





diabetes	 investigate	 the	 role	 of	ANXA1	 in	diabetes.	 Therefore	 the	 objectives	 of	
this	thesis	are:	
• To	measure	the	plasma	levels	of	ANXA1	in	patients	with	T1DM.	
• To	 investigate	 the	 role	of	 endogenous	ANXA1	 in	 the	pathophysiology	of	
type-1	diabetes	in	a	STZ-induced	model	of	type	1	diabetes	in	mice.		
• To	 investigate	 if	 endogenous	 AXNA1	 is	 protective	 against	 the	
development	 of	 microvascular	 complication	 (diabetic	 cardiomyopathy	
and	diabetic	nephropathy)	in	a	STZ-induced	model	of	T1DM	in	mice.	
• Investigate	 if	 prophylactic	 treatment	 with	 human	 recombinant	 ANXA1	
can	be	used	to	alter	the	diabetic	phenotype,	and	prevent	the	development	
of	microvascular	complications	in	a	STZ-induced	model	of	T1DM	in	mice.	
• Investigate	 if	 late	 therapeutic	 intervention	 with	 human	 recombinant	
ANXA1	after	microvascular	 complications	have	developed	 can	halt	 their	
progression	in	a	STZ-induced	model	of	T1DM	in	mice.	
• To	measure	the	plasma	levels	of	ANXA1	in	patients	with	T2DM.	




• To	 investigate	 if	 endogenous	 AXNA1	 is	 protective	 against	 the	
development	 of	microvascular	 complication	 (diabetic	 nephropathy)	 in	 a	
high-	fat	high-sugar	model	of	obesity	induced	T2DM.	
• Investigate	 if	 treatment	with	human	recombinant	ANXA1	can	be	used	to	
alter	 the	 diabetic	 phenotype,	 and	 prevent	 the	 development	 of	
microvascular	 complications	 in	 a	 high-	 fat	 high-sugar	 model	 of	 obesity	
induced	T2DM.	
• To	investigate	if	feeding	a	high-fat	high-sugar	diet	alters	the	permeability	
of	 the	 blood	 brain	 barrier,	 and	 how	 endogenous	 AXNA1	 regulated	 BBB	
integrity.		
• If	 treatment	 with	 hrANXA1	 to	 mice	 fed	 a	 high-fat	 high-sugar	 diet	 can	
restore	BBB	integrity	and	reduce	BBB	permeability.	
• To	investigate	if	feeding	a	high-fat	high-sugar	diet	alters	the	peripheral	T-


















































Type	 1	 diabetes	 is	 an	 autoimmune	 disease	 often	 diagnosed	 in	 childhood	
characterised	 by	 loss	 of	 insulin	 producing	 beta	 cells,	 which	 leads	 to	
hyperglycaemia	 (Atkinson,	 2012).	 Even	 with	 strict	 glycaemic	 control,	 using	
rigorous	 insulin	 management,	 microvascular	 complications	 including	 diabetic	
nephropathy	 (Papadopoulou-Marketou	 et	 al.,	 2016)	 and	 diabetic	
cardiomyopathy	(Bugger	&	Abel,	2014)	develop	over	time.	These	microvascular	
complications	 associated	 with	 diabetes	 are	 key	 drivers	 of	 morbidity	 (and	
ultimately	mortality)	and,	therefore,	put	a	significant	economic	burden	on	health	
care	providers.	DN	is	the	primary	cause	of	death	~20	%	of	patients	with	T1DM	
and	 cardiovascular	 disease,	 which	 includes	 diabetic	 cardiomyopathy,	 accounts	
for	~40	%	of	all	fatalities	in	T1DM	(Martín-Timón	et	al.,	2014).	Both	pathologies	
are	 characterised	 by	 an	 impairment	 in	 function	 (kidney:	 proteinuria	
(Bhattacharjee	 et	 al.,	 2016);	 heart:	 impairment	 in	 systolic	 contractility)	
(Niemann	et	al.,	2013)	caused	by	local	inflammation	(Downs	&	Faulkner,	2015)	
and	 loss	of	 survival	pathways	 (Rask-Madsen	&	King,	2013),	 the	 latter	of	which	
predisposes	tissues	to	injury.		
One	of	the	key	pathways	driving	both	DN	and	cardiomyopathy	are	hypertrophy.	
Previous	 studies	 have	 shown	 that	 the	 activation	 of	 the	 mitogen-associated	
protein	 kinase	 (MAPK)	 mediators	 (p38,	 JNK	 and	 ERK1/2)	 are	 key	 drivers	 of	
hypertrophy,	 fibrosis	 and	 localised	 inflammation.	 Previous	 studies	 have	






mediator	 with	 anti-inflammatory	 and	 pro-resolving	 activities	 (Flower	 &	
Blackwell,	 1979).	 	 The	 C-terminal	 core	 domain	 of	 ANXA1	 harbours	 three	
calcium-binding	 phospholipid	 domain,	 which	 is	 conserved	 amongst	 all	 family	
members,	 while	 the	 N-terminus	 varies,	 giving	 each	 family	 member	 its	 unique	
functionality	 (Rosengarth	 et	 al.,	 2001).	 We	 know	 that	 PKC	 is	 unregulated	 in	
diabetes	 and	 directly	 activated	 key	 effects	 kinase	 of	 the	 MAPK	 pathway.	
Additionally,	PKC	is	essential	for	the	phosphorylation	of	serine-27,	which	allows	
both	 the	 release	 of	 the	 N-terminus	 but	 also	 its	 release	 from	 its	 intracellular	
stores,	where	it	can	act	in	both	and	autocrine	and	paracrine	manner	to	elicit	its	
biological	effects.	
Endogenous	 ANXA1	 levels	 are	 modulated	 in	 many	 autoimmune	 diseases	
including	multiple	sclerosis	(Cristante	et	al.	2013),	cystic	fibrosis	(Bensalem	et	al.	
2005),	Crohn’s	disease	(Sena	et	al.,	2013)	and	rheumatoid	arthritis	(D	’acquisto	
et	 al.	 2008).	 While,	 human	 recombinant	 ANXA1	 (hrANXA1)	 or	 its	 N-terminal	
peptide	 (Ac2-26)	 have	 therapeutic	 benefits	 in	 many	 experimental	 models	 of	
chronic	 disease,	 including	 rheumatoid	 arthritis	 (Renshaw	 et	 al.,	 2010),	














therapeutic	 in	 T1DM	 is	 unknown.	 Therefore,	 this	 study	 was	 designed	 to	
investigate:	
(1)	 the	 plasma	 levels	 of	 endogenous	 ANXA1	 in	 patients	 with	 T1DM	
with/without	diabetic	nephropathy;		
(2)	the	role	of	endogenous	ANXA1	in	an	murine	model	of	T1DM	and	in	the	





(4)	 if	 therapeutic	 intervention	 with	 hrANXA1	 (after	 microvascular	
















in	 adherence	 to	 the	Declaration	of	Helsinki.	All	 subjects	 gave	written	 informed	
consent.	Patients	with	T1DM	were	recruited	from	the	Diabetes	Outpatient	clinic	
of	 Guy’s	 and	 St	 Thomas	 Hospitals	 (London)	 ethical	 committee	 number	
10/H0802/86.	 Healthy	 donors	 were	 recruited	 from	 the	 William	 Harvey	
Research	 Institute	 (London)	and	both	covered	by	ethical	approval.	Non-fasting	





for	 continued	 insulin	 therapy	 within	 3	 months	 of	 diagnosis.	 Patients	 with	
diabetic	nephropathy	(DN+)	had	a	documented	positive	history	of	early	morning	
urine	albumin	creatinine	ratio	 (ACR)	≥3.5	mg/mmol	on	 two	occasions,	arterial	
hypertension	 defined	 as	 treatment	 with	 on	 one	 or	 more	 anti-hypertensive	
agents	and/or	blood	pressure	(BP)	≥130/80	mmHg,	and	diabetic	retinopathy	(as	
proof	 of	 another	microvascular	 complication	 associated	with	 diabetes)	 but	 no	
other	 kidney	 or	 urinary	 tract	 disease.	 Patients	 without	 diabetic	 nephropathy	
(DN-)	had	a	history	of	normal	ACR	(<2.5	mg/mmol	in	men	and	<3.5	mg/mmol	in	
women),	 normal	 BP	 (<130/80	 mmHg)	 on	 no	 antihypertensive	 agents	 and	 a	
duration	 of	 diabetes	 exceeding	 20	 years.	 All	 patients	 had	 preserved	 renal	









The	 animal	 protocols	 followed	 in	 this	 study	 were	 approved	 by	 the	 Animal	
Welfare	Ethics	Review	Board	(AWERB)	of	Queen	Mary	University	of	London	 in	
accordance	 with	 the	 derivatives	 of	 both	 the	 Home	 Office	 guidance	 on	 the	
Operation	 of	 Animals	 (Scientific	 Procedures	 Act	 1986)	 published	 by	 Her	
Majesty’s	 Stationery	 Office	 and	 the	 Guide	 for	 the	 Care	 and	 Use	 of	 Laboratory	
Animals	 of	 the	 National	 Research	 Council.	 All	 research	was	 conducted	 project	
licenses	 reference	 numbers	 PPL:	 70/8350.	 This	 study	 was	 carried	 out	 on	 ten	
week-old	 male	 C57BL/6	 mice	 and	 ANXA1-/-	 mice,	 weighing	 25–30	 g	 (Charles	
River	Laboratories	UK	Ltd.,	Kent,	UK).	The	animals	were	allowed	to	acclimatise	
to	 laboratory	 conditions	 for	 a	 period	 of	 at	 least	 one	 week	 before	 any	





mice	 using	 streptozotocin	 (45	 mg/kg	 i.p.	 in	 0.9	 M	 citrate	 buffer)	 for	 5	
consecutive	days	while	sham	mice	received	vehicle	only	(0.9	M	citrate	buffer	i.p.)	
for	 5	 consecutive	 days.	 Mice	were	 deemed	 diabetic	 if	 blood	 glucose	 level	 was	
>	12	mmol/L;	 blood	 glucose	 level	 was	 determined	 from	 blood	 taken	 from	 the		








Mice	were	 randomly	 assigned	 treatment	 group	 and	 administered	 hrANXA1	 (1	
ug,	 100	 µl,	 Hepes	 50mM;	 140	mM	 NaCl;	 pH	 7.0,	 i.p.)	 or	 while	 vehicle	 100	 µl,	
Hepes	 50mM;	 140	mM	 NaCl;	 pH	 7.0,	 i.p.).	 Previous	 studies	 in	 both	 acute	 and	





Briefly,	mice	were	 fasted	 for	16	h	prior	 to	 testing.	Then	given	an	oral	bolus	of	
glucose	(1	g/kg,	H2O),	blood	glucose	(tail	vein	puncture)	was	measured	at	15	min	




Cardiac	 function	was	assessed	 in	mice	by	echocardiography	 in	vivo.	At	weeks	7	
and/or	 13	 after	 STZ	 induction	 of	 diabetes,	 anesthesia	 was	 induced	 with	 3%	
isoflurane	 and	 maintained	 at	 0.5	 to	 0.7%	 for	 the	 duration	 of	 the	 procedure.	
Before	assessment	of	cardiac	function,	mice	were	allowed	to	stabilise	for	at	least	
10	min.	During	echocardiography,	the	heart	rate	was	obtained	from	ECG	tracing	
and	 the	 temperature	 was	 monitored	 with	 a	 rectal	 thermometer.	 Two-





using	 a	 Vevo-770	 imaging	 system	 (VisualSonics,	 Toronto,	 Ontario,	 Canada).	
Fractional	 area	 change	 (FAC)	 was	 assessed	 from	 two-dimensional	 trace	 of	 B-
mode		(Figure	2.1A	and	B)	by	tracing	the	LV	in	the	parasternal	short	axis	at	the	
level	of	the	papillary	muscle	and	the	measurement	is	derived	using	the	Equation	






Figure	 2.1.	 Typical	 echocardiograph	 M-mode	 and	 B-mode	 traces	 showing	 where	
measurements	were	taken.	
A	and	B)	Show	typical	B-mode	traces	in	diastolic	and	systolic	phase	respectfully.	Measurement	of	
FAC	are	 calculated	by	measuring	around	 the	 left	 ventricle	 in	B)	diastolic	C)	 systolic	phases.	A)	
Shows	 a	 typical	 M-mode	 trace	 from	 which	 EF	 and	 FS	 are	 assessed	 using	 3	 measurements	
between;	 intraventricular	 septum	 (IVS);	 left	 ventricle	 internal	 dimension	 (LVID)	 and	 left	























𝐹𝐴𝐶 = 100 ×  
𝐿𝑉 𝑒𝑛𝑑 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑎𝑟𝑒𝑎 − 𝐿𝑉 𝑒𝑛𝑑 𝑠𝑦𝑠𝑡𝑜𝑙𝑖𝑐 𝑎𝑟𝑒𝑎
𝐿𝑉 𝑒𝑛𝑑 𝑑𝑖𝑎𝑠𝑡𝑜𝑙𝑖𝑐 𝑎𝑟𝑒𝑎 	
Equation	1:	Equation	for	calculation	of	fractional	area	change.	
Fractional	 area	 change	 is	 calculated	 using	 two	 measurements	 a)	 left	 ventricular	 end-diastolic	
area	and	b)	left	ventricular	end-systolic	area.	
𝐸𝐹 = 100 ×  
𝐿𝑉𝐼𝐷 (𝑑)! − 𝐿𝑉𝐼𝐷 (𝑠)!
 𝐿𝑉𝐼𝐷 (𝑑)! 	
Equation	2:	Equation	for	calculation	of	ejection	fraction.	
Ejection	 fraction	 is	 calculated	 using	 left	 ventricular	 internal	 dimension	 in	 both	 diastolic	 and	
systolic	phases.	
	
𝐹𝑆 = 100 ×  
𝐿𝑉𝐼𝐷 𝑑 − 𝐿𝑉𝐼𝐷(𝑠)
 𝐿𝑉𝐼𝐷 (𝑑) 	
Equation	3:	Equation	for	calculation	of	fractional	shortening.	





In	 the	 last	week	of	 the	 study,	mice	were	placed	 in	metabolic	 cages	 for	24	h	 to	
collect	urine.	Urinary	creatinine	and	sodium	was	measured	in	a	blinded	fashion	
by	 a	 commercial	 veterinary	 testing	 laboratory	 (IDEXX	 Ltd,	 West	 Sussex,	 UK).		
Creatinine	 clearance	 was	 calculated	 using	 Equation	 4	 and	 was	 used	 as	 a	
measurement	 of	 renal	 filtration	 rate.	 	 Urinary	 albumin	 was	measured	 using	 a	
mouse	albumin	ELISA	kit	as	per	manufacturers	instructions	(Bethyl	Laboratories	
Inc.,	 USA)	 and	 proteinuria	 was	 calculated	 using	 urinary	 albumin-to-creatinine	







𝑈𝑟𝑖𝑛𝑒 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒   
𝑆𝑒𝑟𝑢𝑚 𝐶𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒  ×  
𝑈𝑟𝑖𝑛𝑒 𝑣𝑜𝑙𝑢𝑚𝑒









ACR	 is	 calculated	by	 using	2	measurements	 a)	 urine	 albumin	 (mg/dL)	 and	b)	 urine	 creatinine	
(mg/dL).	
	
𝐹𝑟𝑎𝑐𝑡𝑖𝑜𝑛𝑎𝑙 𝐸𝑥𝑐𝑟𝑒𝑡𝑖𝑜𝑛 𝑜𝑓 𝑆𝑜𝑑𝑖𝑢𝑚 =
𝑈𝑟𝑖𝑛𝑒 𝑠𝑜𝑑𝑖𝑢𝑚 ÷ 𝑆𝑒𝑟𝑢𝑚 𝑆𝑜𝑑𝑖𝑢𝑚
 𝑈𝑟𝑖𝑛𝑒 𝐶𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 ÷ 𝑆𝑒𝑟𝑢𝑚 𝐶𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒	
Equation	6:	Equation	for	the	calculation	of	Fractional	excretion	of	Sodium	(FENa+).	







was	 measured	 immediately	 using	 a	 glucometer	 (Accu-Chek	 Compact	 System;	
Roche	Diagnostics,	Switzerland).	Organs	were	harvested	and	a	section	of	kidney	
and	heart	was	snap	 frozen	and	put	 in	 long-term	storage	 for	 further	processing	
and	 a	 section	was	 of	 kidney	was	 fixed	 in	 10	%	 neutral-buffered	 for	 48	 h	 and	
transferred	 to	 70	 %	 ethanol	 for	 long	 term	 storage.	 Blood	 was	 collected	 and	










A	homemade	 sandwich	ELISA	was	used	 to	measure	 serum	and	 tissue	 levels	 of	
ANXA1.	 Briefly,	 ELISA-treated	 plates	 (Nunc	 MaxiSorp,	 ThermoScientific,	 UK)	
were	 incubated	 overnight	with	 capture	 antibody	 20µg/ml	 (mouse	monoclonal	
antibody,	 generated	 in	 house)	 in	 bicarbonate	 buffer	 (25	 mM	 NaHCO3,	 25	 mM	
Na2CO3,	pH	9.6).	The	plate	was	then	washed	3	times	with	bicarbonate	buffer	and	
blocked	 in	 blocking	 buffer	 (0.1	%	BSA,	 PBS)	 for	 1	 h	 at	 37	 °C.	 	 Then	 100	 µl	 of	
sample	 and	 standard	 in	 assay	 diluent	 (Tween-20	 0.05	 %	 (v/v),	 PBS)	 where	
loaded	 and	 incubated	 for	 1	 h	 at	 37	 °C,	 then	washed	 5	 times	with	wash	 buffer	
(0.9%	 (w/v)	NaCl,	 0.05	%	 (v/v)	 Tween-20,	 dH2O).	 Following	 this	wells	where	
incubated	 with	 1µg/ml	 of	 detecting	 antibody	 (rabbit	 polyclonal	 anti-
ANXA1;Invitrogen,	 UK)	 for	 1	 h	 at	 37	 °C.	 	 After	 5	 washes,	 immuno-complexes	
were	 detected	 by	 adding	 the	 goat-anti-rabbit	 IgG	 with	 conjugated	 alkaline	
phosphatase	for	30	min.		After	5	washes,	the	substrate,	p-Nitrophenyl	phosphate	
(Sigma	Aldrich,	UK)	was	added	and	left	for	30	min	for	full	development	of	colour.	
The	 plate	was	 then	 read	 absorbance	 at	 405	 nm	 and	 corrected	 at	 540	 nm	 as	 a	













samples	 were	 homogenised	 and	 centrifuged	 at	 4000	 RPM	 for	 5	 min	 at	 4	 °C.	
Supernatants	were	removed	and	centrifuged	at	14,000	RPM	at	4	°C	for	40	min	to	
obtain	the	cytosolic	fraction.	The	pelleted	nuclei	were	re-suspended	in	extraction	
buffer	 and	 centrifuged	 at	 14,000	 RPM	 for	 20	 min	 at	 4	 °C.	 The	 resulting	
supernatants	 containing	 nuclear	 proteins	were	 carefully	 removed,	 and	 protein	
content	 was	 determined	 on	 both	 nuclear	 and	 cytosolic	 extracts	 using	 a	
bicinchoninic	 acid	 (BCA)	protein	 assay	 following	 the	manufacturer’s	 directions	
(Therma	Fisher	Scientific,	Rockford,	IL).	Proteins	were	separated	by	8	%	sodium	
dodecyl	sulphatepolyacrylamide	gel	electrophoresis	(SDS-PAGE)	and	transferred	



























rabbit	 anti-ANXA1	 (37	 kDa);	 rabbit	 anti-total	 Akt;	mouse	 anti-pAkt	 rabbit	 (63	
kDA);	anti	β-actin	(42	kDa).	Bands	where	checked	against	their	molecular	weight	
using	a	 rainbow	 ladder	 (Invitrogen,	UK)	 to	ensure	positive	 identification.	Blots	




of	 the	 bands	 was	 performed	 using	 the	 Gel	 Pro	 Analyser	 4.5,	 2000	 software	





Formulin	 fixed	 kidney	 samples	 were	 embedding	 in	 paraffin	 and	 processed	 to	
obtain	 4	 μm	 sections.	 After	 deparaffinisation	 and	 rehydrated	 through	 graded	
alcohols	to	distilled	water.		
Periodic	 Acid	 Schiffs:	 The	 sections	 were	 then	 incubated	 with	 saturated	 in	
Periodic	Acid	Schiff’s	(Sigma,	UK)	solution	for	30	min	washed	in	distilled	water	
and	counterstained	with	Harris	hematoxylin	(Sigma,	UK).		
Picrosirius	 Red:	 The	 sections	 were	 treated	 with	 phosphomolybdic	 acid	






then	 immediately	 immersed	 in	 hydrochloride	 acid	 for	 2	 min	 (Polysciences,	
Warrington,	PA).		
In	 both	 cases	 sections	 were	 then	 dehydrated	 through	 graded	 alcohols	 and	
cleared	 before	 mounting	 with	 coverslips.	 Images	 were	 acquired	 using	 a	
NanoZoomer	Digital	Pathology	Scanner	 (Hamamatsu	Photonics	K.K.	 Japan)	and	
analysed	using	the	NDP	Viewer	software.	The	diameters	of	20	randomly	selected	
glomeruli	 were	measured	 in	 all	 kidneys	 at	magnification	 	 (200×)	 in	 a	 double-
blinded	 manner.	 Additionally	 10	 randomly	 selected	 fields	 of	 view	 from	 each	
kidney	 were	 used	 to	 assess	 structural	 alteration	 of	 the	 proximal	 convoluted	
tubules	at	magnification		(40×)	in	a	double-blinded	manner.	Percentage	of	Sirius	
Red	 positive	 staining	 was	 calculated	 using	 ImageJ	 software	 in	 10	 randomly	









































































2.3.2	 The	 effect	 of	 treatment	 with	 hrANXA1	 on	 STZ-induced	 diabetes	
mellitus.	
	










































































































































To	 understand	 whether	 endogenous	 ANXA1	 levels	 are	 modulated	 in	 T1DM	 a	
sandwich	 ELISA	 was	 preformed	 on	 plasma	 from	 healthy	 donors	 and	 patient’s	
with	 T1DM	 with/without	 diabetic	 nephropathy.	 Compared	 to	 healthy	 donors,	
patients	 with	 diabetes	 with/without	 nephropathy	 had	 significantly	 elevated	
levels	of	plasma	ANXA1	(Figure2.5A,	P<0.05).	There	was	no	significant	difference	
in	 age	 and	 sex	 between	 groups	 (Table	 1).	 The	 patients	 with	 T1DM	 plus	




inflammation.	 When	 compared	 to	 patients	 with	 T1DM	 and	 no	 nephropathy,	



















with	T1DM	without	 diabetic	 nephropathy	 and	patients	with	T1DM	with	 diabetic	 nephropathy.	




























Patients	(n)	 20	 20	 22	
Sex	(F	%)	 9(45)	 13(65)	 11(50)	
Age	(year)	 48.3±1.9	 42.2±2.2	 54.5±2.3	
Diabetic	duration	
(year)	 n/a	 30.5±2.2	 38.7±2.1	*	
Creatinine	(mmol/L)	 n/a	 64.9±3.2	 93.7±1229*	
BMI	(kg/m2)	 n/a	 26.8±0.9	 26.3±0.8	










ANXA1	 levels	 (A)	 and	 CRP	 (B)	 were	 measured	 by	 sandwich	 ELISA	 in	 patient	 plasma.	 Groups	
analysed:	 Healthy	 donors	 (n=20),	 patients	 with	 T1DM	 without	 diabetic	 nephropathy	 (type	 1	





























































2.4.2.	 Correlation	 of	 BMI	 and	 CRP	 with	 AXNA1	 in	 patients	 with	 type-1	
diabetes.	
	
Here	 I	demonstrate	 that	 there	 is	no	significant	correlation	between	with	either	
body	 mass	 index	 (Figure	 2.6A,	 ns)	 or	 plasma	 CRP	 (a	 marker	 of	 systemic	
inflammation)	 (Figure	 2.6B,	 ns)	 with	 plasma	 ANXA1	 levels	 in	 patients	 with	
T1DM	with	or	without	diabetic	nephropathy.	Additionally	 in	our	patient	cohort	



































































































compared	 to	 sham	 WT-mice,	 WT-mice	 challenged	 with	 STZ	 demonstrated	 no	
significant	difference	in	serum	ANXA1	levels	(Figure	2.7A,	ns).		When	compared	
to	 WT-sham	 mice,	 WT-mice	 challenged	 with	 STZ	 demonstrated	 a	 significant	





































































































returned	 to	baseline	within	60	min	 (Figure	2.8A).	Similarly,	ANXA1-/	mice	 (not	




When	 WT	 mice	 that	 had	 been	 challenged	 with	 STZ	 (45	 mg/kg,	 0.1	 M	 citrate	
buffer,	i.p.	for	5	days)	and	then	challenged	with	glucose	13	weeks	later	resulted	
in	 a	 rise	 in	 blood	 glucose	 from	 9.8	mmol/L	 (fasting	 baseline)	 to	 27.6	mmol/L	















with	STZ	demonstrated	a	 significant	 increase	 in	AUC	 for	blood	glucose	 (Figure	










































































WT + vehicle 
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ANXA1 -/- + STZ






























nephropathy.	 Markers	 of	 renal	 function	 were	 assessed	 from	 serum	 and	 urine	
collected	13	weeks	post	STZ	administration.	When	compared	to	sham	WT-mice,	
WT	 mice	 challenged	 with	 STZ	 demonstrated	 a	 significant	 increase	 in	 the	
albumin-to-creatinine	 ratio	 (ACR)	 (Figure	 2.9A,	 P<0.001),	 suggesting	 the	
development	of	proteinuria.	 	Similarly,	when	compared	to	sham	ANXA1-/-	mice,	
ANXA1-/-	mice	 challenged	with	 STZ	 demonstrated	 a	 significant	 increase	 in	 the	
ACR	(Figure	2.9A,	P<0.001),	suggesting	an	increase	in	proteinuria.	Most	notably,	
the	degree	of	proteinuria	was	greater	in	ANXA1-/-	mice	challenged	with	STZ	than	
in	 WT	 mice	 challenged	 with	 STZ	 (Figure	 2.9A,	 P<0.001),	 suggesting	 that	




a	 significant	 increase	 in	 serum	 urea	 (Figure	 2.9B,	 P<0.001),	 suggesting	 the	
presence	of	renal	dysfunction.		Similarly,	when	compared	to	sham	ANXA1-/-	mice,	
ANXA1-/-	mice	challenged	with	STZ	demonstrated	a	significant	increase	in	serum	
urea	 (Figure	2.9B,	P<0.001).	There	was	no	significant	difference	 in	 serum	urea	








demonstrated	 a	 significant	 increase	 in	 creatinine	 clearance,	 suggesting	 renal	
hyperfiltration	(Figure	3C,	P<0.005).		Similarly,	when	compared	to	sham	ANXA1-
/-,	 ANXA1-/-	 mice	 challenged	 with	 STZ	 demonstrated	 a	 significant	 increase	 in	
creatinine	 clearance	 (Figure	 3C,	 P<0.005).	 	 When	 compared	 to	 WT	 mice	 not	













Figure	 2.9.	 Changes	 in	 renal	 function	 in	 WT	 and	 ANXA1-/-	 mice	 in	 a	 model	 of	 type-1	
diabetes	mellitus.	
Measurements	 of	 renal	 function	 in	 wild-type	 and	 ANXA1-/-	 mice:	 urine	 albumin-to-creatinine	
ratio	(A);	serum	urea	(B);	and	creatinine	clearance	(C),	measured	from	serum	and	urine	at	week	
13	post	 STZ	administration.	Experimental	 groups:	WT	+	vehicle	 (0.1	M	citrate	buffer,	 i.p.	 for	5	
days);	WT	+	STZ	(45	mg/kg,	0.1	M	citrate	buffer,	i.p.	for	5	days);	ANXA1-/-	+	vehicle	(0.1	M	citrate	











































































2.4.6	 The	 effect	 of	 endogenous	 ANXA1	 on	 tubular	 function	 in	 a	 murine	
model	of	STZ-induced	type-1	diabetes	mellitus.		
	
Tubular	 function	 was	 assessed	 by	 measured	 the	 fraction	 excretion	 of	 sodium	
from	 serum	 and	 urine	 samples	 collected	 13	 weeks	 post	 STZ	 administration.	
When	compared	to	sham	WT-mice,	WT	mice	challenged	with	STZ	demonstrated	
a	 significant	 increase	 in	 the	 fractional	 excretion	 of	 sodium	 (Figure	 2.10A,	
P<0.001),	 suggesting	 an	 increase	 in	 tubular	 dysfunction.	 	 Similarly,	 when	




2.10A,	 P<0.001),	 suggesting	 that	 endogenous	 ANXA1	 limited	 the	 degree	 of	
tubular	dysfunction	associated	with	STZ	challenge.		
	
Tubular	 dysfunction	 can	 be	 observed	 histologically	 by	 visualising	 the	 brush	
borders	of	the	convoluted	proximal	tubules	using	Periodic	Acid	Schiff’s	staining,	
which	 stains	 the	 of	 the	 basal	 lamina.	 Sham	WT	 mice	 show	 no	 morphological	
alterations	 in	 their	 tubule	 structures,	 which	 include	 well-preserved	 brush	
borders	 in	 the	 S1-S2	 of	 the	 proximal	 convoluted	 tubules	 (Figure	 2.10A).	
However,	 WT	 mice	 challenged	 with	 STZ	 demonstrated	 some	 morphological	
alteration	including	tubular	dilation,	and	a	distinctive	 loss	of	the	brush	borders	
in	 the	 S1-S2	 segment	 of	 the	 proximal	 convoluted	 tubules	 (Figure	 2.10B).		
Similarly,	 sham	ANXA1-/-	mice	 also	 show	no	morphological	 alterations	 in	 their	






































































Figure	 2.10.	 Changes	 in	 tubular	 function	 WT	 and	 ANXA1-/-	 mice	 in	 a	 model	 of	 type-1	
diabetes	mellitus.	Measurements	 of	 renal	 function	 in	wild-type	 and	ANXA1-/-	mice:	 fractional	
excretion	of	sodium	measured	from	serum	and	urine	(A)	and	Periodic	acid	Schiff’s	staining	of	the	



































2.4.7.	 The	 effect	 of	 endogenous	 ANXA1	 on	 glomerular	 hypertrophy	 in	 a	
murine	model	of	STZ-induced	type-1	diabetes	mellitus.		
	
	A	 classical	 hallmark	of	 diabetic	 nephropathy	 is	 hypertrophy;	 to	determine	 the	
extent	 of	 glomerular	 hypertrophy	 Periodic	 Acid	 Schiff’s	 staining	 was	 used	 to	
stain	 the	 basal	 lamina	 around	 the	 glomerulus,	 so	 glomerular	 area	 could	 be	
calculated.	 	 	 When	 compared	 to	 sham	 WT-mice	 (Figure	 2.11A),	 WT	 mice	
challenged	 with	 STZ	 demonstrated	 a	 significant	 increase	 in	 glomerular	 area	
(Figure	 2.11B/E,	 P<0.05),	 suggesting	 the	 development	 of	 glomerular	
hypertrophy.	 	Similarly,	when	compared	to	sham	ANXA1-/-	mice	(Figure	2.11C),	
ANXA1-/-	 mice	 challenged	 with	 STZ	 demonstrated	 a	 significant	 increase	 in	
glomerular	area	(Figure	3D/E,	P<0.001).	Most	notably,	the	degree	of	glomerular	
hypertrophy	was	greater	in	ANXA1-/-	mice	challenged	with	STZ	than	in	WT	mice	



















































































Another	 classical	 hallmark	 of	 diabetic	 nephropathy	 is	 interstitial	 fibrosis.	 To	
determine	 the	 extent	 of	 renal	 fibrosis	 Sirius	 Red	 staining	 was	 used	 to	 stain	
collagen	I	and	III	fibres.			When	compared	to	sham	WT-mice	(Figure	2.12A),	WT	
mice	 challenged	 with	 STZ	 demonstrated	 a	 significant	 increase	 in	 Sirius	 Red	
staining	 (Figure	 2.12B/E,	 P<0.01),	 suggesting	 the	 development	 of	 renal	
interstitial	 fibrosis.	 	 Similarly,	 when	 compared	 to	 sham	ANXA1-/-	mice	 (Figure	
2.12C),	ANXA1-/-	mice	challenged	with	STZ	demonstrated	a	significant	Sirius	Red	
staining	(Figure	2.12D/E,	P<0.001).	Most	notably,	the	degree	of	renal	interstitial	































































































diabetes,	 left	 ventricular	 function	 was	 assessed	 using	 echocardiography	 13	
weeks	 post	 STZ	 administration.	 When	 compared	 to	 sham	 WT-mice,	 WT	 mice	
challenged	 with	 STZ	 demonstrated	 significant	 reductions	 in	 ejection	 fraction	
(Figure	 2.14A,	 P<0.001),	 fractional	 shortening	 (Figure	 2.14B,	 P<0.001)	 and	
fractional	 area	 change	 (Figure	2.14C,	P<0.0001),	 indicating	 the	development	of	
systolic	dysfunction.		Similarly,	when	compared	to	sham	ANXA1-/-,	ANXA1-/-	mice	
challenged	 with	 STZ	 demonstrated	 significant	 reductions	 in	 ejection	 fraction	
(Figure	 2.14A,	 P<0.0001),	 fractional	 shortening	 (Figure	 2.14B,	 P<0.0001)	 and	
fractional	 area	 change	 (Figure	 2.14C,	 P<0.001).	 	 Most	 notably	 the	 degree	 of	






















Figure	 2.14.	 Changes	 in	 cardiac	 function	 in	WT	 and	 ANXA1-/-	mice	 in	 a	model	 of	 type-1	
diabetes	mellitus.	
Measurements	 of	 cardiac	 function	 in	WT	 and	 ANXA1-/-	 mice:	 ejection	 fraction	 (A);	 fractional	




























































































significant	 increase	 in	 intra	 ventricular	 diameter	 (Figure	 2.15A/E,	 P<0.05),	
suggesting	the	development	of	cardiac	hypertrophy.	 	Similarly,	when	compared	
to	 sham	 ANXA1-/-	 mice	 (Figure	 2.15C),	 ANXA1-/-	 mice	 challenged	 with	 STZ	
demonstrated	 a	 significant	 increase	 in	 intra	 ventricular	 diameter	 (Figure	
2.15D/E,	P<0.05).	However,	the	degree	of	cardiac	hypertrophy	between	WT	and	





































Measurements	 of	 cardiac	 hypertrophy	 in	 WT	 and	 ANXA1-/-	 mice:	 intra	 ventricular	 septum	






































2.4.11.	 Effect	 of	 endogenous	ANXA1	 on	 phosphorylation	 of	 p-38,	 JNK	 and	
ERK1/2	 in	 kidneys	 from	 mice	 subjected	 to	 STZ-induced	 type-1	 diabetes	
mellitus.	
	
The	 potential	 underlying	 mechanisms	 behind	 the	 observed	 renal	 dysfunction	











with	 STZ	 exhibited	 a	 significant	 increase	 in	 the	 phosphorylation	 of	 p38	 on	
Thr180/Thr182	 (Figure	 2.15A,	 P<0.01),	 JNK	 on	 Thr183/Tyr185	 (Figure	 2.15B,	
P<0.0001)	 and	 ERK1/2	 on	 Tyr	 202	 /Tyr204	 (Figure	 2.15C,	 P<0.0001).	 	 When	
compared	 to	WT	mice	 challenged	with	 STZ,	 kidney	 tissue	 from	 ANXA1-/-	mice	
challenged	 with	 STZ	 exhibited	 increased	 levels	 of	 phosphorylation	 of	 p38	 on	








from	 ANXA1-/-	 mice	 not	 challenged	 with	 STZ	 exhibited	 elevated	 levels	 of	
phosphorylation	of	p38	on	Thr180/Thr182,	JNK	on	Thr183/Tyr185,	although	these	3-	




































corrected	 to	 total	 p38	 and	 normalised	 using	 the	WT	 +	 vehicle	 band	 (A);	 phosphorylated	 JNK	
(pThr183/Thr185)	 corrected	 to	 total	 JNK	 and	 normalised	 using	 the	WT	 +	 vehicle	 band	 (B);	 and	





















































































































When	 compared	 to	WT	mice	 not	 challenged	with	 STZ,	 kidneys	 from	WT	mice	
challenged	with	 STZ	 exhibited	 a	 significant	 decrease	 in	 the	phosphorylation	 of	


















































of	 bands	 is	 expressed	 as	 a	 relative	 optical	 density	 (O.D.)	 of	 phosphorylated	 Akt	 (pSer473)	
corrected	to	total	Akt	and	normalised	using	the	WT	+	vehicle	band.	Experimental	groups:	WT	+	

























































with	 STZ,	 hearts	 from	 WT	 mice	 challenged	 with	 STZ	 exhibited	 a	 significant	
increase	in	the	phosphorylation	of	p38	on	Thr180/Thr182	(Figure	2.17A,	P<0.05),	
JNK	 on	 Thr183/Tyr185	 (Figure	 2.17B,	 P<0.05),	 and	 ERK1/2	 on	 Thr202	 /Tyr204	




ANXA1-/-	 mice	 challenged	 with	 STZ	 exhibited	 a	 significant	 increase	 in	 the	
phosphorylation	 of	 p38	 on	 Thr180/Thr182	 (Figure	 2.17A,	 P<0.001),	 JNK	 on	
Thr183/Tyr185	 (Figure	 2.17B,	 P<0.0001),	 and	 ERK1/2	 on	 Thr202	/Tyr204	(Figure	
2.17A,	P<0.0001).		When	compared	to	WT	mice	challenged	with	STZ,	hearts	from	
ANXA1-/-	mice	 challenged	 with	 STZ	 demonstrated	 a	 significant	 increase	 in	 the	
phosphorylation	 of	 p38	 on	 Thr180/Thr182	 (Figure	 2.17A,	 P<0.001),	 JNK	 on	









phosphorylation	 of	 p38	 on	 Thr180/Thr182	 (Figure	 2.17A,	 P<0.01),	 JNK	 on	

































bands	 is	 expressed	 as	 a	 relative	 optical	 density	 (O.D.)	 of	 phosphorylated	 p38	 (pThr180/Thr182)	
corrected	 to	 total	 p38	 and	 normalised	 using	 the	WT	 +	 vehicle	 band	 (A);	 phosphorylated	 JNK	




5	 days)	 and	 ANXA1-/-	 +	 STZ	 (45	 mg/kg,	 0.1	 M	 citrate	 buffer,	 i.p.	 for	 5	 days).	 Representative	
images	from	one	of	three	repeated	experiments	are	shown	in	this	Figure.	Data	analysed	by	a	one-










































































































When	 compared	 to	 WT	 mice	 not	 challenged	 with	 STZ,	 hearts	 from	 WT	 mice	
challenged	with	 STZ	 exhibited	 a	 significant	 decrease	 in	 the	phosphorylation	 of	
Akt	on	Ser473	(Figure	2.18A,	P<0.01).		Similarly,	when	compared	to	ANXA1-/-	mice	



























































/-	 +	 vehicle	 (0.1	M	 citrate	 buffer,	 i.p.	 for	 5	 days)	 and	ANXA1-/-	 +	 STZ	 (45	mg/kg,	 0.1	M	 citrate	
buffer,	i.p.	for	5	days).	Representative	images	from	one	of	three	repeated	experiments	are	shown	























































underlying	 diabetic	 phenotype,	 measurements	 were	 taken	 13	 weeks	 post	 STZ	
administration.	 When	 compared	 to	 sham	WT-mice,	 WT-mice,	 challenged	 with	
STZ	 demonstrated	 a	 significant	 decrease	 in	 serum	 insulin	 (Figure	 2.19A,	
P<0.0001),	and	a	significant	 increase	in	non-fasted	blood	glucose	 levels	(Figure	
2.19B,	 P<0.01).	 	 When	 compared	 to	 WT-mice	 challenged	 with	 STZ,	 WT-mice	
challenged	 with	 STZ	 and	 treated	 with	 daily	 hrANXA1	 (1	 µg	 hrANXA1,	 100	 µl	
Hepes	buffer,	 i.p.,	daily	weeks	1-13)	or	with	hrANXA1	days	1-5	(1	µg	hrANXA1,	
100	 µl	 Hepes	 buffer,	 i.p.,	 days	 1-5)	 demonstrated	 not	 significant	 difference	 in	
serum	insulin	(Figure	2.19A,	ns)	or	non-fasted	blood	glucose	(Figure	2.19B,	ns).	
	
When	 compared	 to	 sham	mice	 not	 challenged	with	 STZ,	mice	 challenged	with	
STZ	demonstrated	a	significant	impairment	in	oral	glucose	tolerance	(measured	





















30,	45,	60,	90	and	120	minutes	post	oral	 glucose	delivery	 (C)	 and	 the	area	under	 the	 curve	of	
OGTT	calculated	(D).		Experimental	groups:	Sham	(non-diabetic);	STZ	+	vehicle	(diabetic);	STZ	+	
daily	hrANXA1	 (diabetic	+	1	µg	hrANXA1,	 i.p.,	 daily	weeks	1-13)	and	STZ	+	hrANXA1	days	1-5	



























STZ + daily hrANXA1















































































































































with	 STZ	demonstrated	 a	 significant	 increase	 in	ACR	 (Figure	2.20A,	 P<0.0001)	
and	 serum	 urea	 (Figure	 2.20B,	 P<0.001)	 suggesting	 the	 development	 of	
proteinuria	and	renal	dysfunction,	 respectively.	 	When	compared	 to	 sham	WT-
mice,	mice	challenged	with	STZ	demonstrated	a	significant	increase	in	urine	flow	






proteinuria	 and	 renal	 dysfunction,	 respectively.	 Similarly,	 when	 compared	 to	
WT-mice	 challenged	with	 STZ,	WT-mice	 challenged	with	 STZ	 and	 treated	with	
daily	hrANXA1	(weeks	1-13)	demonstrated	a	significant	reduction	in	urine	flow	
(Figure	 2.20C,	 P<0.0001)	 and	 creatinine	 clearance	 (Figure	 2.20A,	 P<0.01)	
suggesting	a	reduction	in	hyperfiltration.		However,	when	compared	to	WT-mice	
challenged	with	STZ,	mice	challenged	with	STZ	and	treated	with	hrANXA1	(days	









































































































































































































caused	 by	 STZ	 administration,	 left	 ventricular	 function	 was	 assessed	 using	
echocardiography	 at	 13	 weeks	 post	 STZ	 administration.	 When	 compared	WT-
mice	 not	 challenged	 with	 STZ,	 WT-mice	 challenged	 with	 STZ	 demonstrated	






ejection	 fraction	 (Figure	2.21A,	 P<0.0001),	 fractional	 shortening	 (Figure	2.21B,	
P<0.0001)	and	fractional	areas	change	(Figure	2.21C,	P<0.0001)	 indicating	that	
hrANXA1	 has	 prevented	 the	 development	 of	 systolic	 contractile	 dysfunction.		
When	compared	to	WT-mice	challenged	with	STZ,	WT-mice	challenged	with	STZ	
and	treated	with	hrANXA1	(days	1-5)	demonstrated	no	significant	difference	 in	








Figure	 2.21.	 Effect	 of	 treatment	 with	 hrANXA1	 on	 cardiac	 dysfunction	 caused	 by	 STZ-
induced	type-1	diabetes	mellitus.		
Measures	of	cardiac	 function	ejection	 fraction	(A);	 fractional	shortening	(B)	and	 fractional	area	
change	(C)	were	measured	by	echocardiograph	13	weeks	post	STZ	administration.	Experimental	


















































































































































To	 determine	 the	 effect	 of	 late	 therapeutic	 administration	 of	 hrANXA1	 on	
underlying	 diabetic	 phenotype,	 measurements	 were	 taken	 13	 weeks	 post	 STZ	
administration.	When	compared	to	WT-mice	not	challenged	with	STZ,	WT-mice	
challenged	 with	 STZ	 demonstrated	 a	 significant	 reduction	 in	 insulin	 levels	
(Figure	2.22A,	P<0.0001),	and	a	significant	increase	in	non-fasted	blood	glucose	
levels	 (Figure	 2.22B,	 P<0.01).	 	 When	 compared	 to	 sham	 WT-mice,	 WT-mice	




Similarly,	 when	 compared	 to	 sham	 WT-mice,	 WT-mice	 challenged	 with	 STZ	
demonstrated	a	significant	impairment	to	oral	glucose	(Figure	2.22C)	when	AUC	















































































































































administration.	 When	 compared	 to	 sham	 WT-mice,	 WT-mice	 challenged	 with	
STZ	 demonstrated	 a	 significant	 increase	 in	 ACR	 (Figure	 2.23A,	 P<0.0001),	 and	
serum	urea	 (Figure	 2.23B,	 P<0.05),	 suggesting	 the	 development	 of	 proteinuria	
and	renal	dysfunction.		When	compared	to	sham	WT-mice,	WT-mice	challenged	
with	 STZ	 demonstrated	 a	 significant	 increase	 in	 urine	 flow	 (Figure	 2.23C,	




given	 late	 treatment	 with	 hrANXA1	 from	 weeks	 8-13	 exhibited	 no	 significant	
changes	in	ACR	(Figure	2.23A,	ns).		However,	when	compared	to	mice	challenged	
with	 STZ,	 mice	 challenged	 with	 STZ	 and	 given	 late	 treatment	 with	 hrANXA1	
demonstrated	 a	 significant	 decrease	 in	 serum	 urea	 (Figure	 2.23B,	 P<0.05.	
Similarly	when	compared	to	mice	challenged	with	STZ,	mice	challenged	with	STZ	
and	given	late	treatment	with	hrANXA1	demonstrated	a	small	reduction	in	urine	
flow	 (Figure	 13C,	 ns),	which	was	 not	 significant,	 but	 a	 significant	 reduction	 in	











Figure		 2.23.	Effect	of	 late	 treatment	with	hrANXA1	on	renal	dysfunction	caused	by	STZ-
induced	type-1	diabetes	mellitus.		
Measures	of	renal	function	A)	urine	albumin-to-creatinine	ratio;	B)	serum	urea;	C)	urine	flow	and	
D)	 creatinine	 clearance	 where	 measured	 from	 urine	 and	 serum	 at	 week	 13	 post	 STZ	































































































































To	 determine	 the	 effect	 of	 treatment	 with	 hrANXA1	 on	 cardiac	 dysfunction	
caused	 by	 diabetes,	 left	 ventricular	 function	 was	 assessed	 using	
echocardiography	 13	 weeks	 post	 STZ	 administration.	 Sham	 WT-mice	 had	 no	
significant	 difference	 in	 ejection	 fraction	 (Figure	 2.24A,	 P<0.05),	 fractional	
shortening	 (Figure	 2.24B,	 P<0.05)	 and	 fractional	 areas	 change	 (Figure	 2.24C,	





















































































































































The	 potential	 underlying	 mechanisms	 behind	 the	 observed	 renal	 dysfunction	
were	 investigated	by	semi-quantitative	western	blot	analysis	of	mouse	kidneys	
13	weeks	post	STZ	administration.	When	compared	to	renal	tissue	obtained	from	
sham	mice,	 renal	 tissue	 from	mice	 challenged	with	 STZ	 exhibited	 a	 significant	
increase	in	phosphorylation	of	p38	on	Thr180/Thr182	(Figure	2.25A,	P<0.05),	JNK	
on	Thr183/Tyr185	(Figure	2.25B,	P<0.0001)	and	ERK1/2	on	Tyr	202/Tyr204	(Figure	
2.25C,	 P<0.001)	 suggesting	 strong	 activation	 of	 downstream	 effectors	 of	 the	
MAPK	signal	transduction	pathway.			
	
When	 compared	 to	 mice	 challenged	 with	 STZ,	 kidney	 tissue	 from	 mice	
challenged	with	STZ	and	 treated	with	daily	hrANXA1	(weeks	1-13)	exhibited	a	
significantly	 lower	 degree	 of	 phosphorylation	 of	 p38	 on	 Thr180/Thr182	 (Figure	
2.25A,	P<0.05),	 JNK	on	Thr183/Tyr185	 (Figure	2.25B,	P<0.0001)	and	ERK1/2	on	
Tyr	 202/Tyr204	 (Figure	 2.25C,	 P<0.001).	 	 Similarly,	 when	 compared	 to	 mice	
challenged	 with	 STZ,	 kidneys	 from	 mice	 challenged	 with	 STZ	 given	 late	
treatment	 (weeks	 8-13)	 with	 hrANXA1	 exhibited	 a	 significant	 decrease	 in	 the	
phosphorylation	of	JNK	on	Thr183/Tyr185	(Figure	2.25B,	P<0.01)	and	ERK1/2	on	
Tyr202/Tyr204	 (Figure	 2.25B,	 P<0.05).	 However,	 when	 compared	 to	 mice	
challenged	 with	 STZ,	 kidneys	 from	 mice	 challenged	 with	 STZ	 treated	 with	























corrected	 to	 total	 p38	 and	 normalised	 using	 the	WT	 +	 vehicle	 band	 (A);	 phosphorylated	 JNK	
(pThr183/Thr185)	 corrected	 to	 total	 JNK	 and	 normalised	 using	 the	WT	 +	 vehicle	 band	 (B);	 and	
phosphorylated	 ERK1/2	 (pThr202/Tyr204)	 corrected	 to	 total	 ERK1/2	 and	 normalised	 using	 the	
WT	+	vehicle	band	(C).	Experimental	groups:	Sham	(non-diabetic);	STZ	+	vehicle	(diabetic),	STZ	+	
daily	 hrANXA1	 (diabetic	 +	 1	 µg	 hrANXA1,	 i.p.,	 daily	 weeks	 1-13),	 STZ	 +	 hrANXA1	 days	 1-5	
(diabetic	+	1	µg	hrANXA1,	i.p.,	days	1-5)	and	STZ	+	hrANXA1	(diabetic	+	1	µg	hrANXA1,	i.p.,	daily	

















































































































































































of	 Akt	 in	 kidneys	 from	 mice	 subjected	 to	 STZ-induced	 type-1	 diabetes	
mellitus.	
	
When	 compared	 to	 hearts	 obtained	 from	 sham	 mice,	 hearts	 from	 mice	
challenged	with	 STZ	 exhibited	 a	 significant	 decrease	 in	 the	phosphorylation	 of	
Akt	on	Ser473	(Figure	2.26,	P<0.01).	When	compared	to	mice	challenged	with	STZ,	
hearts	 from	 STZ-mice	 treated	 with	 daily	 hrANXA1	 (weeks	 1-13)	 exhibited	 a	
significantly	 greater	 degree	 of	 phosphorylation	 of	 Akt	 on	 Ser473	 (Figure	 2.26,	
P<0.01).	 	 However,	 when	 compared	 to	mice	 challenged	with	 STZ,	 hearts	 from	
mice	 challenged	with	 STZ	 and	 treated	with	 hrANXA1	 (days	 1-5)	 or	 given	 late	
















































of	 bands	 is	 expressed	 as	 a	 relative	 optical	 density	 (O.D.)	 of	 phosphorylated	 Akt	 (pSer473)	
corrected	to	total	Akt	and	normalised	using	the	WT	+	vehicle	band.	Experimental	groups:	Sham	
(non-diabetic);	STZ	+	vehicle	(diabetic),	STZ	+	daily	hrANXA1	(diabetic	+	1	µg	hrANXA1,	i.p.,	daily	
weeks	 1-13),	 STZ	 +	 hrANXA1	 days	 1-5	 (diabetic	 +	 1	 µg	 hrANXA1,	 i.p..,	 days	 1-5)and	 STZ	 +	
hrANXA1	(diabetic	+	1	µg	hrANXA1,	 i.p.,	daily	weeks	8-13).	Representative	 images	 from	one	of	











































































The	main	 finding	 of	 the	 clinical	 study	 outlined	 in	 this	 chapter	 is	 the	 discovery	
that	 patients	 with	 T1DM,	 with	 or	 without	 diabetic	 nephropathy	 had	 elevated	
plasma	ANXA1	 levels,	when	compared	to	healthy	donors.	Additionally,	patients	
with	diabetic	nephropathy	had	significantly	higher	CRP	level	compared	to	those	
without	 nephropathy,	 suggesting	 greater	 systemic	 inflammation.	 Thus,	 I	
designed	 further	 experiments	 to	 gain	 a	 better	 insight	 into	 the	 biological	
importance	 of	 endogenous	 ANXA1,	 a	 known	 anti-inflammatory	 molecule,	 in	
T1DM.	To	do	this,	I	used	an	animal	model	of	STZ-induced	T1DM	in	both	WT	and	
ANXA1-/-	 mice	 to	 model	 the	 human	 disease.	 The	 main	 findings	 of	 this	
experimental	 study	were	 that	 (i)	 ANXA1	 levels	were	 lower	 in	 the	 kidneys	 and	
hearts,	 of	 mice	 administered	 STZ	 to	 induced	 diabetes	 (ii)	 ANXA1-/-	 mice	 with	
STZ-induced	diabetes	had	a	more	severe	diabetic	phenotype	compared	WT-mice	
administrated	 STZ	 and	 (iii)	 ANXA1-/-	 mice	 with	 STZ-induced	 diabetes	 develop	
more	 severe	 cardiac	 dysfunction	 and	 renal	 dysfunction	 compared	 to	WT-mice	
administrated.	
	
I	 next	wanted	 to	 investigate	whether	ANXA1	 could	be	used	as	 a	potential	new	
therapeutic	agent.	The	main	finding	of	this	experimental,	efficacy	study	were	that	
(i)	 chronic	 treatment	 of	 diabetic	 mice	 with	 hrANXA1	 (weeks	 1-13)	 did	 not	
prevent	 the	 development	 of	 a	 diabetic	 phenotype,	 but	 prevented	 the	
development	 of	 both	 cardiac	 and	 renal	 dysfunction,	 (ii)	 therapeutic	
administration	 of	 hrANXA1	 (weeks	 8-13)	 after	 significant	 cardiac	 and	 renal	





dysfunction	 seen	 in	 diabetic	 WT-mice	 treated	 with	 vehicle	 and	 (iii)	
administration	of	hrANXA1	during	STZ	induction	of	diabetes	(days	1-5)	did	not	




chronic	 inflammation,	 and	 this	 contributes	 to	 tissue/organ	 damage.	 Healthy	
donors	have	 low	 levels	 of	ANXA1	 in	plasma	 (Gavins	&	Hickey,	 2012).	Here	we	
report	that	ANXA1	is	elevated	in	patients	with	T1DM	with/without	nephropathy	
(Figure	 1A).	 Additionally,	 we	 show	 that	 the	 diabetic	 patients	 have	 systemic	
inflammation	and	that	the	degree	of	inflammation	is	even	higher	in	patients	with	
impaired	 renal	 function	 (diabetic	 nephropathy).	 Elevated	 plasma	 CRP	 is	 a	
strongly	 associated	with	 adverse	 outcome	 in	myocardial	 infarction,	 stroke	 and	
coronary	 heart	 disease,	 which	 are	 common	 causes	 of	 death	 in	 patients	 with	
T1DM.	 I	 propose	 that	 the	 elevation	 in	 circulating	 ANXA1	 is	 a	 compensatory	
mechanism	to	protect	the	tissue	from	the	deleterious	effects	of	hyperglycaemia,	
independent	of	the	presence	of	diabetic	nephropathy	and	not	a	consequence	of	
systemic	 inflammation	 (Figure	 1B).	 ANXA1	 is	 found	 in	many	 tissues,	 including	












In	 our	murine	model	we	 also	 show	 that	 circulating	 levels	 are	 increased	 in	 our	
diabetic	mice	 (although	not	significantly)	but	 importantly	 that	 tissue	 levels	are	
decreased,	 supporting	 our	 hypothesis	 that	 ANXA1	 is	 released	 in	 response	 to	
hyperglycaemia.	 ANXA1	 is	 needed	 to	 be	 released	 so	 it	 can	 signal	 in	 both	 a	
autocrine	and	paracrine	manner	through	the	FPR	repertoire	of	receptors.			
	
When	 mice	 were	 challenged	 with	 STZ	 they	 developed	 a	 T1DM	 phenotype	
characterised	 by	 depleted	 serum	 insulin,	 elevated	 non-fasted	 blood	 glucose	
levels	and	impaired	OGTT	within	13	weeks.	STZ	enters	pancreatic	beta-cells	via	
the	glucose	transporter	GLUT2	and	causes	alkylation	of	DNA	(Szkudelski	2001).		
DNA	 damage	 induces	 ADP-ribosylation,	 which	 leads	 to	 depletion	 of	 cellular	
NAD+	 and	 ATP.	 Enhanced	 dephosphorylation	 of	 ATP	 after	 STZ	 administration	
supplies	 a	 substrate	 for	 xanthine	 oxidase	 resulting	 in	 the	 formation	 of	
superoxide	 radicals;	 eventually	 leading	 to	 beta	 cells	 destruction	 by	 necrosis	
(Szkudelski,	2001).	In	patients	with	T1DM,	β-cell	mass	is	irreversibly	reduced	by	
70–80%	 at	 the	 time	 of	 diagnosis	 (Matveyenko	 &	 Butler,	 2008),	 similarly,	 in	
murine	 experimental	models	 of	 T1DM	 a	 diabetic	 phenotype	 is	 only	 evidenced	
with	similar	loss	of	beta	cell	mass	(Akirav	et	al.,	2008).	This	dramatic	beta	cells	
loss	 results	 in	 reduced	 insulin	 synthesis	 and,	 therefore,	 there	 is	 insufficient	












1995).	 I	 found	 that	 baseline	 ANXA1-/-	 mice	 demonstrate	 no	 augmentation	 in	
OGTT	 compared	 to	WT-mice,	 suggesting	 ANXA1-/-	 is	 not	 essential	 for	 ‘normal’	
glucose-stimulated	 insulin	 release.	 This	 is	 consistent	 with	 Rachman	 et	 al.	
findings	 that	 isolated	 and	 cultured	 islets	 from	 ANXA1-/-	 mice	 demonstrate	 no	
augmentation	in	glucose-stimulated	insulin	release	compared	to	islets	from	wild-
type	mice	 (Rackham	et	 al.,	 2016).	However,	 diabetic	ANXA1-/-	mice	 did	 have	 a	
more	 severe	 diabetic	 phenotype	 compared	 to	 diabetic	WT-mice;	 evidenced	 by	





The	 first	 line	 treatment	 strategy	 for	 patients	 with	 T1DM	 is	 the	 rigorous	
management	of	blood	glucose	using	insulin	replacement.	However,	even	patients	
with	well-managed	blood	glucose	develop	microvascular	complications	overtime	
However,	 the	 pathogenesis	 and	 natural	 history	 of	 T1DM	 are	 largely	
understudied,	especially	in	the	context	of	the	molecular	mechanisms	(Atkinson,	
2012)(Papadopoulou-Marketou	 et	 al.,	 2016).	 These	 complications	 include	
diabetic	 cardiomyopathy	 and	 nephropathy.	 When	 compared	 to	 the	 general	
population,	patients	with	T1DM	have	a	5.2-fold	increased	risk	of	a	cardiovascular	





disease	 (Chang	 et	 al.,	 2014).	 I	 have	 demonstrated	 that	 diabetic	 ANXA1-/-	 mice	
develop	more	 severe	 cardiac	 and	 renal	 dysfunction	 compared	 to	 diabetic	WT-
mice	 within	 13	 weeks,	 suggesting	 that	 endogenous	 ANXA1	 limits	 the	
development	 of	 end-organ	 injury/dysfunction	 in	 mice	 with	 STZ-	 induced	
diabetes.		
	
As	hypertrophy	 is	 an	 important	 contributor	 in	diabetes-associated	 cardiac	 and	
renal	 dysfunction	 I	 evaluated	 both	 intra	 ventricular	 spectrum	 diameter	 a	
measure	 of	 concentric	 hypertrophy	 (heart)	 and	 glomerular	 size	 (kidney);	 and	
report	that	both	are	significantly	increased	in	mice	challenged	with	STZ.	Notably,	
both	 glomerular	 hypertrophy,	 but	 not	 cardiac	 hypertrophy,	 was	 significantly	
further	increased	in	diabetic	ANXA1-/-	mice	when	compared	to	diabetic	WT-mice,	
suggesting	 that	 hypertrophy	 is	 not	 the	 lead	 cause	 of	 both	 cardiac	 and	 renal	
dysfunction.	 Cardiac	 hypertrophy	 is	 a	 common	 response	 to	 external	 stressors,	
including	 hyperglycaemia	 and	 oxidative	 stress	 (Festa	 &	 Haffner,	 2005).	
Hypertrophy	 is	a	 compensatory	 response	 to	maintain	cardiac	output,	however,	
when	 stressors	 persist	 (i.e.	 chronic	 hyperglycaemia	 in	 the	 case	 of	 T1DM),	 this	
compensatory	 process	 evolves	 into	 a	 decompensated	 state	 with	 profound	
changes	 contractile	 dysfunction,	 evidenced	 by	 reduced	 EF,	 FS	 and	 FAC	 and	
extracellular	remodeling,	evidence	by	IVSd.	Similarly,	renal	hypertrophy	is	also	a	
compensatory	 mechanism	 (Reidy	 et	 al.,	 2014);	 in	 the	 case	 of	 T1DM	 there	 is	
excessive	 renal	 hyperfiltration	 due	 to	 osmotic	 irregularities	 due	 to	 elevated	
blood	glucose	levels,	putting	stress	on	glomeruli	and	proximal	tubules	(Helal	et	






SGLT2	 sodium	 reabsorption	 pathways	 (Zhao	 et	 al.,	 2016).	 These	 two	
mechanisms	 combine	 and	 cause	 an	 increased	 pressure	 in	 the	 PCT	 and	 is	 a	
leading	 cause	of	hyperfiltration,	 indeed	 I	 clearly	 show	evidence	 that	mice	with	
STZ-induced	diabetes	have	hyperfiltration.	This	added	stress	manifests	in	other	
the	 structural	 loss	of	brush	borders	 if	 the	PCT	and	 compensatory	activation	of	
pro-fibrotic	mechanisms.		Indeed	I	have	demonstrated	that	ANXA1-/-	have	both	a	




complications	 associated	 with	 diabetes,	 I	 wanted	 to	 investigate	 whether	
pharmacological	 intervention	 with	 exogenous	 hrANXA1	 can	 attenuate	 the	
development	of	diabetic	nephropathy	and	cardiomyopathy.	Previously,	both	full	
length	 AXNA1	 and	 Ac2-26	 peptide	 (the	 N-terminal	 functional	 fragment	 of	
ANXA1)	have	been	used	in	vivo	both	eliciting	biological	function.	In	this	study	we	
chose	 to	 use	 full-length	 human	 recombinant	 ANXA1.	 The	 rational	 being	 that	
studies	 have	 reported	 that	 the	 dose	 of	 full-length	 ANXA1	 needed	 to	 induce	
biological	function	(inhibition	of	monocyte	adherence	to	the	endothelial)	is	up	to	












caused	 by	 hyperglycaemia	 and	 excessive	 oxidative	 stress	 (organ	 protection	
rather	 than	 reduction	 of	 diabetes).	 It	 should	 be	 noted	 that	 administration	 of	
ANXA1	for	one	week	during	the	administration	of	STZ	was	also	not	sufficient	to	





This	evidence	all	 supports	 the	hypothesis	 that	ANXA1	must	activate	protective	




renal	dysfunction	associated	with	diabetes?	 	 I	 show	here	 for	 the	 first	 time	 that	
the	 development	 of	 T1DM	 (caused	 by	 STZ)	 in	 mice	 are	 associated	 with	 (i)	 a	
reduction	 in	 endogenous	 ANXA1	 levels	 in	 both	 the	 heart	 and	 the	 kidney	
(increased	secretion),	 and	 (ii)	a	decline	 in	cardiac	and	renal	dysfunction.	Thus,	
we	speculated	 that	endogenous	ANXA1	protects	both	 the	heart	and	 the	kidney	
(and	 hence	 reduces	 organ	 injury/dysfunction)	 by	 acting	 on	 pro-survival	 and	
anti-inflammatory	pathways.		
	
Hyperglycaemia	 leads	 to	 activation	 (phosphorylation)	 of	MAPK’s	 p38,	 JNK	 and	






Pharmacological	 inhibition	 or	 genetic	 deletion	 of	 any	 of	 these	 three	 MAPKs	
reduces	 microvascular	 complications	 (diabetic	 nephropathy,	 cardiomyopathy	
and	retinopathy)	caused	by	T1DM	in	rodents	(Du	et	al.,	2010)(Singh	et	al.,	2017).	
Indeed,	 we	 observed	 a	 significant	 increase	 in	 activated	 (phosphorylated)	 p38,	
JNK	and	ERK1/2	 in	diabetic	WT-mice.	 Interestingly,	ANXA1-/-	mice	 even	 in	 the	
absence	 of	 diabetes	 (no	 STZ	 challenge),	 had	 constitutive	 activation	









even	 when	 hrANXA1	 was	 given	 therapeutically	 (week	 8-13),	 this	 resulted	 in	
attenuated	 the	 activation	 of	 p38,	 JNK	 and	 ERK1/2	 as	 well	 as	 the	 organ	
dysfunction	caused	by	diabetes.	
	
In	 addition	 to	 key	 mediators	 of	 the	 MAPK	 pathway	 another	 key	 pathway	
involved	 in	 tissue	 protection	 is	 the	 degree	 of	 activation	 of	 the	 Akt-survival	
pathway,	which	 is,	 in	 part,	 regulated	 by	 the	 insulin	 receptor	 substrate	 (IRS-1)	
(Guo,	 2014).	 Diabetic	 mice	 demonstrated	 a	 significant	 decrease	 in	 the	
phosphorylation	of	Ser473	on	Akt	(indicating	a	reduction	in	activity	of	the	kinase)	





resistant	 to	 stressor	 stimuli	 (hyperglycaemia)	 and	 subsequent	 organ	 injury.	 In	
contrast,	 treatment	 with	 hrANXA1	 attenuated	 the	 decline	 in	 Akt-activation	
caused	by	diabetes.	Akt	 is	 a	member	of	 the	phosphoinositide-3-3kinase	 (PI3K)	
signal	 transduction	 pathway.	 Insulin	 signalling	 through	 IRS-1	 regulates	 P13K	













of	 patients	 with	 T1DM,	 and	 that	 this	 rise	 is	 independent	 of	 a	 the	 presence	 of	
diabetic	 nephropathy	 and	 systemic	 inflammation.	 I	 have	 also	 clearly	
demonstrated	 that	 endogenous	 ANXA1	 plays	 a	 key	 protecting	 the	 heart	 and	
kidney	 from	 functional	 decline	 an	 animal	 model	 of	 T1DM.	 Specifically,	 I	 have	
shown	 that	 key	 mediators	 of	 the	 MAPK	 pathway	 (p38,	 JNK	 and	 ERK1/2)	 are	
constitutively	activated	in	ANXA1-/-	mice.	Administration	of	hrANXA1	(days	1-5)	
did	not	alter	the	diabetic	phenotype,	while	administration	of	hrANXA1	(weeks	1-





diabetes.	While	 late	 treatment	 (weeks	8-13),	after	 significant	 renal	and	cardiac	
dysfunction	 has	 already	 developed,	 halted	 both	 cardiac	 and	 renal	 dysfunction.	
We	 propose	 that	 attenuation	 of	 activation	 of	 the	 MAPK	 pathway	 and	






















































resistance.	 Insulin	 resistance	occurs	as	a	 result	 if	uncoupling	of	 IRS-1	 from	the	




including	nephropathy,	neuropathy	and	 retinopathy,	 even	 if	 they	manage	 their	
disease	well	 (Habib	&	Brannagan,	 2010).	 Diabetic	 nephropathy	 is	 divided	 into	
five	 stages,	with	 the	 final	 one	 being	 end-stage	 renal	 disease	 (ESRD).	However,	
from	 the	 time	 of	 onset	 it	 commonly	 takes	 over	 20	 years	 for	 patients	 to	 reach	





specific	 therapies	 available	 for	 the	 treatment	 of	 diabetic	 nephropathy.	 Indeed,	
management	 of	 hypertension	 and	 glucose	 is	 the	 only	 therapeutic	 strategies	
available	to	prevent	diabetic	nephropathy	(Nakagawa	et	al.,	2011).	Another	key	




targeting	 and	 small	 molecule	 inhibitors	 of	 RhoA	 have	 been	 targets	 for	 drug	
development	in	the	last	decade,	however,	clinical	trails	in	many	areas	fail	despite	


















































(1) the	 plasma	 levels	 of	 endogenous	 ANXA1	 in	 patients	 with	 type-2	
diabetes	with/without	diabetic	nephropathy;	
(2) the	 role	 of	 endogenous	 ANXA1	 in	 a	murine	model	 of	 high	 fat	 diet	
induced	T2DM	and	diabetic	nephropathy;	
(3) whether	 therapeutic	 intervention	 with	 hrANXA1	 can	 halt	 the	

































in	 adherence	 to	 the	Declaration	of	Helsinki.	All	 subjects	 gave	written	 informed	
consent.	Patients	with	T2DM	were	recruited	from	the	Diabetes	Outpatient	clinic	
of	 SISA	 Bassini	 Hospital,	 Cinisello	 (Italy)	 ethics	 committee	 number	 DGSAF	
0021573-P-12/11/2013	 and	 0001217-P-19/1/2017).	 Healthy	 donors	 were	
recruited	 from	 the	 William	 Harvey	 Research	 Institute	 (London).	 Non-fasting	




All	 animal	 protocols	 used	 in	 this	 study	were	 approved	 by	 the	 Animal	Welfare	
Ethics	 Review	 Board	 (AWERB)	 of	 Queen	 Mary	 University	 of	 London	 in	
accordance	 with	 the	 derivatives	 of	 both	 the	 Home	 Office	 guidance	 on	 the	
Operation	 of	 Animals	 (Scientific	 Procedures	 Act	 1986)	 published	 by	 Her	
Majesty’s	 Stationery	 Office	 and	 the	 Guide	 for	 the	 Care	 and	 Use	 of	 Laboratory	
Animals	 of	 the	 National	 Research	 Council.	 All	 research	was	 conducted	 project	
licenses	 reference	 numbers	 PPL:	 70/8350.	 This	 study	 was	 carried	 out	 on	 ten	
week-old	 male	 C57BL/6	 mice	 and	 ANXA1-/-	 mice,	 weighing	 25–30	 g	 (Charles	
River	Laboratories	UK	Ltd.,	Kent,	UK).	The	animals	were	allowed	to	acclimatise	







ANXA1	 levels	 were	 measured	 in	 healthy	 donors,	 patients	 with	 T2DM	 with	

























In	 the	 last	week	of	 the	 study,	mice	were	placed	 in	metabolic	 cages	 for	24	h	 to	
collect	urine.	Urinary	creatinine	and	sodium	was	measured	in	a	blinded	fashion	
by	 a	 commercial	 veterinary	 testing	 laboratory	 (IDEXX	 Ltd,	 West	 Sussex,	 UK).		
Urinary	albumin	was	measured	using	a	commercially	available	ELISA	kits	as	per	






was	 measured	 immediately	 using	 a	 glucometer	 (Accu-Chek	 Compact	 System;	
Roche	Diagnostics,	 Switzerland).	 A	 section	 of	 liver,	 kidney	 and	 skeletal	muscle	
was	 snap	 frozen	 and	 put	 in	 long-term	 storage	 for	 further	 processing	 and	 a	
section	 was	 of	 kidney	 was	 fixed	 in	 10	 %	 neutral-buffered	 for	 48	 h	 and	
transferred	 to	70	%	ethanol	 for	 long	 term	storage.	A	 section	of	 liver	was	 snap	
frozen	 in	 isopropanol	 and	 stored.	 Blood	 was	 collected	 and	 serum	 isolated;	
biochemical	 markers	 (creatinine)	 were	 measured	 in	 a	 blinded	 fashion	 by	 a	
commercial	 veterinary	 testing	 laboratory	 (IDEXX	Ltd,	West	 Sussex,	UK),	 serum	
insulin	 using	 a	 mouse	 ELISA	 kit	 (Abcam	 Plc.,	 UK),	 serum	 triglyceride	 and	









Western	 Blot	 analysis	 was	 preformed	 as	 described	 previously	 described	
(2.2.11.).	Briefly,	liver	kidney	and	skeletal	muscle	was	homogenised	and	protein	
extracted.	Proteins	were	 separated	by	SDS-PAGE,	 and	 transferred	onto	a	PVDF	
membrane,	blocked	and	incubated	with	primary	antibody	dilution	either	1:200,	
1:400	 or	 1:1000	 (rabbit	 anti-total	 IRS-1;	 rabbit	 anti-pIRS-1	 (180	 kDa);	 rabbit	
anti-total	Akt;	rabbit	anti-pAkt	(63	kDa);	rabbit	anti-total	GSK	-3β; 	rabbit	anti-p	






Periodic	 acid	 Schiffs:	 Formulin	 fixed	 kidney	 samples	 were	 embedding	 in	
paraffin	 and	 processed	 to	 obtain	 4	 μm	 sections.	 After	 deparaffinisation	 and	
rehydratration	 (graded	 alcohols	 to	 distilled	 water),	 all	 sections	 were	 then	
incubated	with	saturated	in	Periodic	Acid	Schiff’s	(Sigma,	UK)	solution	for	30	min	
washed	 in	 distilled	water	 and	 counterstained	with	Harris	 hematoxylin	 (Sigma,	
UK)	 and	 finally	 dehydrated	 through	 graded	 alcohols	 and	 cleared	 before	
mounting	with	coverslips.		
	














where	 n	 represents	 the	 number	 of	 animals	 studied.	 All	 statistical	 analysis	was	
calculated	 using	 GraphPad	 Prism	 6	 (GraphPad	 Software,	 San	 Diego,	 California,	
USA).	Data	without	a	repeated	measurement	was	assessed	by	a	one-way	ANOVA	
or	students	t-test	were	appropriate.	OGTT	testing	analysis	was	preformed	using	

































































3.4.1.	 ANXA1	 levels	 are	 elevated	 in	 patients	 with	 type-2	 diabetes,	
independent	of	having	diabetic	nephropathy.	
	
To	 understand	 whether	 endogenous	 ANXA1	 levels	 are	 modulated	 in	 patients	
with	T2DM,	 a	 sandwich	ELISA	was	preformed	on	plasma	obtained	 from	either	





T2DM	 and	 patients	 with	 T2DM	 plus	 CDK	 (Figure	 3.2B,	 P<0.01).	 When	 we	
compared	ANXA1	levels	of	patients	at	different	stages	of	CDK	3-5,	we	found	no	


























(n)	 28	 19	 130	
Sex		
(F	%)	 16	(57)	 5	(26)	 20	(15)	
Creatinine	
(mg/dL)	 7.67±0.27	 7.49±0.36	 2.05±0.12	
eGFR		
(ml/min)	 na	 32.98±3.98	 28.59±1.23	
Urinary	albumin	






(kg/m2)	 27.39±0.74	 27.18±0.73	 30.23±0.58	
Total	cholesterol	
(mg/dL)	 160.24±6.92	 159.80±6.73	 193.01±3.91*	
HDL-c		
(mg/dL)	 46.65±1.88	 43.35±1.59	 48.91±1.31	
eLDL-c		
(mg/dL)	 87.31±5.45	 87.89±5.55	 116.23±3.29*	
TG		
(mg/dL)	 151.17±12.37	 142.63±11.22	 139.27±9.59	
CRP		











plus	 nephropathy	 (B);	 patients	 with	 type	 2	 diabetes	 plus	 stages	 of	 CKD	 3-5	 (C)	 and	 linear	
regression	 of	 AXNA1	 vs.	 urinary	 albumin	 (D).	 Linear	 regressions	were	 calculated	 by	 the	 least	
squares	method	and	their	significance	were	estimated	by	Fisher’s	F	test.	P<0.05	was	considered	

























































































is	 a	 not	 significant	 difference	 in	 plasma	 CRP	 levels	 (a	 marker	 of	 systemic	
inflammation)	 in	 patients	 with	 T2DM	 due	 to	 stage	 of	 CKD	 (Figure	 3.3A,	 ns).		
There	 is	a	 strong	positive	correlation	between	BMI	and	plasma	ANXA1	(Figure	
3.3B,	P<0.05),	however,	 there	 is	no	significant	correlation	between	plasma	CRP	
levels	and	plasma	ANXA1	 levels	 (Figure	3.3C,	ns)	 in	our	 cohort	of	patient	with	
T2DM.		
	
Although	 BMI	 is	 strongly	 associated	with	 systemic	 inflammation,	 when	 serum	
lipid	 levels	were	correlated	with	plasma	CRP,	 I	 found	no	significant	correlation	
between	 plasma	 ANXA1	 and	 total	 cholesterol	 (Figure	 3.4A,	 ns),	 LDL-c	 (Figure	
3.4A,	ns)	and	HDL-c	(Figure	3.4A,	ns).		
	
However,	 when	 serum	 lipid	 levels	 were	 correlated	 with	 ANXA1,	 there	 was	 a	












	Figure	 3.2.	Measurement	 of	 systemic	 inflammation	 in	 patients	with	 or	without	 diabetic	
nephropathy.	
Plasma	 CRP1	 levels	 were	 in	 patients	 with	 type-2	 diabetes	 with	 different	 stages	 of	 CKD	 (A);	

























































Fgure	3.3.	The	association	between	 in	plasma	 levels	of	plasma	CRP	and	plasma	 lipids	 in	
T2DM	patients	with	or	without	diabetic	nephropathy.	




























































	Figure	 3.5	 Association	 between	 in	 plasma	 levels	 of	 ANXA1	 and	 plasma	 lipids	 in	 T2DM	
patients	with	or	without	diabetic	nephropathy.	
































































3.4.3.	 The	 effect	 of	 treatment	 with	 hrANXA1	 and	 the	 role	 of	 endogenous	
ANXA1	 on	 body	 weights	 in	 a	 murine	 model	 of	 diet-induced	 insulin	
resistance.	
	
Having	 found	 that	 there	 is	 a	 relationship	 between	 T2DM	 and	 plasma	 ANXA1	
levels,	 I	 wanted	 to	 use	 a	 murine	 model	 of	 HFD-induced	 insulin	 resistance	 to	
investigate	 the	 role	 of	 endogenous	 ANXA1	 and	 hrANXA1	 (as	 a	 therapeutic).	
When	 compared	 to	 WT-mice	 fed	 on	 chow	 diet,	 WT-mice	 fed	 on	 HFD	
demonstrated	a	significant	increase	in	body	weight	and	fat	mass	(Table1).	When	






Interestingly,	when	compared	 to	WT-mice	 fed	on	chow	diet,	ANXA1-/-	mice	 fed	
on	 chow	 diet	 did	 not	 gain	 as	 much	 weight	 over	 the	 same	 period	 of	 dietary	
manipulation	 (Table	 1,	 P<0.05).	 However,	 when	 compared	 to	WT-mice	 fed	 on	















Chow	 Chow	+	hrANXA1	 HFD	+	Vehicle	 HFD	+	hrANXA1	 Chow	 HFD	+	Vehicle	 HFD	+	hrANXA1	
Body	weight	gain	
from	baseline	(g)	 9.790±0.602*	 9.857±0.674*	 16.81±0.479	 12.87±0.455*	 4.550±0.276
$@	 13.89±0.772	 7.00±0.447$	
Kidney	%	of	body	
weight	 1.213±0.072	 1.225±0.025	 1.083±0.034	 1.311±0.90	 1.219±0.025
$	 0.814±0.008	 0.931±0.002$	
Liver	%	of	body	
weight	 3.325±0.144	 3.475±0.094	 3.191±0.098	 3.156±0.111	 4.069±0.0189
$	 3.212±0.185	 3.395±0.144$	
Epididimal	fat	%	
of	body	weight	 1.963±0.163*	 2.100±0.255*	 3.570±0.291	 2.867±0.253*	 2.288±0.067
$	 5.609±0.246	 4.361±0.007$	
Inguinal	fat	%	of	





Effects	 of	 chronic	 exposure	 to	 a	 normal	 diet	 (chow)	 or	 a	 high-fat	 high-sugar	 diet	 (HFD)	 on	 body	weight	 and	 kidney,	 liver,	 epididimal	 and	 inguinal	 fat	masses.	
Experimental	groups:	WT	or	ANXA1-/-	mice	treated	fed	on	normal	diet	(chow)	or	high-fat-high-sugar	(HFD)	with	or	without	hrANXA1	(1	µg	hrANXA1,	i.p.,	5	X	per	




















3.4.4.	 The	 effect	 of	 treatment	 with	 hrANXA1	 and	 the	 role	 of	 endogenous	
ANXA1	 on	 Oil	 Red-O	 staining	 in	 a	 murine	 model	 of	 diet-induced	 insulin	
resistance.	
	
To	 measure	 fat	 deposition	 in	 the	 liver,	 Oil	 Red-O	 staining	 was	 carried	 out	 in	
frozen	 liver	 sections.	 When	 compared	 to	 WT-mice	 fed	 on	 chow	 diet	 (Figure	
3.6A),	 WT-mice	 fed	 on	 HFD	 demonstrated	 an	 increase	 in	 Oil	 Red-O	 positive	
staining	 in	 the	 liver	 (Figure	 3.6C),	 suggesting	 a	 large	 deposition	 of	 fat.	 When	




Similarly,	 when	 compared	 to	 ANXA1-/-	 mice	 fed	 on	 chow	 diet	 (Figure	 3.6E),	
ANXA1-/-	mice	fed	a	HFD	demonstrated	an	increase	in	Oil	Red-O	staining	in	the	
liver	 (Figure	 3.6F).	 	 Similarly,	 when	 compared	 to	 ANXA1-/-	mice	 fed	 on	 HFD	
(Figure	 3.6F),	 ANXA1-/-	 mice	 fed	 on	 HFD	 and	 administrated	 hrANXA1	
demonstrated	less	Oil	Red-O	positive	staining	(Figure	3.6G).	
	

















to	WT-mice	 fed	on	 chow	diet,	WT-mice	 fed	on	HFD	demonstrated	a	 significant	






a	 HFD	 demonstrated	 a	 significant	 increase	 in	 triglyceride	 levels	 in	 the	 liver	
(Figure	 3.7A,	 P<0.0001),	 but	 there	was	no	 change	 in	 cholesterol	 levels	 (Figure	
3.7B,	ns).	Similarly,	when	compared	to	ANXA1-/-	mice	fed	on	HFD,	ANXA1-/-	mice	














Figure	 3.7.	 Effect	 of	 hrANXA1	 administration	 and	 the	 role	 of	 endogenous	 ANXA1	 on	
triglyceride	and	cholesterol	level	in	the	liver	a	model	of	diet-induced	insulin	resistance.	
Effects	 of	 chronic	 exposure	 to	 a	 normal	 diet	 (chow)	 or	 a	 high-fat	 high-sugar	 diet	 (HFD)	 on	
triglyceride	 (A)	 and	 cholesterol	 (B)	 levels	 in	 the	 liver	 after	 10	weeks	 of	 dietary	manipulation.	
Experimental	groups:	WT	or	ANXA1-/-	mice	treated	fed	on	normal	diet	(chow)	or	high-fat-high-
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3.4.6.	 The	 effect	 of	 hrANXA1	 administration	 and	 the	 role	 of	 endogenous	






When	 compared	 to	 WT-mice	 fed	 on	 chow	 diet,	 WT-mice	 fed	 on	 HFD	
demonstrated	no	change	in	serum	triglyceride	levels	(Figure	3.8A,	ns),	however	
there	was	a	significant	increase	in	cholesterol	level	(Figure	3.8B,	P<0.01).	When	





a	 HFD	 demonstrated	 a	 significant	 increase	 in	 serum	 triglyceride	 (Figure	 3.8A,	
P<0.01)	and	cholesterol	levels	(Figure	3.8B,	P<0.001).	However,	when	compared	
to	 ANXA1-/-	 mice	 fed	 on	 HFD,	 ANXA1-/-	 mice	 fed	 on	 HFD	 and	 treated	 with	





















WT	 or	 ANXA1-/-	mice	 treated	 fed	 on	 normal	 diet	 (chow)	 or	 high-fat-high-sugar	 (HFD)	with	 or	
without	 hrANXA1	 (1	 µg	 hrANXA1,	 i.p.,	 5	 X	 per	 week).	 Data	 analysed	 by	 a	 one-way	 ANOVA	
followed	by	a	Bonferroni	post-hoc	test,	and	expressed	as	mean	±	SEM.	n=	6	per	group.	**P<0.01,	
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When	 compared	 to	 WT-mice	 fed	 on	 chow	 diet,	 WT-mice	 fed	 on	 HFD	
demonstrated	a	significant	increase	in	the	serum	insulin	(Figure	3.9A,	P<0.001)	
as	 well	 as	 the	 blood	 levels	 of	 (non-fasted)	 glucose	 (Figure	 3.9B,	 P<0.0001).		
When	compared	to	WT-mice	fed	on	chow	diet,	WT-mice	fed	on	HFD	subjected	to	
OGTT	demonstrated	a	significant	impairment	in	tolerance	to	oral	glucose	(Figure	
3.9C/D,	 P<0.01).	 When	 compared	 mice	 fed	 on	 a	 HFD,	 mice	 fed	 on	 HFD	 and	
treated	with	 hrANXA1	 demonstrated	 significantly	 lower	 serum	 insulin	 (Figure	
3.9A,	P<0.0001)	and	blood	glucose	levels	(Figure	3.9B,	P<0.0001).		Additionally,	
when	compared	to	mice	fed	on	HFD,	mice	fed	on	HFD	and	treated	with	hrANXA1	
subjected	 to	 OGTT	 demonstrated	 a	 significant	 improvement	 in	 oral	 glucose	
tolerance	(Figure	3.9C/D,	P<0.001).		
	
When	 compared	 to	ANXA1-/-	mice	 fed	 on	 chow	diet,	 ANXA1-/-	mice	 fed	 on	HFD	
had	 elevated	 serum	 insulin	 (Figure	 3.9A,	 P<0.0001)	 and	 blood	 glucose	 levels	
(Figure	 3.9B,	 P<0.0001).	 When	 compared	 to	 ANXA1-/-	mice	 fed	 on	 chow	 diet,	
ANXA1-/-	mice	fed	on	HFD	demonstrated	a	significant	impairment	in	oral	glucose	
tolerance	 when	 subjected	 to	 OGTT	 (Figure	 3.9C,	 P<0.01).	 When	 compared	 to	
ANXA1-/-	mice	fed	on	HFD,	mice	ANXA1-/-	mice	fed	on	HFD	treated	with	hrANXA1	
(to	recover	their	phenotype	to	WT)	had	significantly	lower	serum	insulin	(Figure	
3.9A,	 P<0.05)	 and	 blood	 glucose	 levels	 (Figure	 3.9B,	 P<0.05).	 Similarly,	 when	


























Figure	 3.9.	 The	 effect	 of	 hrANXA1	 administration	 and	 ANXA1-/-	 mice	 on	 diabetic	
parameters	in	a	model	of	diet	induced	insulin	resistance.	
Effects	of	chronic	exposure	to	a	normal	diet	(chow)	or	a	high-fat	high-sugar	diet	(HFD)	on	serum	
insulin	 measured	 by	 sandwich	 ELSIA	 after	 10	 weeks	 of	 dietary	 manipulation	 (A);	 non-fasted	
blood	 glucose	 measured	 upon	 termination	 at	 week	 10	 (B);	 OGTT	 was	 measured	 after	 6	 h	 of	
fasting	mice.	 Glucose	 levels	measured	 at	 times	 0,	 15,	 30,	 45,	 60,	 90	 and	 120	post	 oral	 glucose	
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on	 insulin	 signalling	 pathways,	 in	 the	 liver,	 in	 a	 murine	 model	 of	 diet-
induced	insulin	resistance.	
	
To	assess	 the	potential	mechanisms	 (insulin	 resistance),	which	account	 for	 the	
rise	 in	 blood	 glucose	 and	 insulin	 levels	 caused	 by	 HFD,	 a	 semi-quantitative	
western	 blot	 analysis	 of	 key	 elements	 of	 the	 insulin	 signalling	 pathways	 was	
performed	 in	 the	 liver.	When	compared	 to	 liver	 tissue	obtained	 from	WT-mice	
fed	 on	 chow	 diet,	 liver	 tissue	 from	 WT-mice	 fed	 on	 HFD	 demonstrated	 a	
significant	increase	in	the	phosphorylation	of	insulin	receptor	substrate-1	(IRS-









significant	 higher	 degree	 of	 phosphorylation	 of	 Akt	 on	 Ser473	 (Figure	 3.10B,	
P<0.0001)	 and	 GSK-3β	 on	 Ser9	 (Figure	 3.10C,	 P<0.0001),	 suggesting	 a	
restoration	of	normal	 insulin	signalling.	 	 Indeed,	 the	degree	of	phosphorylation	
of	 IRS-1	 on	 Ser307,	Akt	 on	 Ser473	 and	GSK-3β	 on	 Ser9	 in	 liver	 samples	 obtained	





Similarly,	 when	 compared	 to	 liver	 tissue	 obtained	 from	 ANXA1-/-	mice	 fed	 on	
chow	 diet,	 liver	 tissue	 from	 ANXA1-/-	 mice	 fed	 on	 HFD	 showed	 a	 significant	
increase	in	the	phosphorylation	of	IRS-1	on	Ser307	(Figure	3.10A,	P<0.0001)	and	




a	 significant	 lower	degree	of	phosphorylation	of	 IRS-1	on	Ser307	 (Figure	3.10A,	
P<0.0001),	 and	 a	 higher	 degree	 of	 phosphorylation	 of	 Akt	 on	 Ser473	 (Figure	
3.10B,	P<0.0001)	and	GSK-3β	on	Ser9	(Figure	3.10C,	P<0.0001).	Thus,	treatment	




















Signalling	 in	 the	 kidney	 was	 assessed	 after	 10	 weeks	 of	 dietary	 manipulation.	 Densitometric	
analysis	 of	 bands	 is	 expressed	 as	 a	 relative	 optical	 density	 (O.D.)	 of	 phosphorylated	 IRS-1	
(pSer307)	 corrected	 to	 total	 IRS-1,	 phosphorylated	 Akt	 (pSer473)	 corrected	 to	 total	 Akt	 (A)	 and	
phosphorylated	 GSK-3β	 (pSer9)	 corrected	 to	 total	 GSK-3β	 (B)	 and	 normalised	 using	 the	WT	 +	
chow	band.	 and	normalised	using	 the	WT	+	 chow	band.	Experimental	 groups:	WT	or	ANXA1-/-	
mice	treated	fed	on	normal	diet	(chow)	or	high-fat-high-sugar	(HFD)	with	or	without	hrANXA1	
(1	 µg	 hrANXA1,	 i.p.,	 5	 X	 per	 week).	 Representative	 images	 from	 one	 of	 three	 repeated	
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for	 the	 rise	 in	 blood	 glucose	 and	 insulin	 levels	 caused	 by	 HFD,	 a	 semi-
quantitative	 western	 blot	 analysis	 of	 key	 elements	 of	 the	 insulin	 signalling	
pathways	was	preformed	in	skeletal	muscle.	When	compared	to	skeletal	muscle	
obtained	from	WT-mice	fed	on	chow	diet,	skeletal	muscle	from	WT-mice	fed	on	







When	 compared	 to	 skeletal	muscle	 from	WT-mice	 fed	on	HFD,	 skeletal	muscle	
from	mice	 fed	on	HFD	and	 treated	with	hrANXA1	demonstrated	a	 significantly	
lower	degree	of	phosphorylation	of	IRS-1	on	Ser307	(Figure	3.11A,	P<0.0001)	as	
well	as	a	significantly	higher	degree	of	phosphorylation	of	Akt	on	Ser473	(Figure	
3.11B,	 P<0.0001)	 and	 GSK-3β	 on	 Ser9	 (Figure	 3.11C,	 P<0.0001),	 suggesting	 a	
restoration	of	normal	 insulin	signalling.	 	 Indeed,	 the	degree	of	phosphorylation	
of	 IRS-1	on	Ser307,	Akt	on	Ser473	and	GSK-3β	on	Ser9	 in	skeletal	muscle	samples	






chow	 diet,	 skeletal	 muscle	 from	 ANXA1-/-	 mice	 fed	 on	 HFD	 demonstrated	 a	
significant	 increase	 in	 the	 phosphorylation	 of	 IRS-1	 on	 Ser307	 (Figure	 3.11A,	
P<0.0001);	 and	 significant	 decreases	 in	 the	 phosphorylation	 of	 Akt	 on	 Ser473		
(Figure	 3.11B,	 P<0.0001)	 and	 GSK-3β	 on	 Ser9	(Figure	 3.11C,	 P<0.001).	 	 When	
compared	 to	 skeletal	 muscle	 obtained	 from	 ANXA1-/-	 mice	 on	 HFD,	 skeletal	
muscle	from	ANXA1-/-	mice	fed	on	HFD	and	administrated	hrANXA1	(to	restore	
their	 phenotype	 to	 WT)	 exhibited	 a	 significantly	 lower	 degree	 of	


























Signalling	 in	 the	 kidney	 was	 assessed	 after	 10	 weeks	 of	 dietary	 manipulation.	 Densitometric	
analysis	 of	 bands	 is	 expressed	 as	 a	 relative	 optical	 density	 (O.D.)	 of	 phosphorylated	 IRS-1	
(pSer307)	 corrected	 to	 total	 IRS-1,	 phosphorylated	 Akt	 (pSer473)	 corrected	 to	 total	 Akt	 (A)	 and	
phosphorylated	 GSK-3β	 (pSer9)	 corrected	 to	 total	 GSK-3β	 (B)	 and	 normalised	 using	 the	WT	 +	
chow	band	 and	normalised	 using	 the	WT	+	 chow	band.	 Experimental	 groups:	WT	or	ANXA1-/-	
mice	treated	fed	on	normal	diet	(chow)	or	high-fat-high-sugar	(HFD)	with	or	without	hrANXA1	
(1	 µg	 hrANXA1,	 i.p.,	 5	 X	 per	 week).	 Representative	 images	 from	 one	 of	 three	 repeated	
experiments	 are	 shown	 in	 this	 Figure.	 Data	 analysed	 by	 a	 one-way	 ANOVA	 followed	 by	 a	
Bonferroni	post-hoc	test,	and	expressed	as	mean	±	SEM.	n=	6-8	per	group.	****P<0.0001	vs.	WT	+	
HFD	and	$$	P<0.01	and	$$$$	P<0.001	vs.	ANXA1-/-	+	HFD.	Quantification	of	bands	for	WT-mice	fed	a	
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Thus,	 renal	 function	 was	 assessed	 by	 measuring	 relevant	 biomarkers	 of	
proteinuria	and	renal	dysfunction	in	serum	and	urine	collected	after	10	weeks	of	




3.12A,	 P<0.05),	 suggesting	 prevention	 by	 hrANXA1	 of	 the	 development	 of	
proteinuria.	 Similarly,	 renal	 function	 was	 assessed	 in	 ANXA1-/-	mice	 after	 10	
weeks	of	dietary	augmentation.	When	compared	 to	ANXA1-/-	mice	 fed	on	chow	
diet,	 ANXA1-/-	mice	 fed	 on	 a	 HFD	 demonstrated	 a	 significant	 increase	 in	 ACR	
(Figure	 3.12A,	 P<0.001),	 indicating	 the	 development	 of	 proteinuria.	 	 When	
compared	 to	 ANXA1-/-	 mice,	 ANXA1-/-	 mice	 fed	 on	 HFD	 and	 administrated	
hrANXA1	 (to	 recover	 their	 phenotype	 to	WT)	 had	 a	 lower	 ACR	 (Figure	 3.12A,	
P<0.01).	 Interestingly,	when	compared	to	WT-mice	fed	on	HFD,	ANXA1-/-	mice	



















































Effects	 of	 chronic	 exposure	 to	 a	 normal	 diet	 (chow)	 or	 a	 high-fat	 high-sugar	 diet	 (HFD)	 urine	
albumin-to-creatinine	ratio	(A);	serum	creatinine	(B)	were	measured	from	urine	and	serum	after	
10	weeks	of	dietary	manipulation.	 .	 	Experimental	groups:	WT	or	ANXA1-/-	mice	 treated	 fed	on	
normal	diet	(chow)	or	high-fat-high-sugar	(HFD)	with	or	without	hrANXA1	(1	µg	hrANXA1,	i.p.,	5	
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performed	 in	 renal	 tissue.	 	When	compared	 to	 renal	 tissue	obtained	 from	WT-
mice	 fed	 on	 chow	 diet,	 renal	 tissue	 from	 WT-mice	 fed	 on	 HFD	 exhibited	 a	
significantly	 lower	 degree	 of	 phosphorylation	 of	 eNOS	 on	 Ser1177	 (Figure	 3.13,	
P<0.05).	When	 compared	 to	 renal	 tissue	 obtained	 from	WT-mice	 fed	 on	 HFD,	





the	 phosphorylation	 of	 eNOS	 on	 Ser1177	 (Figure	 3.13,	 P<0.05)	 However,	 renal	
tissue	 obtained	 from	 ANXA1-/-	mice	 fed	 on	 HFD	 that	were	 given	 hrANXA1	 (to	





































Signalling	 in	 the	 kidney	 was	 assessed	 after	 10	 weeks	 of	 dietary	 manipulation.	 Densitometric	
analysis	 of	 bands	 is	 expressed	 as	 a	 relative	 optical	 density	 (O.D.)	 of	 phosphorylated	 eNOS	
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ANXA1	 levels	 were	 measured	 in	 skeletal	 muscle	 using	 a	 semi-quantitative	
western	blot	analysis	after	10	weeks	of	dietary	manipulation.	When	compared	to	
skeletal	muscle	obtained	 from	WT-mice	 fed	on	chow	diet,	skeletal	muscle	 from	
WT-mice	 fed	 on	 HFD	 exhibited	 a	 significant	 decrease	 in	 the	 levels	 of	 ANXA1	
protein	(Figure	3.14A,	P<0.0001).	When	compared	to	WT-mice	fed	on	HFD,	the	
amount	 of	 ANXA1	 protein	 in	 skeletal	 muscle	 from	 WT-mice	 fed	 on	 HFD	 and	
treated	with	hrANXA1	was	significantly	higher	(Figure	3.14B,	P<0.001).	ANXA1	
levels	 were	 also	measured	 in	 the	 liver	 using	 a	 semi-quantitative	 western	 blot	
analysis	after	10	weeks	of	dietary	manipulation.	When	compared	to	liver	tissue	
obtained	from	WT-mice	fed	on	chow	diet,	liver	tissue	from	WT-mice	fed	on	HFD	
exhibited	 a	 significant	 decrease	 in	 ANXA1	 protein	 (Figure	 3.14B,	 P<0.0001).	
When	 compared	 to	WT-mice	 fed	on	HFD,	 the	 amount	of	ANXA1	protein	 in	 the	
liver	 from	 WT-mice	 fed	 on	 HFD	 and	 treated	 with	 hrANXA1	 was	 significantly	
higher	 (Figure	 3.14B,	 P<0.001).	 Similarly,	 endogenous	 ANAXA1	 levels	 were	
measured	 in	 the	 kidney	 using	 semi-quantitative	western	 blot	 analysis	 after	 10	
weeks	 of	 dietary	manipulation.	When	 compared	 to	 renal	 tissue	 obtained	 from	
WT-mice,	 renal	 tissue	 obtained	 from	 WT-mice	 fed	 on	 a	 HFD	 exhibited	 a	
significant	 decrease	 in	ANXA1	 (Figure	 3.14C,	 P<0.01).	When	 compared	 to	WT-
mice	fed	on	HFD,	the	amount	of	ANXA1	protein	in	kidneys	from	WT-mice	fed	on	









(C).	Densitometric	 analysis	 of	 bands	 is	 expressed	 as	 a	 relative	 optical	 density	 (O.D.)	 of	ANXA1	
corrected	 to	 β-actin	 and	 normalised	 using	 the	WT	 +	 chow	 band.	 Experimental	 groups:	WT	 or	
ANXA1-/-	mice	 treated	 fed	on	normal	diet	 (chow)	or	high-fat-high-sugar	 (HFD)	with	or	without	
hrANXA1	(1	µg	hrANXA1,	i.p.,	5	X	per	week).	Representative	images	from	one	of	three	repeated	
experiments	 are	 shown	 in	 this	 Figure.	 Data	 analysed	 by	 a	 one-way	 ANOVA	 followed	 by	 a	
Bonferroni	 post-hoc	 test,	 and	 expressed	 as	 mean	 ±	 SEM.	 n=	 3-4	 per	 group.	 ***P<0.001,	
****P<0.0001	vs.	WT+	HFD	and	$$$P<0.001	vs.	ANXA1-/-	+	HFD.	Quantification	of	bands	for	WT-
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3.4.12.	 The	 effect	 of	 hrANXA1	 administration	 and	 role	 of	 endogenous	
ANXA1	 on	 RhoA	 and	 MYPT1	 signalling,	 in	 skeletal	 muscle,	 in	 a	 murine	
model	of	diet-induced	insulin	resistance.	
	
When	 compared	 to	 skeletal	 tissue	 obtained	 from	 WT-mice	 fed	 on	 chow	 diet,	
skeletal	muscle	from	WT-mice	fed	on	HFD	exhibited	a	significantly	lower	degree	
of	 phosphorylation	 of	 RhoA	 on	 Ser188	 (Figure	 3.15A,	 P<0.01)	 and	 a	 significant	
increase	 in	 the	 phosphorylation	 of	MYPT1	 on	 Thr853	(Figure	 3.15B,	 P<0.0001).	
The	observed	alterations	in	phosphorylation	of	RhoA	on	Ser188	and	of	MYPT1	on	
Thr853	caused	 by	 HFD	 in	 skeletal	 muscle	 were	 abolished	 by	 treatment	 of	WT-
mice	fed	on	HFD	with	hrANXA1	(Figure	3.15A/B).	
	
When	 compared	 to	WT-mice	 fed	 on	 chow	 diet,	 skeletal	muscle	 from	 ANXA1-/-	
mice	fed	on	chow	diet	exhibited	a	significantly	 lower	degree	 in	the	(inhibitory)	
phosphorylation	 of	 RhoA	 on	 Ser188,	 which	 was	 associated	 with	 a	 significant	
increase	 in	 the	phosphorylation	of	MYPT1	on	Thr853	 (Figure	3.15B,	 P<0.0001).	
When	 compared	 to	 skeletal	muscle	 obtained	 from	ANXA1-/-	mice	 fed	 on	 chow	
diet,	 skeletal	 muscle	 from	 ANXA1-/-	 mice	 fed	 on	 HFD	 showed	 no	 significant	
change	in	the	phosphorylation	of	RhoA	on	Ser188	(Figure	3.15A,	ns)	or	MYPT1	on	
Thr853	(Figure	315B,	ns).	However,	when	compared	to	skeletal	muscle	obtained	
from	 ANXA1-/-	 mice	 on	 HFD,	 skeletal	muscle	 from	 ANXA1-/-	 mice	 on	 HFD	 and	
administrated	hrANXA1	exhibited	a	 significant	 increase	 in	 the	phosphorylation	












analysis	 of	 bands	 is	 expressed	 as	 a	 relative	 optical	 density	 (O.D.)	 of	 A)	 phosphorylated	 RhoA	
(pSer4188)	 corrected	 to	 total	RhoA	and	B)	phosphorylated	MYPT1	 (pThr853)	 corrected	 to	 total	
MYPT1	and	normalised	using	the	WT	+	chow	band.	Experimental	groups:	Wild-type	or	ANXA1-/-	
mice	treated	fed	on	normal	diet	(chow)	or	high-fat-high-sugar	(HFD)	with	or	without	hrANXA1	
(1	 µg	 hrANXA1,	 i.p.,	 5	 X	 per	 week).	 Representative	 images	 from	 one	 of	 three	 repeated	
experiments	 are	 shown	 in	 this	 Figure.	 Data	 analysed	 by	 a	 one-way	 ANOVA	 followed	 by	 a	
Bonferroni	post-hoc	 test,	 and	 expressed	 as	mean	 ±	 SEM.	 n=	 3-4	 per	 group.	 *P<0.05,	 **P<0.01,	
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3.4.13.	 The	 effect	 of	 hrANXA1	 administration	 and	 role	 of	 endogenous	
ANXA1	on	RhoA	and	MYPT1	signalling,	 in	 the	 liver,	 in	a	murine	model	of	
diet-induced	insulin	resistance.	
	
When	compared	 to	 liver	 tissue	obtained	 from	WT-mice	 fed	on	 chow	diet,	 liver	
tissue	 from	 WT-mice	 fed	 on	 HFD	 exhibited	 a	 significantly	 lower	 degree	 of	
inhibitory	 phosphorylation	 of	 RhoA	 on	 Ser188	 (Figure	 3.16A,	 P<0.01)	 and	 a	







3.16A,	 P<0.0001)	 suggesting	 that	RhoA	 is	 constitutively	 active	 in	ANXA1	mice.	
This	was	associated	with	a	significant	increase	in	the	phosphorylation	of	MYPT1	
on	 Thr853	 (Figure	 3.16B,	 P<0.0001).	 When	 compared	 to	 liver	 tissue	 obtained	
from	ANXA1-/-	mice	fed	on	chow	diet,	liver	tissue	from	ANXA1-/-	mice	fed	on	HFD	
had	 no	 significant	 change	 in	 the	 phosphorylation	 of	 RhoA	 on	 Ser188	 (Figure	
3.16A,	ns)	or	MYPT1	on	Thr853	(Figure	3.16B,	ns).	However,	when	compared	to	
liver	tissue	obtained	from	ANXA1-/-	mice	on	HFD,	liver	tissue	from	ANXA1-/-	mice	
on	 HFD	 and	 treated	 with	 hrANXA1	 exhibited	 a	 significant	 increase	 in	 the	










Signalling	 in	 the	 liver	 was	 assessed	 after	 10	 weeks	 of	 dietary	 manipulation.	 Densitometric	
analysis	 of	 bands	 is	 expressed	 as	 a	 relative	 optical	 density	 (O.D.)	 of	 A)	 phosphorylated	 RhoA	
(pSer4188)	 corrected	 to	 total	RhoA	and	B)	phosphorylated	MYPT1	 (pThr853)	 corrected	 to	 total	
MYPT1	and	normalised	using	the	WT	+	chow	band.	Experimental	groups:	Wild-type	or	ANXA1-/-	
mice	treated	fed	on	normal	diet	(chow)	or	high-fat-high-sugar	(HFD)	with	or	without	hrANXA1	
(1	 µg	 hrANXA1,	 i.p.,	 5	 X	 per	 week).	 Representative	 images	 from	 one	 of	 three	 repeated	
experiments	 are	 shown	 in	 this	 Figure.	 Data	 analysed	 by	 a	 one-way	 ANOVA	 followed	 by	 a	
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When	 compared	 to	 kidney	 tissue	 obtained	 from	WT-mice	 fed	 on	 a	 chow	 diet,	
renal	tissue	from	WT-mice	fed	on	a	HFD	exhibited	a	significantly	lower	degree	of	
phosphorylation	 of	 RhoA	 on	 Ser188	 (Figure	 3.17A,	 P<0.0001)	 and	 a	 significant	
increase	 in	 the	 phosphorylation	 of	MYPT1	 on	 Thr853	(Figure	 3.17B,	 P<0.0001).	
When	 compared	 to	 kidney	 tissue	 obtained	 from	 WT-mice	 fed	 on	 HFD,	 renal	
tissue	 from	 mice	 fed	 on	 HFD	 treated	 with	 hrANXA1	 exhibited	 a	 significant	
increased	in	the	phosphorylation	of	RhoA	on	Ser188	(Figure	3.17A,	P<0.0001)	and	




ANXA1-/-	 mice	 fed	 on	 chow	 diet	 exhibited	 a	 significantly	 lower	 degree	 of	
phosphorylation	of	RhoA	on	Ser188		(Figure	3.17A,	P<0.0001)	and	an	increase	in	
the	 phosphorylation	 of	 MYPT1	 on	 Thr853	 (Figure	 3.17B,	 P<0.001).	 When	
compared	 to	 renal	 tissue	obtained	 from	ANXA1-/-	mice	 fed	on	 chow	diet,	 renal	
tissue	 from	 ANXA1-/-	 mice	 fed	 on	 HFD	 exhibited	 no	 significant	 change	 in	 the	
phosphorylation	of	RhoA	on	Ser188	(Figure	3.17A,	ns)	or	MYPT1	on	Thr853	(Figure	
3.17B,	ns).		However,	renal	tissue	obtained	from	ANXA1-/-	mice	fed	on	HFD	that	









Signalling	 in	 the	 kidney	 was	 assessed	 after	 10	 weeks	 of	 dietary	 manipulation.	 Densitometric	
analysis	 of	 bands	 is	 expressed	 as	 a	 relative	 optical	 density	 (O.D.)	 of	 A)	 phosphorylated	 RhoA	
(pSer4188)	 corrected	 to	 total	RhoA	and	B)	phosphorylated	MYPT1	 (pThr853)	 corrected	 to	 total	
MYPT1	and	normalised	using	the	WT	+	chow	band.	Experimental	groups:	Wild-type	or	ANXA1-/-	
mice	treated	fed	on	normal	diet	(chow)	or	high-fat-high-sugar	(HFD)	with	or	without	hrANXA1	
(1	 µg	 hrANXA1,	 i.p.,	 5	 X	 per	 week).	 Representative	 images	 from	 one	 of	 three	 repeated	
experiments	 are	 shown	 in	 this	 Figure.	 Data	 analysed	 by	 a	 one-way	 ANOVA	 followed	 by	 a	
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The	 main	 findings	 of	 this	 chapter	 are	 that	 (i)	 ANXA1	 levels	 are	 elevated	 in	
patients	with	T2DM.	This	elevation	in	ANXA1	was	 independent	of	 the	presence	
of	 an	 impairment	 in	 renal	 function	 (CKD),	 but	 correlated	 positively	 with	 the	
degree	of	proteinuria	(urinary	albumin)	measured	in	these	patients;	(ii)	there	is	
a	 strong	positive	 correlation	between	 the	 increase	BMI	 and	plasma	CRP	 levels	
indicting	 a	 link	 between	 obesity	 and	 systemic	 inflammation	 and	 (iii)	 there	 are	
strong	 correlations	 between	 plasma	 ANXA1	 and	 total	 cholesterol,	 HDL-c	 and	
LDL-c.	 These	 findings	 led	me	 to	want	 to	 investigate	 a)	 the	 role	 of	 endogenous	
ANXA1	 in	 a	 murine	 model	 of	 HFD-induced	 insulin	 resistance	 and	 diabetic	
nephropathy,	 and	 b)	 whether	 treatment	 with	 hrANXA1	 reverses	 insulin	




on	 a	 HFD	 develop	more	 severe	 peripheral	 insulin	 resistance	 compared	 to	WT	
mice	 fed	a	HFD,	while	 therapeutic	administration	with	hrANXA1	prevented	the	
development	of	peripheral	insulin	resistance	in	both	WT	and	ANXA1-/-	mice;	(ii)	
ANXA1-/-	mice	have	more	 severe	 renal	 dysfunction	 and	hepatic	 steatosis	when	
challenged	 with	 a	 HFD,	 while	 the	 therapeutic	 administration	 of	 hrANXA1	
reduced	both	renal	dysfunction	and	hepatic	steatosis	caused	by	a	HFD;	(iii)	WT	














independent	of	an	 impairment	 in	renal	 function	and/or	systemic	 inflammation.		












cardiovascular	 event(s)	 and	 for	 subsequent	 adverse	 outcomes.	 	 In	 accordance	








level)	 when	 they	 studied	 the	 role	 of	 ANXA1	 in	 obesity	 (Kosicka	 et	 al.,	 2013).		
Here	we	show	for	 the	 first	 time	that	plasma	ANXA1	 is	strongly	correlated	with	
increases	 in	 total	 plasma	 cholesterol,	 and	 with	 HDL-c	 and	 LDL-c	 (Figure	 3.5).	
This	 is	 a	 particularly	 striking	 observation	 when	we	 consider	 that	 most	 of	 the	
patients	 included	 in	this	study	are	on	medication	aimed	at	 lowering	circulating	
cholesterol	levels.	This	interesting	finding	is	made	more	striking	by	the	fact	that	




presence	 of	 urinary	 proteinuria.	 Therefore,	 our	 working	 hypothesis	 is	 that	




While,	 lifestyle	 factors	 and	 genetic	 predisposition	 provide	 us	 with	 predictive	
indications	 as	 to	who	 is	 at	 risk	 of	 developing	 T2D,	 the	 pathophysiology	 of	 the	
progression	 of	 microvascular	 complications	 is	 incompletely	 defined	 due	 to	 its	
complexity,	 and	 involvement	 of	 multiple	 signalling	 pathways	 and	 processes.	
Using	a	murine	model	of	HFD-induced	insulin	resistance	I	report	in	this	chapter	
that	ANXA1	plays	a	key	protective	role	 in	T2DM.	Two	lines	of	evidence	suggest	
this:	 (i)	 ANXA1-/-	 mice	 develop	 a	more	 severe	 diabetic	 phenotype	when	 fed	 a	







1/Akt/GSK-3β	 cascade	 is	 a	 key	 regulator	 of	 glucose	 transportation,	 glycogen	
synthesis	and	glycolysis.	Peripheral	insulin	resistance	is	attributed	to	an	increase	




docking	 and	 signal	 transduction	 (Gual	 et	 al.,	 2005).	 This	 results	 in	 blunted	
GLUT4	 translocate	 to	 the	 cell	 surface	 to	 facilitate	 glucose	 uptake	 in	 peripheral	
organs,	 leading	 to	 hyperglycaemia	 (Chiazza	 et	 al.,	 2015).	 I	 demonstrate	 in	 this	
chapter	that	mice	fed	a	HFD	have	increased	phosphorylation	of	Ser307,	which	is	
attenuated	by	hrANXA1	restabilising	the	insulin	receptor	allowing	normal	signal	














including	 sepsis	 (Chen	 et	 al.,	 2017)(Khan	 et	 al.,	 2013),	 haemorrhagic	 shock	
(Yamada	et	al.	2017)(Sordi	et	al.	2017),	renal	ischaemia	reperfusion	(Patel	et	al.,	
2012)	 and	 diabetes	 (Chiazza	 et	 al.,	 2015).	 	 Here	 I	 demonstrate	 that	 the	
prevention	 of	 the	 decline	 in	 Akt	 activity	 by	 hrANXA1	 reduces	 both	 kidney	
(proteinuria)	and	liver	injury	(hepatic	steatosis)	in	animals	challenged	with	HFD,	
supporting	 previous	 evidence	 that	 a	 loss	 of	 Akt	 activity	 predisposes	 organ	 to	
injury.	Most	notably,	both	full	length	ANXA1	and	Ac2-16	(the	N-terminal	peptide	




Another	 function	 of	 activated	 Akt	 is	 to	 inhibit	 GSK-3β	 (Ser9	phosphorylation),	
thus	 activating	 glycogen	 synthase,	 which	 converts	 glucose	 to	 glycogen	 for	
storage	 in	 the	 liver	 effectively	 reducing	 circulating	blood	glucose	 levels.	Here	 I	
demonstrate	that	mice	fed	on	a	HFD	have	decreased	activation	of	GSK-3β,	which	
results	in	a	reduction	in	glycogen	synthesis,	which	may	be	one	of	the	reasons	for	




The	 observed	 improvements	 in	 insulin	 sensitivity	 seen	 in	 mice	 fed	 on	 a	 HFD	
treated	 hrANXA1	 have	 also	 translated	 into	 an	 improved	 lipid	 profile.	 Previous	
studies	have	documented	 that	hyperinsulinaemia	due	 to	 chronic	 exposure	 to	 a	
HFD	can	 induce	greater	 lipid	accumulation	(liver),	which	 is	consistent	with	 the	





lipid	 accumulation	 and	 hepatic	 steatosis,	 which	 was	 more	 severe	 in	 ANXA1-/-	
mice.	Similarly,	Akasheh	et	al.	who	report	increased	adiposity	in	ANXA1	deficient	
mice	fed	a	HFD,	albeit	on	a	different	genetic	background	(Akasheh	et	al.,	2013).	
Indeed,	 excessive	 fat	 in	 the	 liver	 can	directly	 contribute	 to	 the	 exacerbation	of	
the	degree	of	peripheral	 insulin	resistance.	Here	 I	clearly	show	that	 the	 lack	of	
endogenous	ANXA1	dramatically	increased	lipid	deposition	caused	by	HFD	in	the	
liver	and	that	these	mice	also	display	a	more	severe	diabetic	phenotype.	This	is	
consistent	with	other	 reports	 confirming	 that	excessive	 lipid	accumulation	and	
hepatic	 steatosis	 are	key	drives	of	peripheral	 insulin	 resistance	 (Garg	&	Misra,	
2002).	 	Most	notably,	 I	 show	 in	 this	 chapter	 that	 treatment	with	hrAXNA1	can	
not	 only	 reduce	 lipid	 accumulation,	 but	 that	 it	 can	 restore	 insulin	 receptor	
sensitivity	resulting	in	normal	glucose-stimulated	insulin	responses.	
	
Secondary	 to	 peripheral	 insulin	 resistance,	 hyperglycaemia	 leads	 to	 the	
development	 of	 microvascular	 complications.	 Indeed,	 diabetic	 nephropathy	 is	
the	 leading	 cause	 of	 end-stage	 renal	 disease	 and	 in	 patients	 needing	 renal	
replacement	therapy.	The	data	presented	here	demonstrate	 that	ANXA1-/-	mice	
fed	 a	HFD	have	more	 severe	 renal	dysfunction	 (proteinuria)	 compared	 to	WT-
mice	fed	on	a	HFD,	strongly	suggesting	that	ANXA1	protects	the	kidney	from	the	
harmful	 effects	 of	 having	 T2DM	 phenotype.	 Moreover,	 renal	 impairment	 was	
confirmed	histologically	with	 evidence	of	mild	 glomerular	hypertrophy,	 loss	 of	
brush	 borders	 in	 the	 proximal	 convoluted	 tubules	 and	 glomerular	 membrane	















Liao,	 2005);	 and	 (iii)	 signalling	 molecules	 such	 as	 insulin,	 IGF-1	 and	 leptin	
increase	eNOS	phosphorylation.	Here	I	demonstrate	that	mice	fed	on	a	HFD	have	
decreased	 eNOS	 phosphorylation,	 and	 that	 this	 decrease	 in	 eNOS	
phosphorylation	 was	 prevented	 by	 treatment	 with	 hrANXA1.	 Decreased	 eNOS	
phosphorylation	results	in	less	enzymatic	conversion	of	L-arginine	to	nitric	oxide	
(NO),	which	is	a	key	regulator	of	vascular	tone.	Reduced	NO	increases	decreased	
vascular	 tone	 and	 leads	 to	 increased	 constriction	 (Campia	 et	 al.,	 2014),	which	
could	cause	hypertension	within	the	nephron	leading	to	functional	decline	due	to	
hyperfiltration	 and	 proteinuria.	 Activation	 of	 Akt	 is	 known	 to	 modulate	 eNOS	
activity	 through	 phosphorylation	 of	 eNOS	 at	 Ser1177.	 Indeed,	 the	 present	 study	
shows	 that	 mice	 fed	 a	 HFD	 have	 decreased	 Akt	 and	 eNOS	 phosphorylation,	







specifically	 in	 diabetic	 kidney	 disease	 (Gojo	 et	 al.,	 2007)	 (Massey	 et	 al.,	 2003)	
(Miao	 et	 al.,	 2002)	 (Tang	 et	 al.,	 2006).	 Although	 the	 effects	 of	 RhoA	 inhibitors	
have	 been	 investigated	 in	 many	 clinical	 trials,	 albeit	 with	 limited	 success	
(Komers,	 2013).	 In	 this	 study,	 I	 demonstrate	 that	 endogenous	ANXA1	 is	 a	 key	
regulator	 of	 RhoA	 activity.	 ANXA1-/-	 mice	 on	 a	 chow	 diet	 have	 decreased	
inhibitory	 phosphorylation	 of	 RhoA	 at	 Ser188	 making	 the	 small	 GTPase	
constitutively	 active,	 which,	 in	 turn,	 drives	 the	 down-stream	 activation	 of	
MYPT1.	 This	 is	 consistent	 with	 a	 previous	 report	 from	 Christante	 et	 al.	 who	




allows	 for	 the	 activation	 of	 the	 small	 RhoA	 GTPase	 (Cristante	 et	 al.,	 2013).	








directly	 under	 the	 regulatory	 control	 of	 RhoA.	 Activated	 (phosphorylated)	





co-morbidity	of	diabetes,	 and	a	key	driver	of	 renal	dysfunction.	One	of	 the	key	
therapies	 for	 treating	CKD	and	diabetic	nephropathy	 is	 inhibition	of	 the	 renin-
angiotensin	 system.	 Indeed,	we	 report	 that	mice	 fed	 on	 a	HFD	 have	 increased	
phosphorylation	of	MYPT1,	which	was	attenuated	by	 treatment	with	hrANXA1.	
This	evidence	coupled	with	 the	decrease	 in	eNOS	phosphorylation	 leads	 to	 the	
working	hypothesis	that	the	microvascular	compactions	seen	in	mice	fed	a	HFD	
are	driven	at	 least	 in	part	by	hypertension.	 Indeed,	here	we	have	 identified	an	









When	 blood	 glucose	 levels	 are	 increased,	 insulin	 is	 released	 and	 binds	 to	 the	 insulin	 receptor,	 this	
allows	 for	 signalling	 transduction	 through	 the	 IRS-1.	 For	 signal	 transduction	 to	 occur	 tyrosine-308	
must	 be	 phosphorylated.	 This	 then	 allows	 signal	 transduction	 through	 PI3K	 to	 activated	 Akt	 by	
phosphorylating	serine-478,	which	 in	 turn	activates	GSK-3β, 	which	coverts	glucose	 to	glycogen.	 	 In	
T2DM,	cellular	levels	of	ANXA1	are	depleted,	and	there	is	increased	phosphorylation	of	serine-307	on	
IRS-1	 which	 inhibits	 the	 tyrosine	 phosphorylation	 needed	 for	 signal	 transduction	 upon	 insulin	
binding,	 here	 I	 propose	 that	 ANXA1	 signalling	 through	 the	 FPT2	 receptor	 blocks	 the	 inhibitory	
phosphorylation	 of	 serine-307	 on	 IRS-1,	 allowing	 normal	 insulin	 signalling	 events	 to	 occur.	 ANXA1	



























The	 classical	 complications	 of	 T2DM	 are	 well	 known	 and	 include	 diabetic	
nephropathy,	 retinopathy	 and	 neuropathy.	 Hyperglycaemia	 and	 dyslipidaemia	
are	 the	key	drivers	of	 these	pathologies	of	 the	microvasculature	 (Chawla	et	al.,	
2016).	 It	 is	 well	 documented	 that	 endothelial	 dysfunction	 is	 a	 driver	 of	many	
pathologies	 including	 hypertension,	 atherosclerosis	 and	 subsequently	 leads	 to	
increased	 incidence	 of	 both	 myocardial	 infarction	 and	 stroke	 (Deanfield	 et	 al.	




The	 brain	 is	 a	 unique	 organ	 and	 is	 subject	 to	 immune	 privilege	 and	 has	 a	
specialised	barrier,	the	blood	brain	barrier	(BBB),	which	has	extreme	tightness.	
The	extreme	tightness	of	 the	BBB	stops	 the	passage	of	 immune	cells	and	other	
large	particles	 into	 the	brain	parenchyma.	Specialised	tight	 junctions	are	 found	
in	 the	 BBB,	 and	 in-part	 mediate	 the	 tight	 junctions;	 they	 do	 this	 by	 creating	
‘kissing	points’	between	cells	and	the	intracellular	actin	cytoskeleton.	Disruption	
of	these	unique	structures	causes	the	BBB	to	become	more	permeable	and	allows	
immune	cells	 and	 large	particle	 to	 cross	 into	 the	brain.	Cristante	published	 for	
the	first	time	that	ANXA1-/-	mice	have	increased	BBB	permeability	and	that	these	
effects	are	mediated	 through	FPR2	signalling	 to	activate	RhoA	 (Cristante	et	 al.,	
2012).	 Indeed,	 increased	 BBB	 permeability	 and	 increased	 immune	 cell	
infiltration	in	the	central	nervous	system	plays	a	major	role	in	many	neurological	








particularly	 how	 they	 interact	 with	 the	 endothelial	 to	 mediate	 migration	 into	
sites	of	inflammation.	Indeed,	diabetes	is	classically	known	as	being	a	disease	of	
low-grade	 chronic	 inflammation,	 often	 associated	 with	 increased	 monocyte	












































The	 animal	 protocols	 followed	 in	 this	 study	 were	 approved	 by	 the	 Animal	
Welfare	Ethics	Review	Board	(AWERB)	of	Queen	Mary	University	of	London	 in	
accordance	 with	 the	 derivatives	 of	 both	 the	 Home	 Office	 guidance	 on	 the	
Operation	 of	 Animals	 (Scientific	 Procedures	 Act	 1986)	 published	 by	 Her	
Majesty’s	 Stationery	 Office	 and	 the	 Guide	 for	 the	 Care	 and	 Use	 of	 Laboratory	
Animals	 of	 the	 National	 Research	 Council.	 All	 research	was	 conducted	 project	
licenses	 reference	 numbers	 PPL:	 70/8350.	 This	 study	 was	 carried	 out	 on	 10	
week-old	 male	 C57BL/6	 mice	 and	 ANXA1-/-	 mice,	 weighing	 25–30	 g	 (Charles	
River	Laboratories	UK	Ltd.,	Kent,	UK).	The	animals	were	allowed	to	acclimatise	



















Lymph	 nodes	 (inguinal,	 mesenteric,	 axillary,	 brachial,	 superficial	 and	 deep	









bEND5	 cells	were	 plated	 on	 laminin-coated	 transwells	 (Sigma	Aldrich	Plc.	 UK)	
and	 48	 h	 prior	 to	 adhesion/migration	 assay	 and	 grown	 at	 37°C	 in	 10	%	 CO2	
humidity	 in	 Dulbecco’s	 modified	 Eagles	 medium	 (DMEM	 +	 10	 %	 fetal	 bovine	
serum;	100	U/L	penicillin;	100	mg/L	streptomycin;	2nM	glutamine)	before	assay	














cells	were	 permeabilised	with	 permeabilsation	 buffer	 for	 30	min	 at	 37	 °C	 (BD	
Biosciences,	UK)	 and	were	 then	 stained	with	 intracellular	markers	 (FoxP3	and	
RORγt),	and	for	surface	markers	(CD4,	CD8,	CD25)	with	fluorescently	conjugated	






where	 n	 represents	 the	 number	 of	 animals	 studied.	 All	 statistical	 analysis	was	
calculated	 using	 GraphPad	 Prism	 6	 (GraphPad	 Software,	 San	 Diego,	 California,	
USA).	Data	without	a	repeated	measurement	was	assessed	by	a	one-way	ANOVA	
or	students	t-test	were	appropriate.	OGTT	testing	analysis	was	preformed	using	
















4.3.1.	 The	 effect	 of	 hrANXA1	 administration	 and	 the	 role	 of	 endogenous	
ANXA1	on	BBB	permeability	in	mice	fed	a	HFD.	
	
Previous	 reports	 by	 Cristante	 et	 al.	 have	 shown	 that	 ANXA1-/-	 mice	 have	
enhanced	 BBB	 permeability	 under	 physiological	 conditions	 compared	 to	 WT	
littermates.	 In	 vivo,	 BBB	 permeability	 was	 assessed	 in	 both	WT	 and	 ANXA1-/-	
mice.	 Chow	 fed	 ANXA1-/-	 mice	 injected	 with	 Evan’s	 blue	 dye	 (i.v.)	 had	 a	
significantly	 greater	 dye	 content	 in	 the	 brain	 when	 measured	 by	







































Effects	 of	 chronic	 exposure	 to	 a	 normal	 diet	 (chow)	 or	 a	 high-fat	 high-sugar	 diet	 (HFD)	 on	
paracellular	permeability	assessed	by	Evan’s	blue	leakage	into	the	brain	after	10	weeks	of	dietary	
manipulation.	Experimental	groups:	WT	or	ANXA1-/-	mice	treated	fed	on	normal	diet	(chow)	or	
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4.3.2.	 The	 role	 of	 endogenous	 ANXA1	 on	 specific	 CD4+	 lymphocyte	
populations	from	mice	fed	a	HFD.	
	




(Figure	 4.2A).	 Subsets	 of	 CD4+	 T-cell	 preform	 different	 biological	 functions.	
When	 compared	 to	 chow-fed	 WT	 mice,	 chow-fed	 ANXA1-/-	 mice	 have	 a	
significantly	larger	population	of	CD4+0	(Figure	4.2B,	P<0.05),	while	the	number	
of	 CD4+FoxP3+	 T-cells	 remains	 unchanged	 (Figure	 4.2C,	 P<0.05).	 When	
compared	 to	chow-fed	WT	mice,	HFD-fed	WT	mice	have	a	significantly	smaller	




















Effects	 of	 chronic	 exposure	 to	 a	 normal	 diet	 (chow)	 or	 a	 high-fat	 high-sugar	 diet	 (HFD)	 on	
specific	CD4+	 lymphocytes	after	10	weeks	of	dietary	manipulation.	CD4+	 cells	 (A),	CD4+FoxP3+	
cells	as	a	%	of	CD4+	cells	(B)	and	CD4+RORgt+	cells	(C)	as	a	%	of	CD4+	cells.	Experimental	groups:	































































































































4.3.3.	 The	 role	 of	 endogenous	 ANXA1	 on	 the	 ratio	 of	 CD4+FoxP3+	 to	
CD4+RORγt+	lymphocytes	from	mice	fed	a	HFD.	
	
T-cells	 were	 isolated	 from	 draining	 lymph	 nodes	 and	 specific	 CD4+	 T-cells	
populations	 quantified.	 The	 ratio	 of	 specific	 subsets	 of	 CD4+	 T-cell;	 TReg	
(CD4+FoxP3+)	to	Th17	(CD4+RORγt+)	was	calculated.	 	When	compared	to	chow-
fed	WT	mice,	chow-fed	ANXA1-/-	mice	have	a	 lower	CD4+FoxP3+	to	CD4+RORγt+	
T-cell	 ratio	 (Figure	 4.3,	 P<0.001).	 	 Likewise,	 when	 compared	 to	 chow-fed	WT	



































Figure	 4.3.	 The	 role	 of	 endogenous	 ANXA1	 on	 the	 ratio	 of	 CD4+FoxP3+	 to	 CD4+RORγt+	
lymphocytes	from	mice	fed	a	HFD.	
The	effects	of	chronic	exposure	to	a	normal	diet	(chow)	or	a	high-fat	high-sugar	diet	(HFD)	on	the	
ratio	 of	 CD4+FoxP3+	 to	 CD4+RORγt+	 lymphocytes	 after	 10	 weeks	 of	 dietary	 manipulation.	
Experimental	groups:	WT	or	ANXA1-/-	mice	treated	fed	on	normal	diet	(chow)	or	high-fat-high-
































































4.3.4.	 The	 effect	 of	 treatment	with	hrANXA1	on	 specific	 CD4+	 lymphocyte	
populations	in	mice	fed	a	HFD.		
	


















Effects	 of	 chronic	 exposure	 to	 a	 normal	 diet	 (chow)	 or	 a	 high-fat	 high-sugar	 diet	 (HFD)	 on	

























































































































































Figure	 4.5.	 The	 effect	 of	 treatment	 with	 hrANXA1	 on	 the	 ratio	 of	 CD4+FoxP3+	 to	
CD4+RORγt+	lymphocytes	from	mice	fed	a	HFD.	
The	effects	of	chronic	exposure	to	a	normal	diet	(chow)	or	a	high-fat	high-sugar	diet	(HFD)	on	the	
ratio	 of	 CD4+FoxP3+	 to	 CD4+RORγt+	 lymphocytes	 after	 10	 weeks	 of	 dietary	 manipulation.	
Experimental	groups:	WT	or	ANXA1-/-	mice	treated	fed	on	normal	diet	(chow)	or	high-fat-high-





































4.3.6.	 The	 effect	 of	 treatment	 with	 hrANXA1	 on	 lymphocytes	 ability	 to	
adhere	and	transmigrate	through	an	endothelial	monolayer	ex	vivo.	
	
Using	 an	 ex	 vivo	model	 of	 paracellular	 permeability	we	 assessed	 the	 ability	 of	
activated	lymphocytes	to	firstly	adhere	to	and	then	migrate	through	a	monolayer	
of	brain	derived	endothelial	 cells.	When	compared	 to	 lymphocytes	 from	chow-
fed	 mice,	 lymphocytes	 isolated	 from	 HFD-fed	 mice	 and	 put	 in	 contact	 with	 a	
endothelial	 monolayer	 demonstrated	 an	 increased	 number	 of	 lymphocytes	
adhered	 to	 the	 endothelial	 cell	 monolayer	 (Figure	 4.6,	 P<0.001)	 and	 also	 an	
increased	 number	 of	 transmigrated	 lymphocytes	 through	 the	 endothelial	 cell	
monolayer	 (Figure	 4.5,	 P<0.01)	 after	 4	 h	 of	 incubation.	 When	 compared	 to	
lymphocytes	isolated	from	mice	from	HFD-fed	mice,	lymphocytes	from	HFD-fed	























Figure	 4.6.	 The	 effect	 of	 treatment	with	 hrANXA1	 on	 lymphocytes	 ability	 to	 adhere	 and	
transmigrate	through	an	endothelial	monolayer	ex	vivo.	
Effects	 of	 chronic	 exposure	 to	 a	 normal	 diet	 (chow)	 or	 a	 high-fat	 high-sugar	 diet	 (HFD)	 on	
lymphocytes	 ability	 to	 adhere	 (A)	 and	 transmigrate	 (B)	 through	 an	 endothelial	 monolayer.	
Experimental	groups:	WT	or	ANXA1-/-	mice	treated	fed	on	normal	diet	(chow)	or	high-fat-high-









































































4.3.7.	 The	 effect	 of	 treatment	with	hrANXA1	on	 specific	 CD4+	 lymphocyte	
populations	 in	 mice	 fed	 a	 HFD	 that	 adhere	 to	 a	 brain	 endothelial	
monolayer	ex	vivo.		
	
Quantification	of	 specific	CD4+	T-cells	populations	was	 carried	out	 in	 cells	 that	
were	adhered	to	the	brain	endothelial	monolayer	after	4	h	of	incubation.	When	
compared	 to	 lymphocytes	 isolated	 chow-fed	 mice,	 lymphocytes	 isolated	 from	
HFD-fed	mice	and	put	 in	contact	with	endothelial	monolayer	had	a	 larger	CD4+	
population	 of	 adhered	 lymphocytes	 (Figure	 4.7A,	 P<0.001),	 which	 was	
attenuated	by	hrAXNA1.	(Figure	4.7A,	P<0.01).	
	
When	 compared	 to	 lymphocytes	 isolated	 from	 chow-fed	 mice,	 lymphocytes	
isolated	from	HFD-fed	mice	and	put	in	contact	with	endothelial	monolayer	had	a	
increased	 CD4+CD25+	 (Figure	 4.7B,	 P<0.05)	 and	 decreased	 CD4+CD25-	 T-cell	
populations	(Figure	4.7C,	P<0.05),	which	was	attenuated	by	hrAXNA1.		
	
When	 compared	 to	 lymphocytes	 isolated	 chow-fed	mice,	 lymphocytes	 isolated	
from	 HFD-fed	 mice	 and	 out	 in	 contact	 with	 endothelial	 monolayer	 had	 an	
increased	 CD4+FoxP3+	 (Figure	 4.7D,	 P<0.05)	 and	 CD4+RORγt+	 (Figure	 4.7E,	














Effects	 of	 chronic	 exposure	 to	 a	 normal	 diet	 (chow)	 or	 a	 high-fat	 high-sugar	 diet	 (HFD)	 on	
specific	CD4+	 lymphocyte	populations	ability	 to	 adhere	 to	 a	brain	endothelial	monolayer.	CD4+	
cells	(A),	CD4+CD25-	(B)	CD4+CD25+	cells	(C)	CD4+FoxP3+	cells	(D)	CD4+RORγt+	cells	and	(E)	as	a	
%	of	CD4+	cells.	Experimental	groups:	WT	or	ANXA1-/-	mice	treated	fed	on	normal	diet	(chow)	or	








































































































































4.3.8.	 The	 effect	 of	 treatment	with	hrANXA1	on	 specific	 CD4+	 lymphocyte	
populations	 in	 mice	 fed	 a	 HFD	 that	 transmigrate	 through	 a	 brain	
endothelial	monolayer	ex	vivo.		
	
Quantification	 of	 specific	 CD4+	 T-cells	 populations	 was	 carried	 out	 in	
lymphocytes	that	transmigrated	through	the	brain	endothelial	monolayer	after	a	
4	 h	 incubation.	 When	 compared	 to	 lymphocytes	 isolated	 chow-fed	 mice,	
lymphocytes	isolated	from	HFD-fed	mice	and	put	in	contact	with	an	endothelial	
monolayer	 had	 an	 increased	 CD4+	 population	 of	 transmigrated	 lymphocytes	
(Figure	 4.8A,	 P<0.05).	When	 compared	 to	 lymphocytes	 isolated	 from	 HFD-fed	
mice,	 lymphocytes	 isolated	 from	HFD-fed	mice	 and	 treated	with	 hrANXA1	 did	
not	 prevent	 the	 increase	 in	 CD4+	 cells	 that	 transmigrated	 through	 the	 brain	
endothelial	monolayer	(Figure	4.8A,	ns).		
	
When	 compared	 to	 lymphocytes	 isolated	 from	 chow-fed	 mice,	 lymphocytes	
isolated	 from	HFD-fed	mice	 and	 put	 in	 contact	with	 an	 endothelial	monolayer	
had	 a	 increased	 CD4+CD25+	 (Figure	 4.8B,	 P<0.05)	 and	 decreased	 CD4+CD25-	
(Figure	 4.8C,	 P<0.05)	 T-cell	 populations	 of	 transmigrated	 lymphocytes.	 When	
compared	 to	 lymphocytes	 isolated	 from	 HFD-fed	 mice,	 lymphocytes	 isolated	




When	 compared	 to	 lymphocytes	 isolated	 chow-fed	mice,	 lymphocytes	 isolated	




increased	 CD4+FoxP3+	 (Figure	 4.8D,	 P<0.5)	 and	 CD4+RORγt+	 	 (Figure	 4.8E,	
P<0.05)	 T-cell	 populations	 of	 transmigrated	 lymphocytes.	 When	 compared	 to	
lymphocytes	 isolated	 chow-fed	mice,	 lymphocytes	 isolated	 from	HFD-fed	mice	
and	treated	with	hrANXA1	attenuated	the	increases	in	both	CD4+FoxP3+	(Figure	





































Effects	 of	 chronic	 exposure	 to	 a	 normal	 diet	 (chow)	 or	 a	 high-fat	 high-sugar	 diet	 (HFD)	 on	
specific	 CD4+	 lymphocyte	 populations	 after	 10	 weeks	 of	 dietary	 manipulation.	 Experimental	









































































































































CD4+RORgt+	 lymphocytes	 from	 mice	 fed	 a	 HFD	 that	 adhere	 to	 and	
transmigrate	through	a	brain	endothelial	monolayer	ex	vivo.	
	
We	 next	 compared	 the	 ratio	 of	 TReg	 (CD4+FoxP3+)	 to	 Th17	 (CD4+RORγt+)	
subsets	 of	 CD4+	T-cells	 that	 adhered	 to	 a	monolayer	 of	 brain	 endothelial	 cells	
after	4	h	of	 incubation.	When	compared	to	 lymphocytes	 isolated	to	from	chow-
fed	mice,	 lymphocytes	 isolated	 from	HFD-fed	mice	 had	 a	 decrease	 in	 the	 ratio	
CD4+RORγt+:	 CD4+FoxP3+	 T-cells	 that	 adhered	 to	 the	 brain	 endothelial	
monolayer	 (Figure	 4.9A,	 P<0.01).	 When	 compared	 to	 lymphocytes	 isolated	 to	




When	 compared	 to	 lymphocytes	 isolated	 to	 from	 chow-fed	mice,	 lymphocytes	
isolated	 from	 HFD-fed	 mice	 had	 an	 increase	 in	 the	 ratio	 of	 CD4+RORγt+:	
CD4+FoxP3+	T-cells	that	transmigrated	through	the	brain	endothelial	monolayer	
(Figure	4.9B,	P<0.05).	When	compared	to	lymphocytes	isolated	to	from	HFD-fed	
mice,	 lymphocytes	 isolated	 from	 HFD-fed	 mice	 and	 treated	 with	 hrANXA1	













Figure	 4.9.	 The	 effect	 of	 treatment	 with	 hrANXA1	 on	 the	 ratio	 of	 CD4+RORγt+	 to	
CD4+FoxP3+	lymphocytes	from	mice	fed	a	HFD	that	adhere	to	and	transmigrate	through	a	
brain	endothelial	monolayer	ex	vivo.	
Effects	of	 chronic	exposure	 to	a	normal	diet	 (chow)	or	a	high-fat	high-sugar	diet	 (HFD)	on	 the	
ratio	of	CD4+CD25-	to	CD4+CD25+	(A/B)	and	CD4+FoxP3+	to	CD4+RORγt+	(C/D)	that	had	adhered	
to	 (A/C)	 or	 transmigrated	 through	 (C/D)	 a	 brain	 endothelial	monolayer.	 Experimental	 groups:	
WT	 or	 ANXA1-/-	mice	 treated	 fed	 on	 normal	 diet	 (chow)	 or	 high-fat-high-sugar	 (HFD)	with	 or	







































































































to	 and	 transmigrate	 through	 a	 bEND5	 endothelial	 monolayer	 ex	 vivo,	 while	
treatment	 with	 hrANXA1	 reduced	 lymphocyte	 ability	 to	 adhere,	 but	 not	 to	
transmigrate	 through	 a	 bEND5	 endothelial	 monolayer	 ex	 vivo;	 and	 (v)	
lymphocytes	 from	mice	 fed	 a	 HFD	 have	 elevated	 number	 of	 both	 FoxP3+	 and		
RORγt+	T-cells	 that	adhered	 to	and	 transmigrated	 through	a	bEND5	endothelial	
monolayer	ex	vivo,	which	was	attenuated	by	hrANXA1.			
	
BBB	tightness	 is	highly	regulated.	One	of	 the	main	components	responsible	 for	
its	 extreme	 tightness	 are	 tight	 junction.	 Disruption	 of	 BBB	 integrity	 has	 been	
implicated	 in	 many	 neurological	 conditions	 such	 as	 multiple	 sclerosis,	
Alzheimer’s	 disease,	 cognitive	 decline	 and	 aging.	 Recently,	 there	 have	 been	







blue	 dye	 in	 to	 the	 brains	 of	 WT-mice	 fed	 a	 HFD.	 Additionally,	 our	 data	 also	
confirms	 that	BBB	permeability	 is	 significantly	 increased	 in	 chow-fed	ANXA1-/-	
mice	compared	to	WT	littermate	 fed	a	chow	diet.	Most	notably,	when	ANXA1-/-	
mice	are	fed	a	HFD,	there	is	a	significant	increase	in	BBB	permeability	compared	
to	 chow-fed	ANXA1-/-	mice.	This	 key	 finding	 indicates	 that	 endogenous	ANXA1	
plays	a	pivotal	role	in	the	regulation	of	BBB	integrity.	Previously,	Cristante	et	al.	
demonstrated	 that	 this	 increase	 in	 permeability	 in	 ANXA1-/-	 mice	 could	 be	
reserved	 by	 treatment	 with	 hrAXNA1	 24	 h	 prior	 to	 Evan’s	 Blue	 injection.	 In	






Endogenous	 ANXA1	 stabilises	 tight	 junctions,	 which	 is	 critical	 to	 ensuring	 the	
tightness	 of	 the	 endothelial	 of	 the	BBB.	 Critical	 to	 this	 process	 is	 the	 ability	 of	
ANXA1	to	regulate	cellular	polarity	and	consequently	the	formation	of	tight	and	
adhesion	junction	(Cristante	et	al.,	2013).	ANXA1	interacts	with	cytosolic,	rather	
than	 fibular	 actin;	 binding	 predominantly	 to	 soluble	 G-actin	 (Cristante	 et	 al.,	
2013).	Additionally,	activation	of	 the	small	GTPase	RhoA is	known	to	 initiate	a	
signaling	 pathway	 resulting	 in	 the	 destabilisation	 of	 the	 actin	 cytoskeleton,	






(Cristante	 et	 al.,	 2013).	 I	 have	 shown	 in	 chapter	 III	 that	 the	 GTPase	 RhoA	 is	
constitutively	activated	in	ANXA1-/-	mice	and	that	feeding	mice	a	HFD	leads	to	a	
further	increase	in	RhoA	activation.	This	data	suggests	that	activation	of	RhoA	is	
the	 mechanism	 by	 which	 the	 initial	 leakage	 of	 the	 BBB	 is	 caused	 and	 the	
mechanism	 by	 which	 treatment	 with	 hrAXNA1	 restored	 BBB	 integrity.	
Suggesting	 that	a	 type-2	diabetic	phenotype	 (elevated	blood	glucose	 leading	 to	
shedding	 of	 intracellular	 ANXA1)	 could	 cause	 activation	 of	 RhoA	 allowing	 for	
actin	 rearrangements	 and	 ultimately	 de-stabilising	 tight	 junctions	 and	 causing	
increased	BBB	permeability.		
	
One	 consequence	 of	 having	 a	more	permeable	BBB	 is	 that	molecules	 and	 cells	
that	should	be	blocked	from	migrating	into	the	brain	parenchyma	penetrate	 in.	
Here	 I	 investigated	 whether	 mice	 fed	 a	 HFD	 have	 altered	 peripheral	 T-cell	
populations	and	whether	these	lymphocytes	would	have	an	increased	ability	to	
penetrate	 through	 an	 endothelial	 monolayer.	 Specifically,	 I	 have	 used	 flow	
cytometry	 to	 identify	 specific	 populations	 of	 CD4+	 T-cells	 isolated	 from	 lymph	
nodes	 from	 mice	 fed	 a	 HFD.	 	 Both	 Th17	 and	 TReg	 cells	 express	 specific	





I	 clearly	 demonstrate	 that	 chow-fed	 ANXA1-/-	 mice	 have	 an	 increased	 Th17	




role	 for	 endogenous	 ANXA1,	 in	 the	 regulation	 of	 both	 expansion	 and	





(CD4+CD25+),	 however,	 there	 is	 a	 specific	 change	 in	 the	 number	 of	 terminally	






blocked	 and	 restore	 T-cell	 population	 size	 to	 those	 seen	 in	WT-mice	 fed	 on	 a	
chow	diet	(Figure	4.10C).	Previous	ex	vivo	studies	using	isolate	CD4+	T-cells	and	
in	 vivo	 studies	 in	 mice	 have	 shown	 that	 glucocorticoids	 promote	 a	 Th2	 cells	
response,	however,	here	we	show	that	endogenous	ANXA1	limits	the	expansion	
of	 the	 Th17	 population,	 while	 therapeutic	 administration	 of	 hrANXA1	 to	 HFD	
prevents	 the	 expansion	 of	 Th17	 cells,	 and	 promotes	maintenance	 of	 the	 TReg	
population.	
	
ANXA1	 is	 a	 well-known	 mediator	 of	 glucocorticoid	 action.	 Most	 of	 the	 work	
regarding	 ANXA1	 biology	 has	 predominantly	 been	 carried	 out	 in	
polymorphonuclear	 leukocytes,	 as	 these	 are	 the	 cell	 type	 that	 expresses	most	






state.	 	 Hyperglycaemia	 is	 a	well	 characterised	 activator	 of	 immune	 cells;	 after	
activation	 lymphocytes	 up-regulate	 adhesion	 molecules,	 which	 allow	 them	 to	
adhere	 more	 readily,	 and	 to	 roll	 and	 transmigrate	 through	 the	 endothelium	
(Morigi	et	al.,	1998).		These	results	demonstrate	a	lymphocyte	specific	change,	as	
the	 endothelial	 monolayer	 is	 grown	 in	 basic	 medium,	 suggesting	 that	 the	




cellular	 store	 where	 is	 inhibits	 leukocyte	 to	 bind	 to	 endothelium.	 Here	 we	
demonstrate	 that	 treatment	 with	 exogenous	 hrANXA1	 plays	 a	 role	 in	 the	
adhesion,	but	not	in	the	migration	of	the	total	population	of	lymphocytes	through	
the	 brain	 endothelial	 monolayer	 (Figure	 4.6).	 Interestingly,	 real-time	 in	 vivo	
analysis	of	activated	PBMNC’s	in	cremaster	muscle	microcirculation	of	ANXA1-/-	
mice	demonstrated	a	subtle	yet	significant	increase	in	leukocyte	emigration,	but	
not	 rolling	 or	 adhesion	 (Chatterjee	 et	 al.,	 2005),	 these	 results	 suggest	 that	
endogenous	ANXA1	may	block	the	process	of	migration	in	the	cremaster	muscle	
microcirculation.	 The	 results	 represents	 a	 subtle	 difference	 in	 the	 role	 of	
endogenous	ANXA1	compared	to	therapeutic	administration	of	ANXA1	or	its	N-
terminal	fragments.	Here	we	show	that	exogenously	given	hrANXA1	inhibits	the	
first	 step	 in	extravasation,	while	endogenous	ANXA1	 inhibits	 transmigration	at	
least	on	the	total	population	of	lymphocytes.	The	next	curious	finding	is	I	looked	




transmigrate	 through	 a	 brain	 endothelium	 monolayer	 I	 found	 that	 Th17	 and	
TReg	 cells	 from	 mice	 fed	 a	 HFD’s	 have	 an	 increased	 ability	 to	 adhere	 to	 and	
transmigrate	 through	a	brain	endothelial	monolayer.	One	 interesting	 finding	 is	
that	 treatment	 with	 hrANXA1	 decreased	 Th17	 and	 TReg	 T-cells	 from	 both	
adhering	 to	 and	migrating	 through	 a	 brain	 endothelial	monolayer.	 	 This	 result	




leukocytes.	This	 integrin	 is	elevated	 in	monocytes,	 leukocytes	and	 lymphocytes	
from	 diabetic	 patients	 (Stulc	 et	 al.,	 2012)(Noda	 et	 al.,	 2012).	 VLA4	 as	 has	 also	
been	 implicated	 in	 diseases	 such	 as	 multiple	 sclerosis,	 were	 immune	 cells	
infiltration	 in	 to	 the	brain	 is	a	key	driver	of	disease	progression.	VLA4	is	one	of	
the	essential	integrins	by	which	T-cells	gain	access	to	the	brain,	and	is	a	current	
therapeutic	 target.	 The	 aim	 is	 to	 block	 VLA4	 resulting	 in	 reduced	 T-cells	
infiltrating	into	the	brain	from	the	peripheral	system.	ANXA1	has	been	shown	to	
directly	block	the	α4β1	subunit	of	VLA4	effectively	blocking	leukocytes	ability	to	
adhere	 to	 the	 endothelium	 (Solito	 et	 al.,	 2000).	Here	 I	 speculate	 that	 a	 similar	
mechanism	 could	 be	 involved	 in	 the	 inhibition	 of	 lymphocyte	 adhesion	 and	
migration	 through	 the	endothelium	of	 the	BBB.	Three	 lines	of	 thought	 support	
this	hypothesis,	 (i)	only	activated	 lymphocytes	express	VLA4;	 (ii)	hrANXA1	has	
been	shown	to	bind	to	the	α4β1	of	integrin	VLA4,	and	(iii)	we	show	that	hrANXA1	





Indeed	 little	work	has	been	has	been	conducted	on	 the	 cross	 talk	between	 the	
infiltrating	 cells	 and	 the	 resident	 cells	 (neurons,	 microglia,	 astrocytes	 and	
oligodendrocytes).	However,	 there	 is	an	emerging	bulk	of	 literature	that	points	
towards	an	increase	in	central	inflammation	and	cognitive	decline	(Cunningham	
&	Hennessy	2015),	 indeed	 there	 is	 also	 strong	evidence	of	 cognitive	decline	 in	
patients	with	obesity	and/or	diabetes	(Cunningham	&	Hennessy	2015)(Nguyen	
et	 al.,	 2014)(Kodl	&	 Seaquist,	 2008)(Bruce	 et	 al.,	 2003).	 	 Specifically,	 it	will	 be	
very	 important	 to	 understand	 how	 different	 subsets	 of	 T-cells	 interact	 with	
different	 cell	 types	 in	 the	 brain	 parenchyma,	 and	 if	 these	 drive	 different	





The	 results	presented	 in	 this	 chapter	 suggest	 a	 central	 role	 for	ANXA1	 in	both	
BBB	 functionality	 and	 lymphocyte	 extravasation	 through	 the	 BBB	 for	 these	
specific	 reasons;	 (i)	 in	 vivo,	 ANXA1-/-	 mice	 have	 a	 more	 permeable	 BBB,	 (ii)	
feeding	mice	a	HFD	increases	BBB	permeability,	while	treatment	with	hrAXNA1	
restores	BBB	tightness;	(iii)	diabetes	enhances	lymphocytes	ability	to	adhere	to	















Th17	 cells.	 Additionally,	 ANXA1	 in	 endothelial	 cells	 inhibits	 RhoA	 activity	 allowing	 for	 the	
formation	 of	 stable	 tight	 junctions	 and	 BBB	 integrity	 to	 be	 maintained.	 (B)	 Under	 diabetic	
conditions,	 intracellular	ANXA1	 levels	decrease	 in	TReg	cells,	and	there	 is	no	signaling	 through	
FPR2.	This	allows	for	the	clonal	expansion	of	TReg	cells	increasing	their	number.		Additionally,	at	
the	 level	 of	 the	 BBB,	 ANXA1	 levels	 are	 depleted,	 RhoA	 is	 activated	 and	 actin	 destabilisation	





















providers,	 including	 the	NHS.	 Indeed,	 the	 treatment	 of	 diabetes	 annually	 costs		
£10	billion,	which	accounts	for	10	%	of	the	NHS	budget,	and	some	80	%	of	this	
cost	is	spent	on	the	complications	of	diabetes.		In	a	report	published	by	Diabetes	
UK,	 cardiovascular	 events	 and	 kidney	 related	 costs	 rank	 in	 the	 top	 3	 most	
expensive	costs	associated	with	diabetes	(NHS,	2014).		Due	to	the	huge	increase	
in	 costs,	 there	 is	 an	 even	 greater	 need	 for	 a	 better	 understanding	 of	 the	
pathophysiology	of	the	microvascular	complication	of	diabetes.	
	
In	 this	 thesis,	 I	 have	 used	 serum	 samples	 from	 patients	 with	 both	 T1DM	 and	
T2DM	 to	 measure	 ANXA1	 levels	 to	 understand	 whether	 the	 levels	 of	 in	 this	
known	 anti-inflammatory	 protein	 are	 modulated	 in	 both	 T1DM	 and	 T2DM.	 	 I	
then	used	 two	murine	models	 to	diabetes	 (i)	 STZ-induced	T1DM	and	 (ii)	HFD-
induced	T2DM	to	gain	a	better	insight	into	the	role	of	endogenous	ANXA1	in	the	
pathophysiology	 of	 diabetes	 and	 also	 to	 evaluate	 whether	 the	 administration	
hrANXA1	 is	 of	 potential	 therapeutic	 benefit.	 	 Both	 of	 these	 animal	models	 are	
well	 established	 and	 have	 been	 used	 extensively	 in	 pre-clinically	 studies	 in	
rodents,	 mostly	 mice	 and	 rats.	 	 Thus,	 these	 models	 represent	 affordable	 and	










and/or	 lipids	 in	 the	 blood	 allowing	 ANXA1	 to	 act	 on	 its	 cell	 surface	 receptor	
FPR2.	 This	 conclusion	 is	 supported	 by	 the	 following,	 three	 observations:	 	 (i)	
patients	 with	 both	 T1DM	 and	 T2DM	 plus	 a	 diagnosis	 of	 diabetic	
nephropathy/CKD	did	not	cause	a	further	rise	in	ANXA1	but	did	cause	a	further	
increase	 in	 CRP	 levels.	 This	 suggests	 that	 ANXA1	 is	 not	 shed	 in	 response	 to	
increased	 chronic	 inflammation,	 but	 rather	 that	 ANXA1	 release	 occurs	 in	
response	to	excessive	glucose	or	lipid	load	in	the	plasma.	This	was	confirmed	by	
the	 lack	 of	 correlation	 between	 ANXA1	 and	 CRP	 levels	 in	 patients	 with	 both	
T1DM	and	T2DM;	(ii)	in	patients	with	T2DM	plasma	cholesterol	levels	correlated	

















event	 (Buckley	 et	 al.,	2015)	 (Ridker	 et	 al.,	 2000).	 	 Here	 I	 show	 that	 CRP	 was	





order	 to	 (i)	 get	 a	 better	 insight	 into	 the	 role	 of	 endogenous	 ANXA1	 in	 these	
disease	 states	 and	 (ii)	 to	 evaluate	 the	 efficacy	 of	 hrANXA1	 in	 experimental	
diabetes.	 In	 the	 clinical	 setting,	 patients	 will	 be	 on	 the	 best	 standard	 of	 care,	
meaning	that	they	will	be	on	medication	to	manage	their	diabetes.	Patients	with	
T1DM	will	 be	 on	 insulin	 replacement	 therapy	 to	 regulate	 blood	 glucose	 levels,	
while	 patients	 on	 T2DM	 will	 most	 likely	 be	 on	 a	 lipid	 lowering	 agents	 (for	
example	a	statin)	and/or	a	blood	pressure	lowering	agent.	The	main	limitations	
of	 these	 in	 vivo	 animal	 models	 is	 that	 the	 mice	 were	 not	 treated	 for	 their	
‘diabetes’.	There	are	also	good	reasons	for	not	managing	the	diabetic	phenotype,	
as	hyperglycaemia	 is	one	of	 the	key	drivers	of	 the	microvascular	complications	
and	must,	therefore,	be	allowed	to	persist.		In	the	STZ-induced	model	of	T1DM,	if	
I	 treated	with	 insulin	 to	 lower	 blood	 glucose	 levels	 the	mice	would	 appear	 to	
have	 no	 diabetic	 phenotype	 indeed	 this	 is	well	 established	 the	 insulin	 therapy	
prevents	 the	 development	 of	 microvascular	 complications	 by	 reducing	 the	
glycaemic	 load	(Havel	et	al.,	2000).	Additionally,	 the	 length	of	 time	required	 to	
develop	microvascular	complications	would	be	much	more	if	I	had	used	insulin	
to	 achieve	 rigorous	 glycaemic	 control.	 In	 chapter	 2,	 I	 show	 that	 after	 6	weeks	











Endogenously	ANXA1	 appears	 to	 be	 a	 tissue	 protective	 protein.	 In	 chapter	 II	 I	
show	 that	 ANXA1-/-	 mice	 administered	 STZ	 have	 a	 more	 severe	 diabetic	
phenotype	by	week	13,	which	in	turn	results	in	a	greater	degree	of	cardiac	and	
renal	dysfunction.	In	chapter	III	I	show	that	ANXA1-/-	mice	fed	a	HFD	also	have	a	
more	 severe	 diabetic	 phenotype,	 which	 was	 associated	 with	 increased	 liver	
injury	and	renal	dysfunction.	Then	in	chapter	IV,	I	show	that	ANXA1-/-	mice	have	
a	 major	 permeability	 defect	 in	 their	 BBB,	 which	 was	 further	 augmented	 in	






suggesting	 that	 ANXA1	 maybe	 involved	 in	 the	 secretion	 of	 insulin.	 However,	
under	normal	physiological	conditions	ANXA1-/-	mice	displayed	normal	glucose-
stimulated	 insulin	 secretion,	 suggesting	 that	 the	 increased	 severity	 of	 the	
diabetic	 phenotype	 is	 independent	 of	 insulin	 secretion.	 Studied	 using	 isolated	






induced	 model	 there	 is	 no	 insulin	 produced,	 therefore	 these	 effects	 are	
independent	 of	 insulin	 secretion.	 Additionally,	 in	 chapter	 II,	 I	 report	 that	
treatment	 with	 hrANXA1	 does	 not	 affect	 the	 diabetic	 phenotype	 in	 the	 STZ-
model;	mice	treated	with	hrANXA1	still	had	an	augmented	OGTT,	suggesting	that	
in	a	system	devoid	of	insulin,	ANXA1	has	little	effect.	Yet,	in	chapter	III,	I	report	
that	 mice	 fed	 a	 HFD	 and	 treated	 with	 ANXA1	 have	 an	 improved	 diabetic	
phenotype;	 mice	 treated	 with	 hrANXA1	 displayed	 lower	 plasma	 insulin	 and	
glucose	 levels,	 and	 an	 improved	 OGTT.	 From	 the	 outset	 this	 may	 seem	 like	 a	
dichotomy	 in	 findings	 between	 the	 two	 studies.	 However,	 when	 the	 induction	
mode	of	each	model	is	assessed	the	picture	becomes	clearer.	Streptozotocin	is	a	
chemical,	 which	 specifically	 targets	 beta	 cells	 for	 destruction.	 It	 does	 this	 by	
causing	alkylation	of	DNA	leading	cells	death	by	necrosis.	Beta	cells	are	on	of	a	
number	of	cell	types	that	once	destroyed	cannot	be	replaced;	therefore	it	is	not	




consumption	 of	 dietary	 fats	 and	 sugar.	 	 This	 leads	 to	 an	 augmentation	 in	
signaling	events	ultimately	resulting	in	peripheral	insulin	resistance.	Therefore,	








In	 this	 thesis	 I	undertook	an	 in-depth	mechanistic	 analysis	of	 the	pathways	by	
which	 endogenous	 ANXA1	 exerts	 its	 protective	 effects;	 whether	 this	 was	 in	
limiting	the	development	of	cardiac	or	renal	dysfunction	(chapter	II	and	III),	liver	
injury	 (chapter	 III)	 or	 by	 increasing	 BBB	 tightness	 (chapter	 IV).	 I	 have	
demonstrated	 that	 AXNA1	 plays	 a	 central	 role	 in	 regulating	 many	 biological	
pathways;	and	a	key	role	in	modulating	the	phosphorylation	states	of	numerous	
targets	 proteins.	 For	 example,	 I	 show	 in	 chapter	 II	 that	 ANXA1-/-	 mice	 have	
increased	phosphorylation	of	the	MAPK’s	p38,	JNK	and	ERK1/2,	while,	in	chapter	
III,	 I	 have	 shown	 that	ANXA1-/-	mice	 have	 decreased	 phosphorylation	 of	 RhoA.	
These	 changes	 in	 phosphorylation	 state	 result	 in	 activation	 of	 these	 proteins.	
Indeed,	activation	of	all	 these	proteins	 is	associated	with	negative	outcomes	 in	
many	 disease	 states.	 The	 development	 of	 a	 diabetic	 phenotype	 was	 also	
associated	 with	 a	 decrease	 in	 the	 intracellular	 levels	 of	 ANXA1	 resulting	 in	
reduced	intracellular	signaling	through	FPR2.	The	outcome	of	this	was	activation	
of	the	MAPK’s,	and	RhoA,	again	suggesting	that	intracellular	signaling	of	ANXA1	
through	 FPR2	 is	 key	 to	 normal	 physiology.	 Interestingly,	 in	 chapter	 III	 when	
HFD-fed	 mice	 where	 treated	 with	 hrANXA1,	 intracellular	 ANXA1	 levels	 were	
maintained	 at	 a	 physiological	 level.	 However,	 the	 mechanism	 behind	 this	
increase	is	unknown;	the	increase	could	be	due	to	an	increase	in	transcription,	or	








One	of	 the	key	pathways	 investigated	 in	 this	 thesis	 is	activation	of	Akt.	 	 I	show	
that	mice	 subjected	 to	 STZ-induced	 T1DM	 (chapter	 II)	 and	 in	mice	 challenged	
with	 HFD	 to	 induce	 diabetes	 T2DM	 (chapter	 III),	 that	 the	 phosphorylation	 of	
Ser473	 on	 Akt	 is	 decreased.	 This	 means	 that	 the	 kinase	 is	 less	 active,	 leaving	
organs	more	vulnerable	to	stressor	stimuli.	Indeed,	in	both	models	of	T1DM	and	
T2DM,	 I	 have	 shown	 that	 when	 Akt	 activity	 is	 decreased	 organs	 are	 more	
susceptible	to	injury	and	develop	dysfunction	over	time.	Additionally,	when	mice	
were	 treated	 with	 hrANXA1,	 the	 phosphorylation	 of	 Ser473	 on	 Akt	 was	
maintained	at	a	higher	level,	increasing/restoring	its	kinase	activity.	Indeed,	the	




I	 have	 shown	 that	 patients	with	 diabetes	 have	 elevated	 CRP,	 indeed	 there	 are	
many	other	epidemiological	studies	that	have	demonstrated	that	CRP	is	related	
to	cardiovascular	risk;	however	few	show	a	relationship	with	insulin	resistance.	
There	is	a	 lot	of	 in	vivo	and	 in	vitro	evidence	that	suggests	a	clear	 link	between	
CRP	 and	 insulin	 resistance.	 CRP	 can	 suppress	 insulin-induced	 NO	 production,	
inhibit	 eNOS	 and	Akt	 phosphorylation	 and	 also	 initiate	 the	 phosphorylation	 of	









prevented	 the	 increase	 in	RhoA	and	 JNK	activity	 resulting	 from	 feeding	a	HFD;	
this	results	in	increased	phosphorylation	of	IRS-1	and	eNOS	and	an	ultimately	an	
improved	 diabetic	 phenotype	 and	 limit	 the	 development	 of	 microvascular	
complications.		
	
In	 chapter	 IV,	 I	 have	 changed	 focus	 away	 from	 treating	 the	 conventional	
microvascular	 complications	 of	 diabetes	 and	 an	 attempt	 to	 link	 changes	 in	
peripheral	 T-cell	 biology	 with	 the	 central	 nervous	 system.	 These	 preliminary	
data	show	that	endogenously	AXNA1	is	a	key	regulator	of	BBB	integrity,	and	that	
the	specialised	endothelium	of	the	BBB	is	altered	in	mice	fed	a	HFD.	Additionally,	
these	 results	 show	 that	 ANXA1	 is	 a	 key	 regulator	 of	 both	 Th17	 and	 TReg	
differentiation	in	the	peripheral	system.	I	have	also	shown	that	Th17	and	TReg	
cells	 more	 readily	 adhere	 to	 and	 transmigrate	 through	 a	 brain	 microvascular	




studies	 into	 the	 mechanisms	 by	 which	 diabetes	 affects	 ANXA1	 levels	 and	 its	











Indeed	 the	 results	 presented	 in	 this	 thesis	 I	 believe	 have	 translatable	 worth.	
Therapeutically,	 giving	 ANXA1	 could	 be	 an	 add	 on	 therapy	 to	 conventional	
insulin	treatment	in	type-2	diabetes.	Three	lines	of	evidence	would	support	this;	





development	of	 complications	 that	 arise	 from	diabetes.	 	 I	 have	 shown	 that	 the	






the	same	delivery	route	(sub	cutaneous)	 is	 the	 ideal	method	 for	a	slow	release	
protein	therapy.	Therefore,	with	good	insulin	management	you	are	also	boosting	
your	 levels	 of	 a	 naturally	 occurring	 endogenous	 anti-inflammatory	 and	 tissue	
protective	protein.	
	
Here	 I	 have	 presented	 a	 novel	 therapeutic	 agent	 that	 has	 lipid-lowering	







1. One	of	 the	main	questions	 that	 remain	 to	be	 answered	 is	whether	ANXA1-/-	
mice	have	a	hypertensive	phenotype.	Activation	of	MYPT1	is	associated	with	a	
slowing	of	the	relaxation	of	the	myosin	light	chain	of	smooth	muscle.	This	can	
lead	 to	 increased	 contraction	 in	 resistance	 vessels.	 Along	 the	 same	 lines,	 it	
would	 be	 interesting	 to	 know	 whether	 WT	 mice	 fed	 a	 HFD	 develop	
hypertension.	Two	lines	of	evidence	suggest	that	this	may	be	the	case:	(i)	WT	
mice	fed	HFD	have	activated	MYPT1	(increasing	vasoconstriction)	and	(ii)	WT	




stress	of	 fitting	 the	cuff	often	 tends	 to	result	 in	hypertension	resulting	 in	an	
overestimation	of	 the	 reading;	 	 (ii)	 in	vivo	 telemetry	 can	be	used	 to	 insert	 a	
telemetry	probe	into	the	carotid	and	the	mouse	then	recovers	for	anaesthsia	
goes	 back	 to	 it	 cage.	 The	 advantage	 of	 this	 technique	 is	 that	 you	 get	 a	
continuous	 measurement	 of	 blood	 pressure,	 which	 allows	 for	 diurnal	
variation,	which	can	be	very	important.	
	
2. At	 the	 levels	 of	 the	BBB	 it	would	be	useful	 to	 assess	RhoA	activation	 in	 the	
microvasculature	 of	 the	 brain.	 Our	 hypothesis	 is	 that	 RhoA	 activation	 is	
causing	 actin	 destabilisation,	 which	 reduces	 the	 tightness	 of	 the	 tight	





junctions	 are	 only	 present	 of	 the	 endothelial	 so	 a	 more	 specific	 technique	
could	be	to	isolate	specifically	the	brain	microvascular	endothelial	cells.	This	
would	 allow	 for	 the	 specific	 determination	 of	 if	 RhoA	 is	 activated	 in	 the	
endothelial.	
	
3. In	 diabetic	 mice	 it	 would	 be	 interesting	 to	 assess	 the	 quality	 of	 the	 tight	
junctions.	 This	 could	 be	 achieved	 by	 doing	 immunofluorescence	 of	 frozen	
brain	 sections,	measuring	 the	 expression	 of	 ANXA1,	 occludin,	 F-actin,	 ZO-1,	




4. It	 would	 also	 be	 very	 interesting	 to	 look	 for	 the	 presence	 of	 infiltrating	
immune	cells	in	the	brain	of	mice	in	different	treatment	groups.	This	could	be	
done,	using	 immunofluorescence	or	by	FAC	sorting	brain	homogenates.	This	
would	 allow	 for	 the	 investigation	 of	which	 sub-sets	 of	 T-cells	more	 actively	
migrate	 into	the	brain	parenchyma	in	mice	 fed	a	HFD,	and	 if	 treatment	with	
hrANXA1	has	the	same	effect	in	vivo	as	it	does	in	vitro.	
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